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ABSTRACT
Anti-retroviral therapy comprises a combination of three or more drugs from at 
least two classes. Following long term therapy some patients experience metabolic side- 
effects including abnormal fat distribution, dyslipidaemia, lipoatrophy, hyperlipidaemia, 
impaired lipid and glucose metabolism. Metabolic nuclear receptors may be implicated in 
some of these deleterious side effects.
RTV is widely implicated in the deleterious metabolic side effects of ARVs, whilst 
ATV has been shown to have a better lipid profile than RTV. Previous studies had not 
determined whether this was due to differences in intra-cellular accumulation of the two 
drugs. Cellular accumulation of ATV was detennined to be 2 fold greater than that of RTV 
in the hepatic cell line, Huh7. This confirmed that the metabolic disruption and the 
deleterious side effects associated with RTV were not due to its higher intracellular 
accumulation.
LXRa was significantly up-regulated by RTV, and it was detennined to be a 
regulator of key downstream target gene expression, including SREBP-lc, PPARa, ApoA- 
I, VLDLR, ApoC-II and ApoC-III. Inhibition of LXRa by 22(S)-hydroxycholesterol and 
by siRNA knockdown of LXRa was used to confirm these findings. Biological knockdown 
of LXRa by siRNA resulted in down-regulation of LXRa gene expression in the presence 
of RTV, which could provide a potential future therapeutic mechanism for inhibition of 
LXRa in vivo,
LXRa was involved in the regulation of gene expression of bile acid and 
cholesterol transporters including: ABCA1, ABCB2, ABCG1, ABCG4, ABCG5, ABCG8 
and the glucose transporter GLUT4, which were up-regulated by RTV. LXRa was 
involved in the regulation of ABCB11 and ABCC2 but data suggested that LXRa was not 
the master regulator. Gene expression of these metabolic transporters differs in response to 
RTV and ATV. The actions of RTV can be blocked through modulation of LXRa gene 
expression. LXRa was also involved with the regulation of ABCB1 and ABCC1 gene 
expression.
A polymorphism in LXRa, rs2279238C/T, could influence the risk of HADL 
development in Caucasian HTV+ populations. The results indicate further investigation 
would be required in a larger HIV cohort to substantiate this association.
Elevated LDL-c levels were observed in HIV+ Caucasians homozygous GG 
genotype for the ApoB rs7575840GT SNP and with at least one copy of the A allele for the 
ABCA1 rs2230806G/A SNP. The C allele in the LDLR rsl529729C/T SNP was associated 
with elevated total cholesterol, LDL-c and TG levels. Elevated total cholesterol and 
increased LDL-c levels were observed when this SNP was combined with the GG 
genotype for ApoB rs7575840GT and the C allele for the LDLR SNP rs2228671C/T. 
Decreased HDL-c was observed in HIV+ patients with the T allele of the SCARB1 SNP 
rs2278986C/T when associated with a combination of demographic factors and the 
following SNPs: ABCA1 rs2230806G/A, A allele; LDLR rs!529729C/T, C allele; ABCG1 
rs 1893590A/C, C allele; ABCG8 rs6544713C/T, T allele; and ApoB rs693A/G, G allele.
In summary the data in this thesis indicates LXRa is a regulator of metabolic target 
genes involved in cholesterol homeostasis, bile acid metabolism and the response to RTV 
in a hepatic cell line. The role of RTV as an agonist of LXRa was confirmed. The 
contrasting lipid profiles of RTV and ATV are not due to higher intracellular concentration 
of the former. This thesis has also identified a potential therapeutic use for LXRa 
modulation. SNPs in LXRa and key cholesterol transporters have correlated with 
metabolic complications in HIV+ cohorts which merit further investigation in larger 
patient cohorts to validate the associations.
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1. General Introduction
1.1 History of HIV and HIV Life Cycle
Human immunodeficiency virus (HIV) is a retrovirus which uses the cells of the 
human immune system to survive and reproduce. There are two main types of HIV, 
HIV-1 and HIV-2, the former is the more virulent whereas the latter is confined 
mainly to West African populations and sexual partners. Recognised sub-types of 
both HIV-1 and HIV-2 are known to exist. By the end of 2009, it was estimated that 
around 33.3 million people worldwide were living with HIV/AIDS (acquired 
immunodeficiency syndrome), there were around 2.6 million new HIV infections and 
approximately 1.8 million people died from AIDS during the same year (UNAIDS, 
2010). There is no current cure or vaccine for HIV or AIDS. Current drug therapy 
aims to reduce the viral load in plasma to below detectable levels and to maintain this 
for as long as possible. Antiretroviral drugs dramatically increase life expectancy but 
there are side effects associated with long-term use.
HIV infection of cells commences when the HIV virion (HIV virus is known as a 
virion when outside the cell), which is surrounded by a glycoprotein envelope, binds 
to both a CD4 receptor and a chemokine co-receptor on the surface of the host’s 
immune cells. These include T-helper cells, monocytes, macrophages and microglial 
cells. Viral tropism refers to the cell types infected by HIV. Macrophage (M-tropic) 
strains of HIV-1 use the chemokine co-receptor CCR5 for entry and T-tropic isolates 
replicate in primary CD4h T cells as well as in macrophages and use the a~ 
chemokine receptor, CXCR4, for entry. More than seven chemokine co-receptors act 
as co-receptors for HIV entry to cells, including CXCR4 and CCR5 (major co-
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receptors in vivo). HIV variants which use CXCR4 or both CXCR4 and CCR5 (dual 
tropic) co-receptors are temporarily associated with accelerated CD4+ T-cell 
depletion and rapid disease progression (Simmons et al, 1996).
The key stages of the HIV Lifecycle are outlined in Figure 1.1 (Abbas et aL, 2003 ). 
The HIV yirion envelope is a complex composed of a transmembrane glycoprotein 
(gp41) subunit and an external gpl20 subunit. The virion envelope is expressed as a 
trimeric structure comprised of three gpl20/gp41 pairs, which mediates a multistep 
process of fusion of the virion envelope with the membrane of the host cell. The first 
step involves the binding of the gpl20 subunits to CD4 molecules, inducing a 
confonnational change which promotes secondary gpl20 binding to a chemokine co­
receptor. Co-receptor binding causes a conformational change in gp41 exposing a 
hydrophobic region known as the fusion peptide, which inserts into the cell 
membrane enabling fusion of the viral and host cell membranes (Abbas et al, 2003 ).
Once inside the cell, the virion uncoats and enzymes within the nucleoprotein 
complex are activated initiating the viral reproductive cycle. Reverse transcriptase 
transcribes the RNA genome of HIV into double stranded DNA, which enters the 
host cell nucleus with the viral enzyme integrase, and catalyses the integration of 
viral DNA into the host cell genome. This integrated HIV DNA is the provirus. Viral 
replication is initially repressed by host intracellular factors and by the CD8+ 
cytotoxic T-cell mediated immune response. It can remain latent for long periods, 
during which the virus is highly active within the cell but new virus particles are not 
released into the bloodstream (Abbas et al, 2003 ; Kim et aL, 2006a).
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Activation of latently infected T-cells initiates viral replication. The proteins which
form new HIV particles are assembled within the host cell through the translation of
messenger RNA. These proteins are then spliced by viral protease into smaller
sections which form the structure, enzymes and replication proteins of the new HIV
particle. Once this assembly is complete, the new viral particle buds off the host cell
and is released into the bloodstream resulting in the infection of more CD4+ cells.
HIV virion1 Virion binding to CD4 and 
chemokine 
receptor
Plasma 
membrane
V
Chemokine
receptor
Fusion of HIV 
membrane with cell 
membrane: entry 
of viral genome 
into cytoplasm
f Cytokine HIVgpl20/
gp41
Reverse 
transcriptase- 
mediated synthesis 
of proviral DNA
Integration of 
provirus into 
cell genome
Cytoplasm
Cytokine activation 
of cell: transcription 
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transport of spliced 
and unspliced RNAs 
to cytoplasm
Nucleus
Expression of 
gpl20/gp41 
on cell surface: 
budding of 
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HIV core 
structure
Synthesis of HIV 
proteins: assembly 
of virion core structure
HIV proteins
Figure 1.1: HIV life cycle - showing the sequential steps of the replication process. From 
Abbas and Lichtman: Cellular and Molecular Immunology, 2003; Figure 20-5.
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Highly Active Anti-Retroviral Therapy (HAART)
Highly active antiretroviral therapy (HAART) comprises a combination of three or 
more antiretroviral drugs from at least two different classes, and has been around 
since the mid-1990s. HAART has significantly reduced the mortality and morbidity 
of HIV infection, giving a much transformed outlook to the infected (Falutz, 2007). 
It is a lifelong drugs regimen and with long-tenn therapy side-effects are common 
(Behrens et al, 2000; Bonfanti et ai, 2000; Carr, 2000; Mallon, 2007). HAART can 
in many cases drive down the virus level in the body to levels undetectable by 
current assays. This, however, is not always successful and a significant number of 
individuals have high levels of HIV despite their potent drug regime, whilst others 
experience transient improvement before their viral load returns to pre-treatment 
levels (Cressey et al, 2007; Owen et al, 2008; Telenti et al., 2008).
The major causes of treatment failure include drug resistance and non-compliance 
with the complex drug regimen, but individual phannacokinetic variability can also 
play a key role (Cressey et al., 2007). A significant obstacle to finding a cure is the 
ability of the virus to find sanctuary from the host’s immune response in the brain, 
other body compartments and the lymphatic system. The virus can remain latent in 
sanctuary reservoirs for long periods prior to being triggered for replication by a fall 
in drug concentrations. Viral replication under therapy can positively select drug 
resistant strains leading to virologic failure.
Drug intolerance (side-effects), poor access to medical care, inadequate support 
networks and substance abuse all contribute to non-compliance. HIV-1 positive
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(HIY+) individuals receiving antiretroviral therapy sometimes experience serious 
metabolic side-effects including lipoatrophy, gains in visceral fat, hyperlipidaemia 
and insulin resistance (Mallon, 2007; Mallon et al, 2003). It is likely that numerous 
mechanisms contribute to these side-effects, although prolonged treatment with a 
HAART regimen is widely implicated (Behrens et ai, 2000; Dube el aL, 2006; 
Falutz, 2007; Mallon et al., 2003).
Thirty-two antiretroviral drugs (ARVs) including combination therapies are currently 
approved by the Food and Drug Administration (FDA), in the United States (twenty- 
nine in Europe) which fall into four major classes: reverse transcriptase (RT) 
inhibitors (including nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) 
and non-nucleoside reverse transcriptase inhibitors (NNRTIs)); protease inhibitors 
(Pis); chemokine co-receptor antagonists (entry and fusion inhibitors (Els)); and 
integrase inhibitors (IIs). Multidrug combinations incorporate more than one class 
into a single product.
Pis inhibit the action of the HEV viral enzyme protease. The protease enzyme cleaves 
the inert polyprotein product of translation into the smaller structural and functional 
proteins required for viral growth, infectivity and replication. NRTIs require 
intracellular conversion to the corresponding tri-phosphate nucleotide for activation. 
The active tri-phosphates then competitively inhibit viral reverse transcriptase 
causing tennination of DNA chain elongation once incorporated. NNRTIs bind to the 
viral enzyme reverse transcriptase close to the catalytic site causing a conformational 
change which inactivates the enzyme.
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Fusion inhibitors interfere with the entry of HIV-1 into cells by inhibiting the fusion 
of viral and cellular membranes. Enfuvirtide is the only licensed fusion inhibitor in 
clinical use. It acts by binding to the first heptad repeat (HR1) in the gp41 subunit of 
the viral envelope glycoprotein preventing the conformational changes required for 
the fusion of viral and cellular membranes. Els block the chemokine co-receptors on 
the host cells to prevent the HIV virion binding. Maraviroc is the only licensed El 
currently in clinical use. It acts by blocking CCR5 preventing HIV from binding to 
the receptor. When CCR5 is unavailable, CCR5-tropic HIV cannot infect a CD4 cell. 
The CCR5-tropic variant of the virus is common in early HIV infection, whereas 
viruses adapted to use the CXCR4 receptor gradually become dominant in some 
patients as HIV infection progresses. IIs block the catalytic activity of HIV-1 
integrase, an enzyme required for viral replication. Integrase inhibition prevents the 
covalent insertion of unintegrated, linear HIV-1 DNA into the host cell genome, 
preventing the formation of HIV-1 provirus. Raltegravir is the only II currently in 
clinical use, although others including elvitegravir are in development. Figure 1.2 
(Spach, 2007), shows the current antiretroviral drug targets at the key stages in the 
HIV Lifecycle.
Chapter 1
8
Figure 1.2: HIV life cycle and current drug targets by class (NRTIs - nucleoside reverse 
transcriptase inhibitors; NNRTIs - non-nucleoside reverse transcriptase inhibitors) - Adapted 
from HIV Web Study- www. HIVwebstudv.ora.
1.3 HrV/HAART-Associated Dyslipidaemic Lipodystrophy (HADL)
The direct toxicity attributed to long-term HAART together with the complex 
interactions with HIV infection combined with possible other factors, (e g. genetic 
predisposition, environmental) influence the risk of developing HIV/HAART- 
associated dyslipidaemic lipodystrophy (HADL). Successful treatment regimens 
have greatly improved morbidity and mortality outcomes for HIV+ individuals but 
the onset of HADL greatly increases the risk of developing cardiovascular disease 
and associated metabolic complications (Kim et al., 2006b; Mallon, 2007).
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HIV infection has been shown to cause changes in lipid metabolism, including 
decreases in total, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) 
cholesterol (Falutz, 2007; Mallon, 2007). Treatment with ARVs (including Pis) has 
resulted in elevations in total and LDL cholesterol levels whilst HDL cholesterol 
levels remained low (Mallon, 2007). HIV infection together with the impact of 
HAART, co-infection with hepatitis C virus (HCV), which is not uncommon in 
HIV+ cohorts (Buxton et al.\ Rockstroh et aL, 2004), increases the risk of fat 
redistribution abnormalities and the other metabolic complications associated with 
HAART (Duong et al, 2001). This together with a genetic predisposition to 
dyslipidaemias create a complex multi-factorial mechanism leading to an array of 
metabolic complications (Capeau et aL, 2006; El-Sadr et aL, 2005; Falutz, 2007; 
Lagathu et aL, 2005). Differences in the pharmacokinetics of many ARVs including 
ATV have been reported between HIV+ individuals and healthy volunteers 
(Dickinson et aL, 2008). Together these factors have contributed to the identification 
of wide ranging mechanisms involved in the deleterious metabolic side effects 
(Behrens et aL, 2000; Carr, 2000; El-Sack et aL, 2005; Falutz, 2007; Hraz, 2006; Lee 
et aL, 2005; Mallon, 2007). Single nucleotide polymorphisms (SNPs) in drug 
disposition genes, transporters and genes involved in lipid homeostasis may play a 
key role in varied metabolic side-effect profiles seen in HIV+ individuals on 
HAART (Mallon, 2006; Telenti etaL, 2008).
Dyslipidaemia is common in HEV+ individuals on long-term HAART. It is 
characterised by elevated total and LDL cholesterol, significantly elevated 
triglycerides together with a decrease in HDL cholesterol, resulting in a profile with
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atherogenic potential (Falutz, 2007; Mallon, 2007). The three major classes of 
ARYs: Pis, NRTIs and NNRTIs, have been implicated in dyslipidaemia, although 
Pis are most widely implicated (Table 1.1) (Behrens et al., 2000; Carr, 2000; Carr et 
al, 1998; Falutz, 2007; Mallon, 2006). Insulin resistance is also commonly 
associated with Pis and NRTIs (Falutz, 2007; Lagathu et al, 2005). Pis have been 
shown to impact several molecular pathways key to lipid metabolism including intra­
nuclear transcription factors and the nuclear proteasome (Lagathu et al, 2005; 
Mallon, 2007).
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Table 1.1: Major classes of approved antiretroviral drugs and associated metabolic 
complications_______________ ___________________ ______________________
Class Generic Name Metabolic Complications
Reverse
transcriptase
(RT)
inhibitors
NRTI - 
(Nucleoside 
& Nucleotide 
analogues)
Abacavir
Didanosine (ddl)
Emtricitabine (FTC)
Lamivudine (3TC) Elevated triglyceride & cholesterol 
levels
Stavudine (d4T) Fat redistribution syndrome,
increased insulin resistance,
decreased adipocyte differentiation
Tenofovir (TDF)
Zalcitabine (ddC)
Zidovudine (AZT) Increased insulin resistance,
decreased adipocyte differentiation
NNRTI - 
(Non-
Nucleosides)
Delavirdine Elevated HDL cholesterol levels
Efavirenz Elevated triglyceride & cholesterol 
levels
Nevirapine Elevated HDL cholesterol levels
Protease
Inhibitors Pis
Tipranavir Hyperglycaemia, hyperlipidaemia, 
fat redistribution, increased insulin 
resistance (amprenavir)
Amprenavir
Damnavir
Fosamprenavir
Atazanavir Lower hypeilipidaemia than other
Pis
Indinavir Hyperglycaemia, elevated 
triglyceride levels, increased insulin 
resistance, hypeilipidaemia, fat 
redistribution
Lopinavir/ritonavir
Nelfmavir
Ritonavir
Saquinavir Hyperglycaemia, hyperlipidaemia, 
fat redistribution & lipid 
abnormalities
Entry (El) & 
Fusion (FI) 
inhibitors
Els & FIs
Enfuviitide (T20) Weight loss
Maraviroc
Integrase
inhibitors
IIs Raltegravir
1.4 Adenosine Tri-Phosphate (ATP) Binding Cassette (ABC) Family Transporters
The adenosine tri-phosphate (ATP) binding cassette (ABC) transporters are members 
of a superfamily of transmembrane proteins which transport a wide variety of 
endogenous substrates and xenobiotics across extracellular and intracellular 
membranes. ABC transporters utilise the energy from ATP hydrolysis to facilitate
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this transport. ABC transporters play a crucial role in multidrug resistance via the 
efflux of therapeutic drugs from cells (Ho et al.9 2005; Tirona et aL, 2005). The main 
examples of this mechanism covered in this thesis are ABCB1 (P-glycoprotein, P-gp, 
multidrug resistance protein 1), ABCC1 and ABCC2 (the multidrug resistance 
associated proteins 1 and 2, respectively) which extrude drugs from human cells, and 
have been implicated in modulating the levels of anti-retroviral drugs in cells and 
tissues (Telenti et al., 2002; Telenti et al, 2008). This drug transport system is 
thought to have evolved as a protective mechanism in which multiple pathways exist 
for the elimination of potentially harmful xenobiotics. The synergistic or additive 
functions of these multiple transport systems may need to be considered when 
examining a particular drug’s disposition profile (Ho et aL, 2005). Multidrug 
resistance transporters may contribute to reduced intracellular drug concentrations at 
sanctuary sites (Pan et al., 2007).
The membrane efflux transporter ABCB1 extrudes diverse hydrophobic peptides and 
drugs (organic cationic and neutral compounds) from human cells in many key sites 
for drug metabolism and elimination including the small intestine, liver and kidney 
(Telenti et al, 2008; Urquhart et al, 2007). ABCB1 has a critical role in drug 
absorption, biliary excretion, renal secretion and central nervous system (CNS) entiy 
of a wide range of hydrophobic xenobiotics. ABCBlis expressed in tissues which 
provide barriers to systemic drug exposure and exhibit broad substrate specificity, 
there is a significant substrate overlap with CYP3A4. Significant inter-individual 
variability of ABCB1 expression in the intestine and other organs exists (Urquhart et 
al., 2007). HIV-1 Pis and NNRTIs are known substrates of ABCB1 (Ho et al, 2005;
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Telenti et aL, 2008). ABCB1 expression is also regulated by the activation of PXR 
and CAR as previously stated (Kast et aL, 2002; Pascussi et ah, 2008; Urquhart et 
aL, 2007).
ABCBland ABCC1 are mainly located in the plasma membrane of the epithelium 
and endothelium of the liver, intestine, blood-brain barrier (BBB) and the testes (Ho 
et aL, 2005; Pan et aL, 2007; Urquhart et aL, 2007). Current research seeks to 
address drug resistance through a variety of mechanisms including the identification 
of polymorphisms in drug transporters which account for inter-individual variations 
in response (Cressey et aL, 2007; Owen et aL, 2006; Rodriguez-Novoa et aL, 2006; 
Telenti et aL, 2008).
ABCC2 is a drug efflux transporter which is expressed in the intestine, liver and 
kidney. Its primary function is the excretion of organic anions from Phase II drug 
metabolism reactions, e.g. glutathione, glucuronide and sulphate conjugates, from 
hepatocytes into bile. ABCC2 is also responsible for the transport of endogenous 
substrates including oestrogens, bilirubin and bile salts (Urquhart et aL, 2007). As 
discussed in detail in sections 1.6.2 and 1.6.3, ABCC2 expression is regulated by the 
NRs PXR, FXR and CAR. Increased ABCC2 expression has been evidenced 
following induction of the NRs by the paradigm inducers rifampicin (PXR), 
chenodeoxycholic acid (FXR) and phenobarbital (CAR) (Urquhart et aL, 2007).
The induction of ABCC3 (multidrug resistance associated protein 3) and ABCC4 
(multidrug resistance associated protein 4) by NRs has been discussed in detail in 
section 1.6.1. ABCC3 is a drug efflux transporter expressed on the basolateral
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membrane of ceils in the liver, kidney and small intestine (Ho et al., 2005; Urquhart 
et al, 2007). VDR, PXR and CAR are known to induce the expression of ABCC3 
whilst SHP (NR0B2) is known to down-regulate its expression (Makishima et al, 
2002; Pascussi et al, 2008; Tirona et al, 2005). ABCC4 is a drug efflux transporter 
in the liver which transports conjugated steroids and bile acids from the hepatocytes 
into the blood. It has been speculated that AJBCC4 compensates for disrupted 
canalicular bile acid efflux during cholestasis by facilitating transport into the blood 
for renal excretion (Urquhart et al, 2007). Two polymorphisms in ABCC4 may have 
clinical relevance in respect of HAART, The NRTIs lamivudine and zidovudine have 
been associated with elevated intracellular levels linked to T4131G and G3724A 
respectively (Rodriguez-Novoa et al, 2006). CAR has been shown to induce the 
expression of MRP4 (Tirona et al, 2005).
1.5 Cytochrome P450 (CYP) Disposition Genes
The gene superfamily of haem proteins, the cytochrome P450 (CYP450, CYP) 
encodes the main enzymatic system for metabolism of lipophilic substrates of diverse 
structures and may be subdivided into those which metabolise purely endogenous 
chemicals and those involved in xenobiotic metabolism. CYPs are important in the 
oxidative, peroxidative and reductive metabolism of numerous endogenous 
compounds including steroids, bile acids, fatty acids, prostaglandins, leukotrienes, 
biogenic amines, and retinoids. Phase I drug metabolism reactions, which involve 
oxidation, reduction or hydrolysis of the drug, are primarily undertaken by CYPs (Ho 
et al, 2005).
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CYP1A1, CYP1A2 and CYP1B1 are involved in drug and steroid (especially 
oestrogen) metabolism. The CYP2 subfamily; including the key members CYP2B6, 
CYP2B10, CYP2C9, CYP2C19, CYP2D6 and CYP2E1, are also involved in drug 
and steroid metabolism. The NRs PXR, CAR, VDR and LXRa are associated with 
the regulation of CYP2B6, as discussed in Sectionl.6. VDR and CAR are also 
associated with the regulation of CYP2B10 and CYP2C9 (Handschin et al, 2003). 
The CYP4 subfamily contains the PPAR regulated CYP4A11 and is involved in 
arachidonic acid and fatty acids metabolism. The CYP7 and CYP8 subfamilies are 
regulated by PXR, LXR and FXR and are involved in cholesterol homeostasis and 
bile acid metabolism (Handschin et al, 2003; Tirona et al, 2005).
Human CYP3A4 is the most abundantly expressed hepatic drug metabolising CYP 
(Martinez-Jimenez et al, 2007) and accounts for the metabolism of more than 50% 
of clinically used drugs (Lehmann et al, 1998; Luo et al, 2002; Plant, 2007). It is 
also expressed in the small intestine, where it contributes to the first pass metabolism 
of many drugs (Luo et al, 2002; Paine et al, 1996). Hepatic and intestinal 
expression can be induced by a wide variety of therapeutic drugs leading to the 
accelerated metabolism of the drugs and concomitantly administered therapies 
leading to altered therapeutic effects and drug-drug interactions (Luo et al, 2002). 
Inclusion of the PI ritonavir in HIV combination therapies has been shown to 
significantly improve circulating concentrations of co-administered drugs. 
Improvement in drug serum concentrations have been attributed to a reduction in 
overall drug metabolism due to direct inhibition of CYP3A4 by RTV. The NRs PXR,
Chapter 1
16
CAR, VDR, LXRct, GR and HNF4a are all known regulators of CYP3A4 
expression.
Human CYP3A subfamily members comprise CYP3A4, CYP3A5, CYP3A7 and 
CYP3A43. Despite the similarity of DNA sequences the expression pattern of these 
are quite different. CYP3A4 is predominantly expressed in the adult liver and 
intestine. CYP3 A5 is polymorphically expressed in a variety of tissues, especially the 
adult liver, kidney and lung. CYP3A7 is expressed in human foetal liver and 
CYP3A43 is highly expressed in the adult prostate (Luo et ah, 2004; Matsumura et 
al, 2004). There is wide inter-individual variation in the hepatic expression and 
activity levels of CYP3A4 which has consequences for the efficacy and toxicity of 
many drugs (Luo et aL, 2004; Matsumura et al., 2004).
1.6 Nuclear Receptors
Nuclear receptors (NRs) are the largest known family of transcription factors which 
function as regulators of tissue gene expression. There are 49 known members of the 
nuclear receptor superfamily and each member shares key structural features. NRs 
are divided into 6 NR sub-families based on conserved structure and function (Owen 
et al., 2000), Figure 1.3 below outlines the phylogenetic tree and evolutionary 
relationship of the NRs (Benoit et al., 2006). NRs are cellular proteins which are 
responsible for sensing hormones and xenobiotics. NRs work in concert with other 
proteins to regulate the expression of specific genes, thereby regulating metabolism, 
development and homeostasis (Urquhart et al, 2007).
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EAR2 (NR2F6) 
COUP-TF I (NR2F1) 
COUP-TF II (NR2F2) 
TR2 (NR2C1)
TR2 (NR2C2)
PNR (NR2E3)
TLX (NR2E1)
DAX-1 (NR0B1)
SHP (NR0B2)
HNF4 alpha (NR2A1) 
HNF4 gamma (NR2A3) 
NGFI-B (NR4A1) f-
NURR1 (NR4A2) LI
NOR1 (NR4A3)
ERR alpha (NR3B1) 
ERR beta (NR3B2)
ERR gamma (NR3B3) 
SF-1 (NR5A1)
LRH-1 (NR5A2)
GCNF (NR6A1)
Rev-Erb alpha (NR1D1) 
Rev-Erb beta (NR1D2) 
ROR alpha (NR1F1) 
ROR beta (NR1F2)
ROR gamma (NR1F3)
Figure 1.3: A phylogenetic tree and schematic structure of structurally diverse nuclear 
receptors. Reproduced with permission from Vincent Laudet (Vincent.Laudet@ens-lvon.fr) 
From Benoit et a!., 2006.
NRs have evolved with structural features which are common to the entire NR 
superfamily (see section 1.6.1 below) whilst ligands for the metabolic NRs are 
present in high concentrations unlike those for the classical NRs such as the 
oestrogen receptor (ER), (Francis et al., 2003; Gronemeyer et al., 2004b). Figure 1.4 
below illustrates the differences in binding affinity between the metabolic NRs and 
the oestrogen receptor-a (ERa).
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Figure 1.4: The differences in ligand binding affinity between the metabolic nuclear receptors 
and the oestrogen receptor-a (ERa), Red = nanomolar (nM) binding; Yellow = micromolar 
(pM) binding; and Green = Binding with variable/unknown affinity.
Over the last twenty years, important new insights have been made in relation to the 
ligand activated NR mechanisms which regulate the expression of drug metabolising 
enzymes and transporters. Convincing evidence exists which demonstrates that an 
array of NRs including: the pregnane X receptor (PXR), constitutive androstane 
receptor (CAR), famesoid X activated receptor (FXR), liver X activated receptor
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1.6.1
(LXR), vitamin D receptor (VDR), hepatic nuclear factor 4a (HNF4a) and the aryl 
hydrocarbon receptor (AhR) control the expression of many clinically important drug 
metabolising enzymes and drug transporters including: the cytochrome P450 (CYP) 
enzymes: CYP3A4; CYP2B6; CYP2C9; and CYP2C19; Adenosine tri-phosphate 
binding cassette-Bl (ABCB1); ABCC2; and ABCC4 (Kast el aL, 2002; Lehmann el 
al., 1998; Pascussi el al., 2008; Thummel el ai, 2001). The influence of NRs on the 
regulation of drug disposition genes has greatly influenced the drug development 
process (Tirona et al.t 2005; Urquhart el al, 2007). NRs have evolved to bind 
distinct ligands and regulate physiological processes, many of these functions have 
been highly conserved through evolution (Owen et al, 2000).
Nuclear Receptor Structure
NRs comprise three major protein domains: an amino terminal A/B domain or 
hypervariable region which contains the activation function 1 (AF-1) domain; a 
centrally located deoxyribonucleic acid (DNA) binding domain (DBD) or C region; 
and a carboxyl tenninus ligand binding domain (LBD) or E/F region (the F region is 
not found in all NRs (Zhang et al, 2004)), which contains the activation function 2 
(AF-2) domain; (Figure 1.5, below) and a hinge region.
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COOHNH2
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9-c/s retinoic acid 
retinoid-X receptor
DBD DBD
AGGTCA (N)x AGGTCA
---------- ► ---------- ► DR-x
target gene
ER-x
* IR-x
Figure 1.5: Structure and DNA binding of nuclear receptors. A: - The molecular structure of 
a nuclear receptor: The A/B N-terminal with AF-1 region; the C region DBD; the D region - 
flexible hinge domain; and the E region LBD with AF-2 domain, (the F region is not shown as 
it is common to all NRs). B: - DNA binding of nuclear receptors. The xenobiotic-sensing 
nuclear receptors bind as heterodimers with RXR to repeats of AG(G/T)TCA with variable 
spacing. The hexamers can be arranged as direct repeats (DR), everted repeats (ER) or 
inverted repeats (IR). Comparison of the amino acid sequences of the xenobiotic sensing 
NRs (RXR and CAR) and closely related NRs VDR, the bile acid sensor FXR, and the 
cholesterol sensors LXRa and LXR(3 reveals a high level of similarity. Adapted from 
Handschin and Meyer, 2003 and Fiorucci eta!., 2007.
These protein domains can be categorised based on function and amino acid position 
along the polypeptide chain. NR functions are directed by specific activation 
domains termed AF-1 and AF-2 (Gronemeyer et al., 2004a; Flandschin et ai, 2003; 
Rosenfeld et al., 2001; Urquhart et al, 2007). A unique property of NRs which 
differentiates them from other classes of receptors is their ability to directly interact 
with and control the expression of genomic DNA (Giguere, 1999). Consequently 
nuclear receptors play key roles in development and homeostasis of organisms. NRs
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may be classified either according to mechanism or homology (Giguere, 1999; 
Gronemeyer el al., 2004a).
Activation of the acidic AF-1 transactivation domain is ligand-independent or 
constitutively functional via the recognition of other transcription factors and co­
activators. The AF-1 contains sites targeted for phosphorylation by a variety of 
signalling pathways. Activation effects due to phosphorylation are receptor-specific 
and can result in either enhanced or diminished receptor activation. The AF-2 
domain is located within the carboxyl terminus LBD. Although AF-1 and AF-2 are 
capable of regulating transcription alone, full transcriptional activation by AF-2 
requires functional interplay between the two regions. This interaction facilitates 
sustained receptor activation and robust gene transcription through stabilisation of 
helix 12, which prevents premature dissociation of the ligand, and mutual binding of 
co-activators (Francis et al9 2003; Gronemeyer etal, 2004a; Urquhart et al, 2007).
The DBD interacts with DNA response elements (RE) on target genes to modulate 
their transcription. The DBD is GC-rich and contains two zinc finger motifs with a 
carboxyl-terminal extension containing T and A boxes which are critical for 
monomeric DNA binding of the RE half-sites. The DBD is the most highly 
conserved region across the NR superfamily. The first zinc finger contains the 
proximal (or P-box) region which is responsible for high affinity recognition of the 
core half site of the RE. The distal (or D-box) region is located within the second 
zinc finger and is a site which mediates receptor dimerisation (Khan et al, 2003).
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The LBD varies greatly between NRs but all share a common structure of twelve a- 
helices organised around a hydrophobic binding pocket for lipophilic ligand-binding. 
Residues within the binding pocket confer specificity. Ligand-dependent 
transactivation requires the AF-2 domain which is located at the extreme terminus of 
the LBD. The LBD binds an array of small, lipophilic endogenous ligands including 
hormones, fatty acids, oxysterols, bile acids and lipids, together with exogenous 
ligands including drugs and other chemicals (xenobiotics) (Urquhart et al., 2007). 
The LBD is multifunctional with sequences critical for nuclear localisation, receptor 
dimerisation and the binding of heat shock proteins (HSPs), co-regulators and other 
transcription factors. Binding of the ligand triggers the rearrangement of the LBD 
helices which initiates the release of the HSPs and co-repressors (Francis et al., 2003; 
Giguere, 1999; Handschin et al., 2003).
The hinge or D region is located between the DBD and LBD. The hinge region is 
variable in both length and sequence between different NRs. It contains binding 
sequences for co-repressors which are essential for transcriptional silencing. It allows 
for conformational changes in the protein structure once the ligand is bound, and 
provides flexibility to the receptor domains for proper orientation for both RE 
binding and dimer formation (Khan et al., 2003; Rosenfeld et al, 2001).
The REs are comprised of two hexameric nucleotide sequences known as half-sites. 
The sequence, arrangement and spacing of these half-sites determine the 
responsiveness of a gene to the NRs. Steroid NRs typically bind as homodimers 
preferentially recognising half-sites with the sequence AGAACA. NRs which form a
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heterodimer with RXR recognise the half site sequence AGGTCA with variable 
spacing between the two half-sites (Figure 1.5). Receptor specificity is conveyed by 
the nucleotide spacing of the half-sites together with the arrangement as direct (DR) 
(AGGTCA-Nx-AGGTCA), inverted (IR) (AGGTCA-Nx-ACTGGA) or everted 
repeats (ER) (ACTGGA-Nx-AGGTCA), (N is any nucleotide and x is any number of 
residues between 0 and 10) (Khan et aL, 2003). Table 1.2 below illustrates the 
response elements recognised by the key metabolic NRs and identifies the 
mechanisms involved in NR functional redundancy and crosstalk.
Table 1.2: The binding arrangements and response elements recognised by the key 
metabolic NRs together with a summary of the mechanisms involved in NR Cross-talk.
Monomer, 
Homodimer or 
Heterodimor
Half site
recognition
sequence
Response Element Receptor
Crosstalk
Mechanisms
PPARa (NR1C1) Heterolmer AGGTCA DR-1
PPARy (XR1C3) Heterodimer AGGTCA DR-1 PPARyPXR Induction of PPARy by 
activated PXR
LXRu (XR1H3) Heterodimer AGGTCA DR-4 CAR-PXR'LXR Inliibition ofCAR-PXR
LXRp (NR1H2) Heterodimer AGGTCA DR-4 traiscriptional activity by activated LXR
FXR (NR1H4) Heterodimer AGGTCA DR-4 CAR-PXR/FXR FXR aid PXR share agonists;
PXR (NR1I2) Heterodimer AGGTCA & 
AGTTCA
DR-3 (distal enhancer region)
DR*4
FXRtransactivatesCAR- 
PXR target genes
AG(G'T)CA ER-6 (in tlie proximal promoter region) 
ER8 PXR-CAR'TOR PXR-CAR'TOR
CAR (XR1I3) Monomer or 
hetcrodimer
AGGTCA & 
AGTTCA
AGGTCA
DR-3 (distal enhancer region)
DR-4
DR-S
Share response elements.
AG(G'T)CA ER-6 (in the proximal promoter region)
VDR (NR1I1) Heterodimer AGGTCA DR-3 (distal enliancer region)
DR-4
TGAACT ER-6 (in the PXRE ER6 motif in the 
CYP3A4 proximal promoter or in the 
TORRE proximal promoter)
RXR« (NR3B1) Homodimer &
Heterodimer
partner
AGGTCA DR-l
DR-4
HN'F4o (NR2A1) Homodimer AGGTCA DR-1
DR-2
ER« (XR3A1) Homodimer AGAACA IR-3
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Activation of the NRs starts in the cytoplasm where the NRs typically reside bound 
to transcriptional co-repressors. The co-repressors recruit specific histone 
deacetylase-containing complexes, which facilitate the regulation of DNA 
transcription (Legube et al, 2003). Drug ligands pass through the cell membrane, by 
either diffusion or selective transport, and bind to the LED causing dissociation of 
the histone deacetylase-containing complex and receptor translocation to the nucleus. 
Once in the nucleus, the ligand-receptor complex recruits co-activators and fonns 
either a homodimer or in most cases heterodimerises the retinoid X receptor (RXR). 
The homodimer or heterodimer complex then binds to the DNA response elements 
(RE) in the regulatory (promoter and enhancer) regions of target genes (Urquhart et 
al, 2007). NR activation can also be influenced by other mechanisms including 
phosphorylation by cellular kinases in cell signalling pathways and protein-protein 
interactions through contacts with other transcription factors (Spiegelman et al, 
2004).
Inactivated NRs generally form a complex with co-repressors including RIP 140, 
nuclear receptor co-repressor 1 (NCoRl) and silencing mediator for retinoid and 
thyroid hormone receptor (SMRT, also known as NCoR2) which inhibit 
transcriptional activity, often through histone deacetylase recruitment (Francis et al, 
2003; Pascussi et al, 2008). Receptor activation by ligand binding or 
phosphorylation induces a conformational change resulting in co-repressor 
dissociation and co-activator recruitment (Figure 1.6). Co-activators associated with 
NR activation include the pi60 family (SRC-1 (steroid receptor co-activator 1)), 
TIF2, GRIP-1, ACTR), p/CIP, CBP/p300, PGC-1, PRIP, PGC-2 and ARA70
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(Francis et al., 2003; Handschin et ai, 2003; Pascussi et ai, 2008). The specific co­
regulators recruited by NRs depend on the ligand induced conformational changes, 
and the promoter and cellular context (Francis et ai, 2003; McKenna et ai, 1999).
Tissue
Promoter- Chromatin
Specific Remodeling Platform Proteins / HAT Activation Functions Mediator-like Complex
Repression Histone and factor 
deacetylation
Figure 1.6: Activation and repression of nuclear receptors regulated by ligand - control of 
recruitment of either co-activators or co-repressors. From Rosenfeld, M. G. et al. J. Biol. 
Chem., 2001.
Peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-la) 
has recently been shown to play a critical role in xenobiotic metabolism (Pascussi et 
ai, 2008). PGC-la has no intrinsic histone acetyl transferase activity, which prevents 
it from regulating DNA transcription in its own right (Finck et al, 2006; Legube et 
ai, 2003). When PGC-la is docked to transcription factors or NRs, however, it 
provides a platform for recruiting co-activators with histone acetyl transferase
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activity (Finck et aL, 2006; Legube et al, 2003). PGC-la plays a key role in cellular 
energy metabolism through co-ordination of transcriptional programs of 
mitochondrial biogenesis, adaptive thermogenesis and fatty acid (3-oxidation. PGC- 
la is involved in the co-activation of key transcription factors of hepatic 
gluconeogenesis (Glass, 2006; Pascussi et al., 2008). Hepatic PGC-la expression is 
induced by fasting. PGC-1 isoforms affect the activity of multiple NRs including 
PPARy, RXR, GR, FXR, LXR, HNF4a, PXR and CAR (Pascussi et aL, 2008). 
Specific NR co-regulator complexes fine tune the biological response to ligand 
receptor interaction and underpin the variability of gene responses to different 
ligands and metabolic environments (Francis et al, 2003; Gronemeyer et al, 2004a; 
Handschin et al, 2003; Tirana et al, 2005).
Constitutive and inductive expression of drug disposition genes is under co-ordinate 
transcriptional control by NRs. Functional REs for NRs within a gene may bind 
different NRs, e.g. REs in CYP2B, CYP2C and CYP3A can be transactivated by 
PXR, CAR and VDR providing a level of redundancy to environmental xenobiotic 
exposure (Ho et al, 2005; Tirana et al, 2005). PXR and CAR mediated induction of 
CYP2B, CYP2C and CYP3A genes is regulated by GR signalling (Handschin et al, 
2003). NR regulation complexity is highlighted in the modulation of CYP3A4 
expression (Handschin et al, 2003; Ho et al, 2005; Smirlis et al, 2001; Thummel et 
al, 2001; Tirana et al, 2003). The effect of PXR and CAR induction on CYP3A4 
expression is critically dependent on HNF4a acting on the distal enhancer (Pascussi 
et al, 2008; Tirana et al, 2003; Urquhart et al, 2007). The combined actions of the
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transcription factors C/EBPa and AP-1 together with HNFda influence the CYP3A4 
expression (Tirona et al., 2003).
NR mediated induction can be mutually repressed by other NRs and transcription 
factors. PPARy and FXR can repress CAR mediated gene induction by co-activator 
competition. LXRa can directly compete with CAR and PXR on CYP3A and 
CYP2B NR REs to suppress transcription. An emerging theme in regulation of gene 
expression is the interconnected regulation of NR expression by other NRs. HNF4a, 
and GR are particularly important in regulating the expression of other ligand- 
activated transcription factors such as PXR, CAR and FXR. PXR also regulates the 
expression of CAR and itself (Francis et al, 2003; Gronemeyer et al, 2004a; 
Pascussi et al, 2008; Tirona et al, 2005). The complex nature of the metabolic NRs 
involved in bile acid metabolism and detoxification together with the drug 
disposition genes and transporters regulated by the activation of the NRs is outlined 
in Figure 1.7, below.
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Figure 1.7: Metabolic NRs involved in bile acid metabolism: Green lines = transcriptional 
activation, red lines = transcriptional suppression (A) Genes activated by bile acid dependent 
mechanisms. (B) Genes suppressed by bile acid-mediated mechanisms. Discontinuous 
green lines = bile acid synthesis. Red crosses over green lines = bile acid-mediated 
suppression of otherwise stimulatory pathways. From Eloranta et a!., Arch Biochem Biophys, 
2005.
The Pis ritonavir (RTV) and atazanavir (ATV) have been shown to be substrates 
for/activators of the NRs including PXR and CAR (Dussault et al., 2001; Healan- 
Greenberg et ai, 2008; Lehmann et ai, 1998). Pis have also been shown to impact 
several molecular pathways key to lipid metabolism including intra-nuclear
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transcription factors and the nuclear proteasome (Lagathu et ah, 2005; Mallon, 
2007). Previous studies have focused on the roles of PXR and CAR in the 
metabolism of RT V and ATV with limited investigation of the role of the metabolic 
NRs controlling lipid and bile homeostasis in response to PI metabolism. FXR and 
LXRa are master regulators of cholesterol homeostasis, and modulate the 
transcription of many key genes involved in drug and lipid metabolism including the 
sterol regulatory element binding protein-1c (SREBP-lc), the most abundant sterol 
regulatory binding protein (SREB) isoform in adult human liver and a key player in 
lipogenesis (Hui, 2003; Liang etal, 2001; Osborne, 2000).
RTV is no longer used as a PI in highly active antiretroviral therapy (HAART) but it 
is used at low dose to boost the activity of other Pis through its inhibition of the 
cytochrome P450 (CYP) enzyme CYP3A4. RTV has no intrinsic antiviral activity at 
low dose but it has been widely implicated with hypertriglyceridaemia (Kim et al, 
2006b; Mallon, 2007; Purnell et ai, 2000). The pathogenesis of the RTV-induced 
effects has been linked to the effect of RTV on hepatic and adipocyte SREBs 
including SREBP-lc (Hui, 2003; Liang et al., 2001; Osborne, 2000). RTV has also 
been associated with enhancing the formation of veiy low density lipoproteins 
(VLDL). A study in the human adipocyte cell line, Simpson Golabi Behmel 
Syndrome (SGBS), has shown that ATV is associated with fewer signs of the 
deleterious metabolic side effects seen in lipodystrophy (Kim et al, 2006b). Clinical 
trials have also shown that ATV has a better lipid profile than other Pis including 
RTV (Flammer et al., 2009; Fuster et al., 2005). Co-infection with HIV and hepatitis 
C virus (HCV) increases the risk of fat redistribution abnormalities and the other
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metabolic complications associated with HAART (Duong el ai, 2001). Differences 
in the pharmacokinetics of many ARVs including ATV have been reported between 
HIY+ individuals and healthy volunteers (Dickinson et al, 2008). Current research 
into metabolic disorders has included investigations into the role of NRs including 
PXR, PPARa, PPARy, FXR, LXR and VDR in these disorders (Cha et al, 2007; 
Edwards et aL, 2002; Fiorucci et al., 2007; Francis et al, 2003).
1.6.2 Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR)
The pregnane X receptor (PXR, NR1I2) is expressed in the liver (predominantly), 
small intestine, colon, kidney, lung, uterus, ovary, breast, placenta and lymphocytes 
(Chang et al, 2005; Francis et al, 2003; Tirona et al, 2005). It is activated by a 
broad range of structurally diverse xenobiotics and endogenous ligands. PXR plays a 
key role in the detoxification and clearance of xenobiotics; PXR REs have been 
identified in CYPs, drug efflux transporters and phase II drug metabolising enzymes 
(Goodwin et al, 2002; Maglich et al, 2002; Waxman, 1999),
PXR is involved in the up-regulation of CYP1A1, CYP1A2, CYP2A4, CYP2A6, 
CYP2B6, CYP2B10, CYP2C8, CYP2C9, CYP2C19, CYP3A4, CYP3A7, CYP3A11 
and CYP24A1 and the down regulation of CYP7A1 (Handschin et al, 2003; Luo et 
al, 2002; Maglich et al, 2002; Plant, 2007; Staudinger et al, 2001; Tirona et al, 
2005). PXR target genes also include the UDP-glucoronosyltransferases (UGTs) 
1A1, 1A3, 1A4 and 1A6, glutathione S-transferase A2 (GSTA2),
dehydroepiandrosterone sulphotransferase (SULT2A1) and organic anion 
transporting polypeptides (Chang et al, 2005; Maglich et al, 2002; Rosenfeld et al, 
2001). PXR initiates up-regulation by the binding of the PXR-RXR heterodimer to a
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xenobiotic responsive enhancer module (XREM) on its target CYP gene. PXR 
initiates increased expression of the drug transporters ABCB1 and ABCC2 (Tirona et 
ai, 2005). Recent studies suggest that many clinically significant drug-drug 
interactions involving CYP3 A induction are largely a consequence of drug-mediated 
activation of PXR (Luo et ai, 2004; Matic et al., 2007). PXR RE sequences 
identified in the promoter region of the CYP3A4 gene have indelibly linked its 
transcriptional regulation to the activation of PXR (Lehmann et al, 1998). Activators 
of PXR are mainly comprised of substrates and inhibitors of CYP3A4 which 
provides a mechanistic loop for effective drug clearance (Dussault et al, 2001).
PXR is associated with the co-repressors: small heterodimer partner (SHP), RIP 140, 
NCoR and SMRT which inhibit transcriptional activity (Francis et al, 2003; Pascussi 
et al, 2008). Co-activators associated with PXR activation include SRC-1, GRIP, 
PGC-la and PBP (Francis et al, 2003; Handschin et al, 2003; Pascussi et al, 2008). 
Increased gene transcription by PXR is initiated by ligand binding to the receptor 
followed by cytoplasmic nuclear translocation. HIV Pis are known activators of PXR 
and have been shown to increase expression of CYP3A4. Indinavir and nelfinavir are 
not thought to bind PXR (Dussault et al, 2001).
PXR activation involves the ligand binding to the receptor, heterodimerisation with 
RXR, binding of the RXR heterodimer to REs of target genes, release of co-repressor 
proteins, and recruitment of co-activators and transcription factors. PXR-RXR 
heterodimers bind to hexameric sequence pairs (S’-AG^/T^TCAG7) arranged as a
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DR3 in the distal enhancer region, DR4, ER6 in the proximal promoter region, or 
ER8.
In addition to its role as a xenobiotic sensor, PXR has been linked to the regulation of 
lipid homeostasis. Activated PXR inhibits forkhead box A2 (FoxA2) transcriptional 
activity leading to a decrease in fatty acid metabolism (Pascussi el aL, 2008). It has a 
regulatory role in lipid and cholesterol pathways via activation by endogenous sterol 
metabolites. PXR is activated in the presence of high levels of bile acids, especially 
lithocholic acid (LCA), and oxysterols in the liver (Staudinger el aL, 2001). PXR 
activation results in down-regulation of CYP7A1, the rate-limiting enzyme involved 
in the conversion of cholesterol to bile acids, a role also performed by FXR. Recent 
data suggests that FXR and PXR may co-operate to promote robust liver 
detoxification in the presence of high levels of bile acids to facilitate LCA clearance 
(Staudinger el aL, 2001). PXR also plays an important role in lipogenesis through its 
activation of the fatty acid transporter Cluster of Differentiation 36 (CD36) and 
accessory lipogenic enzymes including Stearoyl-CoA desaturase 1 (SCD-1) and long 
chain free fatty acid elongase (Zhou el al, 2006).
PXR is implicated in the regulation of gluconeogenic gene transcription (Kodama el 
al., 2004; Pascussi el al, 2008). Regulation of gluconeogenic enzymes by PXR 
occurs through crosstalk with the forkhead transcription factor (FOXOl). FOXOl is 
an insulin responsive transcription factor which increases gluconeogenic gene 
transcription including phosphoenolpyruvate carboxykinase 1 (PEPCK1) and 
glucose-6-phosphatase (G6Pase). FOXOl activity is inhibited through insulin
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signalling upon feeding. PXR activation inhibits FOXOl activity by blocking the 
binding of FOXOl to insulin response sequences in the promoters of target genes. 
Crosstalk regulation at FOXOl may be needed to control the balance between the 
cofactors NADPH and NADH. PXR inactivation of gluconeogenesis would increase 
availability of NADPH for use by drug metabolising enzymes including CYP3A4, 
for which NADPH is an essential electron donor (Kodama et al, 2004).
Many xenobiotics interact with both PXR and CAR as agonists, inverse agonists or 
activators. Phenobarbital, oestrogen and the oestrogen precursor, DHEA, are 
activators of both PXR and CAR. Androstanol is a PXR activator but an inverse 
agonist of CAR. Bile acids including cholic acid, 12-ketocholic acid and its 
derivatives are primary ligands of LXR and FXR, activators of PXR and suppressors 
of CAR. PXR and CAR induce an overlapping series of genes and, as a consequence, 
primary activation pathways are dependent upon the respective levels of the 
particular receptor. CITCO (6-(4-chlorophenyl)imidazo[2,1 -b] [ 1,3]thiazole-5 - 
carbaldehyde-(9-(3,4-dichlorobenzyl) oxime) has been developed as a specific CAR 
activator to discriminate between the activation of human PXR or human CAR 
(Pascussi et al., 2008).
The constitutive androstane receptor (CAR, NR1I3) is expressed in the liver, 
intestine and lung, and is involved in the up-regulation of the drug metabolising 
genes CYP1A1, CYP2A4, CYP2A6, CYP2B6, CYP2B10, CYP2C9, CYP2E1, 
CYP3A4 and CYP3A11. CAR is also implicated in the increased expression of the 
drug transporters ABCC2, ABCC3 and ABCC4 (Tirona et al, 2005). CAR binds to
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hexameric REs (S’-AGIG/TOTCA-S’) arranged as a DR3 in the distal enhancer 
region, DR4, DR5 (5’-AGGTCA-3’) (as a heterodimer with RXR or ER6 (5*- 
AG^/TOTCA-S’) in the proximal promoter region (Francis et at., 2003; Giguere, 
1999; Goodwin et al7 2004; Pascussi et aly 2008).
CAR activity is suppressed by its endogenous inverse agonist ligands androstenol 
and androstanol which act by causing the dissociation of co-activator proteins 
(Giguere, 1999). CAR activation by phenobarbital reverses the action of the 
endogenous inverse agonists and suggests that CAR, like PXR and PPARa, 
participates in a NR mediated CYP induction pathway in response to exogenous 
xenobiotics and endogenous lipids and steroids (Giguere, 1999). Activated CAR 
translocates to the nucleus where it initiates the transcription of genes including 
members of the CYP2B family. CAR plays an important role in regulating bilirubin 
clearance and bile acid detoxification via crosstalk with PXR, FXR, LXR and SHP 
(Pascussi et al, 2008).
1.6.3 Farnesoid X Activated Receptor (FXR) and Liver Oxysterol Activated Receptor 
(LXR)
The farnesoid X activated receptor (FXR, NR1H4) is expressed in the liver, intestine, 
kidney, adrenal cortex, gall bladder and vascular endothelium (Francis et al, 2003; 
Gronemeyer et al, 2004a; Handschin et al, 2003; Pascussi et al, 2008). FXR is 
involved in the down regulation of CYP7A1 and CYP8B1. FXR regulates the 
increased expression of ABCC2 and ABCB11 (the bile salt export pump, BSEP). 
FXR shares agonists with PXR leading to increased xenobiotic metabolism by bile
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acids. FXR also transactivates PXR and CAR target genes (Pascussi et al, 2008; 
Tirona et al, 2005).
FXR and the liver X activated receptor alpha (LXRa) play a pivotal role in total body 
cholesterol homeostasis. FXR, the counterbalance of hepatic LXR action, is activated 
by bile acid accumulation resulting from the LXR-mediated conversion of 
cholesterol to bile acids. Bile acids are important for the solubilisation and transport 
of dietary lipids and are the major products of cholesterol catabolism. High 
concentrations of bile acids can be toxic to the cell and FXR functions to minimise 
this by inhibiting further bile acid production. Inhibition of bile acid synthesis is 
achieved by FXR down regulating CYP7A1, the rate-limiting enzyme in bile acid 
synthesis, through indirect signalling involving the increased expression of the SHP- 
1 liver receptor homolog-1 (LRH-1) pathway. SHP-1 represses CYP7A1 expression 
by binding to promoter sequences and preventing further RE binding of activated 
LXR (Eloranta et aL, 2005).
FXR facilitates the elimination of bile acids through the activation of bile acid 
inducing enzymes and transport processes including UGT2B4, SULT2A1, BSEP and 
the intestinal bile acid binding protein (IBABP) (Francis et ai, 2003; Giguere, 1999; 
Pascussi et al., 2008). FXR impacts drug disposition genes via the formation of 
heterodimers with RXR and has a similar mechanism of action to PXR. FXR-RXR 
heterodimers bind to hexameric sequence pairs (55~AGGTCA-3’) arranged as a DR4 
or an IR1 (Francis et al., 2003; Giguere, 1999; Gronemeyer et aL, 2004a; Pascussi et 
al.9 2008).
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Recent publications have shown that FXR activation has positive effects on glucose 
metabolism. Positive effects of FXR agonists on glucose tolerance are brought about 
through the hepatic activation of FXR, the resulting repression of gluconeogenic 
genes (PEPCK and G6Pase) and increased hepatic glycogen synthesis. FXR 
activation improves serum lipid profiles through suppression of hepatic triglyceride 
synthesis via repression of SREBP-lc and increased expression of lipid metabolism 
genes including PLTP, LCAT and ApoC-II (Fiorucci et ah, 2007). SREBP-lc is a 
target gene of FXR via a SHP-1 dependent pathway. The consequence of FXR 
down-regulation of SREBP-lc in vivo would be the repression of hepatic triglyceride 
and fatty acid synthesis (Zhang et al., 2008), although FXR mediated inhibition of 
fatty acid synthesis may be transient. Prolonged exposure to high levels of bile acids 
or potent agonists does not appear to have the same beneficial effects on plasma 
lipids as short term exposure. SHP-1 mediated suppression of SREBP-lc via FXR 
activation appears to be overcome through the direct activation of fatty acid synthase 
(FAS) by FXR which is necessary for sufficient fatty acid synthesis under states of 
cholesterol and bile acid excess to avoid cholesterol toxicity (Fiorucci et al, 2007).
LXRa (NR1H3) is expressed in the liver (predominant), intestine, kidney, adipose 
tissue, macrophages, ovary, brain, lung and spleen. LXRp (NR1H2) has ubiquitous 
tissue and organ expression. LXRa is a regulator of cholesterol homeostasis in the 
liver and macrophages (Gronemeyer et al, 2004a; Kalaany et aL, 2006; Pascussi et 
al, 2008). It facilitates the processing and storage of cholesterol by up-regulating the 
cytochrome P450 7A1 enzyme (CYP7A1) and is implicated in the increased 
expression of ABCA1 (cholesterol efflux regulatory protein, CERP), ABCG1,
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ABCG5 and ABCG6 (Eloranta et al., 2005; Pascussi et al, 2008; Tirona et al, 
2005). LXRa is also abundant in adipose tissue, where its activation has been shown 
to increase basal glucose uptake and the incorporation of TGs into lipid droplets 
(Lehrke et al., 2005). The most potent activating oxysterol ligands of LXRa have 
been identified as 24(S), 25-epoxycholesterol, 22(R)-hydroxycholesterol and 24(S)- 
hydroxycholesterol (Edwards et al., 2002). These potent ligands are known to 
activate both LXRa and LXRp (Bradley et al, 2005).
The transcriptional activity of LXRa is induced by elevated levels of naturally 
occurring oxysterols, which increase proportionally to cellular cholesterol content, 
and 6a-hydroxy bile acids (Eloranta et al., 2005; Francis et al., 2003). LXR responds 
to high cholesterol levels by increasing fatty acid synthesis to increase the formation 
of cholesterol esters, rendering the excess cholesterol pool biologically inactive 
(Giguere, 1999; Pascussi et al, 2008; Urquhart et al, 2007). LXR also facilitates 
efflux of cholesterol from the periphery, including macrophages, through the 
increased expression of ABC transporters. Induction of ABC transporters increases 
the transfer of cholesterol and phospholipids to apolipoprotein A-I (ApoA-I) 
containing lipoproteins. Activation of LXRa decreases intestinal absorption of 
cholesterol mediated through the induction of ABC transporters including ABCG5 
and ABCG8 (Kalaany et al, 2006; Pascussi et al, 2008).
The effects of LXRa on fatty acid synthesis are mediated through the increased 
expression of SREBP-lc, a stimulator of lipogenesis. SREBIMc is a transcription 
factor which has been previously associated with PI induced lipodystrophy (Bastard
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et aL, 2002; Telenti et al, 2002). Increased production of liver triglycerides 
alongside transient increases in plasma levels resulting from the up-regulation of 
SREBP-lc remains a hurdle in the development of therapeutic LXRa agonists. LXR 
mediated improvement in glucose tolerance is associated with decreased expression 
of rate-limiting enzymes of gluconeogenesis including PEPCK and G6Pase, and the 
induction of genes for glucose uptake and utilisation in the liver (L-GK) and 
periphery (GLUT4) (Kalaany et aL, 2006).
Studies in LXR null mice identified the function of LXR as a sensor of cellular 
oxysterols and a regulator of the target gene expression of CYP7A1, ABCG1, 
ABCA1, ApoE, CETP, SREBP-lc, LPL, LXRa self-regulation, FAS, ABCG5, 
ABCG8, ApoC-I, ApoC-II, ApoC-IV and PLTP (Edwards et aL, 2002; Joseph et aL, 
2003). These LXR target genes all encode proteins which have major roles in 
controlling cholesterol and fatty acid homeostasis in tissues which include the liver, 
intestine, macrophages and possibly adipose tissue (Edwards et aL, 2002). Studies in 
murine models have shown that LXR agonists exert desirable antiatherogenic effects 
in macrophages, but they also increase hepatic and sermn triglyceride levels (Bradley 
et aL, 2005; Peet et aL, 1998a; Peet et aL, 1998b). The hepatic expression of key 
fatty acid metabolism genes involved in LXRa mediated lipogenesis is reduced in 
LXRa knockout mice, these include SREBPl-c, FAS and SCD-1. LXRfl knockout 
mice, however, do not show a similar phenotype (Bradley et aL, 2005; Peet et aL, 
1998b).
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LXR-RXR heterodimers bind to DR4 (S’-AGGTCA-S’) REs (Francis et al, 2003). 
LXRa and LXRp transcriptional activity is induced by naturally occurring oxysterols 
and 6a-hydroxy bile acids (Eloranta et al., 2005; Francis et al., 2003). LXRs regulate 
the metabolism of several important lipids, including cholesterol and bile acids. 
LXR-f3 is an oxysterol-activated member of the LXR subfamily of the nuclear 
receptor superfamily of transcription factors. Like its genetic homologue LXRa, 
LXRp is an important regulator of cholesterol homeostasis in the liver and 
macrophages (Bradley et al., 2005; Kalaany et al, 2006; Pascussi et al., 2008). 
Schultz et al hypothesised that LXRa was capable of compensating for the loss of 
LXRp in LXR(3 double knockout mice as there was no obvious loss of lipid 
phenotype in these mice in response to cholesterol feeding (Schultz et al, 2000). 
LXRp was unable to compensate for the loss of LXRa in LXRa deficient mice in the 
regulation of SREBPl-c expression in the presence of LXR and RXR agonists and 
dietary cholesterol, suggesting that LXRa is the more important regulator of this 
pathway (Millatt et al, 2003).
1.6.4 Retinoid X Receptor (RXR)
The retinoid X receptor (RXR) family of NRs is comprised of three isotypes, a, p 
and y. RXRa is the dominant RXR isoform and the preferred heterodimer partner of 
metabolic NRs including the PPARs, PXR, VDR, LXRs and FXR. Along with other 
members of the RXR family, 50-80% of retinoids are stored in liver stellate cells. 15- 
20% of the remaining retinoids are stored in adipose tissue via direct import from the 
bloodstream through the cellular retinol-binding protein, and via the LPL-mediated 
uptake of retinyl esters from chylomicrons. RXRp and RXRy have a role in 
regulating the effects of retinoic acid but are outside the scope of this research.
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RXRa. (NR2B1) is ubiquitously expressed and is involved in the up-regulation of 
drug metabolising genes through its role as a heterodimer partner of other NRs 
(Giguere, 1999; Gronemeyer el ai, 2004a; Pascussi et aL, 2008; Tirona et aL, 2005). 
RXRa can form pennissive heterodimers (can be activated by either the partner 
ligand or RXRa ligand) or non-permissive heterodimers (can only be activated by the 
partner ligand). FXR and LXRa form pennissive heterodimers with RXRa (Eloranta 
et ah, 2005). RXRa is activated by 9-cis retinoic acid, a product of vitamin A 
(retinol) metabolism which can promote the formation of RXR-RXR homodimers 
which bind to a DR1 RE (Giguere, 1999).
Phytanic acid, a fatty acid metabolite of chlorophyll found in the human diet, is a 
specific RXR ligand (Giguere, 1999). RXR affinity for fatty acids negates the 
possibility that RXR, like its heterodimer partners, including LXRa, FXR and the 
PPARs, also operates as a sensor of energy metabolism with the potential to drive 
metabolic responses through the concerted activation of RXR heterodimers (Kassam 
et al, 2003; Repa et al,, 2000). The similarity of effects may be due to the 
preferential activation of the RXR/PPARy heterodimer by RXR activators. RXRa 
selective ligands known as rexinoids have been suggested as potential anti-diabetic 
agents for the treatment of insulin-independent (Type II) diabetes (Vivat-Hannah et 
aLt 2005). The therapeutic potential for the development of RXRa ligands to treat 
long term disorders in counterbalanced by the toxic side effects of retinoids, 
including bone toxicity and hyperlipidaemia, although the latter is more widely 
associated with the retinoic acid receptors (RARs) (Vivat-Hannah et al, 2005). The 
RXRa ligand, 9-cis retinoic acid, has been shown to be a potent activator of LXR
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transcriptional activity (Giguere, 1999). Furthermore, the HIV Pis RTV, saquinavir 
(SQV) and nelfinavir (NFV) have been shown to block adipogenesis and increase 
lipolysis in vitro in studies in the presence of insulin and agonists for RXR and 
PPARy (Lenhard et al., 2000). RXRa plays roles in a variety of processes including 
embryonic patterning and organogenesis, cell proliferation and differentiation.
1.6.5 Vitamin D Receptor (VDR)
The vitamin D receptor (VDR, NR1I1) is a la-25 dihydroxy vitamin D3 activated 
member of the NR superfamily of transcription factors. It plays critical roles in 
calcium homeostasis, bone development and mineralisation, together with a control 
of cell growth and differentiation. VDR is expressed in the liver, small intestine, 
bone, kidney and parathyroid gland, and is involved in the up-regulation of the drug 
metabolising genes CYP2B6, CYP2C9, CYP3A4, CYP24A1 and SULT2A1 
(Martinez-Jimenez et al., 2007; Pascussi et al., 2008; Tirona et al., 2005). VDR is 
also implicated in the increased expression of the drug transporter ABCC3 in the 
intestine (Makishima et al, 2002; Pascussi et al., 2008).
VDR forms non-permissive heterodimers with RXR (Gronemeyer et al, 2004a). 
VDR-RXR heterodimers bind to hexameric REs (S’-AG^/T^CA-S5) arranged as a 
DR3 in the distal enhancer region, DR4, ER6 (in the PXRE ER6 motif of the 
CYP3A4 proximal promoter), ER6 (5 ’ T G A ACT caaagg-AGGTCA-3 ’) in the 
VDRRE proximal promoter region or IR (Makishima et al., 2002; McKenna et al, 
1999; Pascussi et al, 2008).
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Bile acids including lithocholic acid are VDR agonists, and have been suggested to 
regulate intestinal CYP3A4 expression (Urquhart et al, 2007). An observation that 
lot-25 dihydroxy vitamin D^-induced CYP3A4 expression in intestinal Caco-2 cells 
indicated that VDR regulated this drug metabolising enzyme (Bodin et al, 2005; 
Thummel el al., 2001). Given the co-expression of VDR and CYP3A4 in 
enterocytes, dietary vitamin D may modulate intestinal first-pass drug metabolism.
PXR, CAR and VDR share REs which initiate a mechanism for NR crosstalk. The 
consequences of this crosstalk surround the catabolism of vitamin D hormones by 
CYP3A4 leading to decreased levels of vitamin D and its metabolites together with a 
disruption of VDR target genes by xenobiotics (Pascussi et al, 2008). The 
deleterious effects of long-term drug therapy on vitamin D blood levels and bone 
mineralisation have recently been reported (Pascussi et al, 2008; Xu et al, 2006). 
HAART (especially Pis) has been suspected to play a part in this process as 
significant bone disorders are common in HIV infected individuals (Fernandez- 
Rivera et al, 2003). Three mechanisms, which may not be mutually exclusive, have 
been proposed to explain these long-tenn therapy effects but further investigation 
will be required for the proof of concept. The first mechanism proposed involves 
drug mediated inhibition of vitamin D3 bioactivation resulting from decreased 25- 
hydroxylation of vitamin D3 in the liver. The second proposed mechanism is PXR 
agonist induced crosstalk between PXR-VDR leading to up-regulation of CYP24. 
The third potential mechanism involves the inactivation of la-25 dihydroxy vitamin 
D3 by the induction of intestinal CYP3A4 (Pascussi et al, 2008).
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1.6.6 Peroxisome Proliferator Activated Receptor (PPAR)
The peroxisome proliferator activated receptor (PPAR) has three isotypes, a, y and 
(3/5. The role of PPARa (NR1C1) in metabolic gene regulation and dyslipidaemia has 
been investigated (Barbier et al, 2003; Duval et aL, 2007). PPARa is activated by a 
wide range of endogenous and dietary fatty acids (FAs) and their derivatives 
including prostaglandins, leukotrienes and eicosanoid derivatives of the lipo- 
oxygenase or cyclo-oxygenase pathways, and non-steroidal anti-inflammatory drugs 
(NSAIDs) (Francis et al, 2003; Giguere, 1999; Gronemeyer et al., 2004a). PPARs 
regulate lipid, cholesterol and glucose homeostasis through co-ordination of gene 
transcription effects in liver, muscle and adipose tissue. PPARs share common 
ligands but with variable affinity, this together with differential tissue expression and 
distinct co-activator recruitment preference results in isotype specific effects on 
target gene expression. PPARa directs lipids to the liver whereas PPARy initiates 
lipid storage in peripheral tissues to maintain balance between energy storage and 
utilisation (Giguere, 1999).
PPARs may regulate metabolic gene expression by the formation of a NR 
heterodimer with LXRa (Giguere, 1999). PPARs have been implicated in metabolic 
diseases such as hyperlipidaemia, insulin resistance, coronary artery disease, obesity, 
diabetes and metabolic syndrome. Metabolic syndrome is characterised by visceral 
fat accumulation, hyperlipidaemia, elevated triglycerides, elevated blood pressure 
and hyperglycaemia, symptoms similar to those in HADL (Francis et al, 2003; 
Giguere, 1999; Villarroya et al., 2007). PPARa directs lipids to the liver where it is 
involved in energy homeostasis, inflammatory responses and fatty acid catabolism.
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PPARa is expressed in the liver (predominant), kidney, heart, skeletal muscle, 
adipose tissue, monocytes and other metabolically active tissues (Francis et al, 2003; 
Pascussi et al, 2008).
PPARa enhances the uptake and transport of circulating fatty acids (FAs) through 
modulation of target genes including apolipoprotein A-I (ApoA-I), fatty acid binding 
proteins and lipoprotein lipase (LPL). PPARa regulates lipid homeostasis through 
the above mechanisms (Francis et al, 2003) and bile acid homeostasis through its 
action on bile acid transport genes including BSEP and Ntcp, and the metabolism 
genes OATP1 and MDR2 (Tirona et al, 2005). PPARa induction leads to the 
repression of ApoC-III (Duval et al, 2007; Feldman et al, 2008; Yamada et al, 
2007).
Activation of PPARa by dietary polyunsaturated fatty acids (PUFAs) and the fibrate 
class of drugs has been shown to have beneficial effects on circulating triglyceride 
levels and plasma lipid profiles. PPARa is involved in energy homeostasis, 
inflammatory responses and FA catabolism. It is involved in the up-regulation of 
metabolising enzymes including CYP4A11 and acyl Co A oxidase and is also 
implicated in the increased expression of UGT1A9, UGT2B4 and ABCB4 (Tirona et 
al, 2005). Fatty acid (3-oxidation also occurs in skeletal muscle but PPARa is not the 
sole regulator at this site. PPARa also effects gluconeogenesis in the liver and 
pancreatic islets by promoting the use of pyruvate in gluconeogenesis rather than 
fatty acid synthesis through up-regulation of pyruvate dehydrogenase kinase 4 
(PDK4) (Francis etal, 2003; Giguere, 1999).
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SREBP-lc is a natural stimulatory ligand of PPARy (NR1C3) and is thus an inducer 
of PPARy mediated adipogenesis and adiponectin production (Lee et ai, 2003). Pis 
have been shown to inhibit SREBP-lc and impact PPARy mediated glucose and lipid 
metabolism (Bastard et al, 2002; Telenti et al.9 2002). At the molecular level, 
adiponectin expression is stimulated by the PPARy/SREBP-lc pathway. Adiponectin 
acts by enhancing the suppression of insulin-induced hepatic gluconeogenesis whilst 
increasing FFA p-oxidation and insulin-dependent transport in muscle (Iwaki et al, 
2003). Low levels of adiponectin and its mRNA expression have been shown in 
conditions associated with insulin resistance and fat redistribution, including HADL 
(Haque et al, 2002). The effect of RTY on PPARy has been associated with 
decreased adipogenesis, lipogenesis and increased lipolysis, which together with a 
decrease in adipocyte LPL mRNA levels have been implicated in the dyslipidaemia 
and insulin resistance mechanisms of HADL (Carr, 2000; Lenhard et al., 2000).
PPARy is ubiquitously expressed and has three isoforms PPARy 1, PPARy2 and 
PPARy3 (Francis et al., 2003; Pascussi et al., 2008). PPARy 1 is expressed in adipose 
tissue (predominant), large intestine and haematopoietic cells (low levels are found 
in kidney, liver, pancreas, small intestine, skeletal and smooth muscle), PPARy2 
expression is restricted to white adipose tissue (where it comprises 30% of total 
PPARy), PPARy3 is expressed in the large intestine and macrophages (Francis et al., 
2003; Pascussi etal, 2008). PPARy is involved in energy homeostasis, inflammatory 
responses, adipogenesis and the storage of fatty acids (Francis et al, 2003; Giguere, 
1999). PPARy is involved in the up-regulation of CYP4B1 and is also implicated in 
the increased expression of ABCC1 (Tirona et al, 2005).
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PPARy is a major regulator of adipocyte differentiation, the subsequent uptake and 
storage of lipids in the mature adipocyte, and a major regulator of insulin sensitivity. 
Activation of PPARy promotes cell cycle arrest through the induction of cell cycle 
inhibitors together with the repression of cyclins and inhibitors of cyclin-dependent 
kinase. Adipose differentiation related protein, a PPARy target gene, is up-regulated 
during pre-adipocyte to mature adipocyte differentiation and is essential for the 
maintenance of lipid droplet structure (Francis et al, 2003; Khan et aL, 2003).
PPAR5 is ubiquitously expressed and is involved in glucose and lipid metabolism 
(Fredenrich et aL, 2005; Kota et ah, 2005). In the liver, PPARS’s major function is 
the promotion of glycolysis (Lehrke et aL, 2005). PPAR5 induction is associated 
with up-regulated FA (3-oxidation, increased PIDL cholesterol and elevated 
uncoupling protein (UCP) expression, together with a decrease in TGs (Kota et aL, 
2005; Lee et aL, 2003). Increased HDL cholesterol via PPAR8 induction is achieved 
through its up-regulation of ABCA1 mRNA expression (Takahashi et aL, 2007). A 
single nucleotide polymorphism (SNP), 294T/C, has been identified in exon 4 of the 
PPAR5 gene, which has been associated with elevated LDL cholesterol and 
decreased HDL cholesterol in hyperlipidaemic males who are homozygous for the 
rare C allele (Takahashi et aL, 2007).
Peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-la) 
has been shown to play a critical role in xenobiotic metabolism (Pascussi et aL, 
2008). It has a key role in cellular energy metabolism through co-ordination of 
transcriptional programs of mitochondrial biogenesis, adaptive thennogenesis and
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FA p-oxidation and is involved in the co-activation of key transcription factors of 
hepatic gluconeogenesis (Glass, 2006; Pascussi et aL, 2008). PGC-la affects the 
activity of multiple NRs (including PPARy, RXRa, FXR, LXRa, HNF4a, PXR and 
CAR) to fine tune the biological response to ligand receptor interaction and underpin 
the variability of gene responses to different ligands and metabolic enviromnents 
(Francis et al., 2003; Gronemeyer et aL, 2004a; Handschin et al., 2003; Pascussi et 
ah, 2008; Tirona et al, 2005).
PPARa and PPARy impact drug disposition genes via the fonnation of heterodimers 
with RXR which bind to peroxisome proliferator REs (PPRE) (55-AGGTCA-3’) 
arranged as a DR1 in the target gene (Francis et al, 2003; Giguere, 1999; Urquhart el 
al, 2007). PPREs have been in genes controlling all aspects of lipid and 
carbohydrate metabolism (Giguere, 1999). Ligand binding to PPARs and their 
dimerisation partner RXR results in permissive transcriptional activation (Tirona et 
al, 2005). PPARs may regulate gene expression by the formation of a NR 
heterodimer with LXRa (Giguere, 1999).
1.6.7 Hepatic Nuclear Factor-4a (HNF4a)
Hepatic nuclear factor 4a (HNF4a, NR2A1) is expressed at high levels in the liver, 
small intestine, pancreas and kidney, but only low levels are found in the testes 
(Giguere, 1999). HNF4a is involved in the up-regulation of the drug metabolising 
genes CYP2C9, CYP2B6, CYP2A6, CYP2D6, CYP3A1, CYP3A16, CYP3A23, 
CYP3A4 and CYP7A1. HNF4a is also implicated in the increased expression of 
ABCB1, PXR, CAR, FXR and PPARa (Pascussi et al, 2008; Tirona et al., 2005),
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HNF4a is a member of the NR superfamily critical to the maintenance of hepatic 
phenotype. It functions as a homodimer to DRl-HREs and is constitutively active 
through its binding of integral fatty acids. It regulates the expression of genes 
involved in cholesterol, xenobiotic, carbohydrate, lipid and amino acid metabolism 
(Giguere, 1999). HNF4a is a critical regulator in the constitutive expression of CYP 
genes. HNF4a constitutive induction is achieved through interactions with steroid 
hormone co-activators and p300, indicating that an endogenous ligand found in most 
cell types regulates its activity (Giguere, 1999). Induction of gene transcription by 
PXR and LXR appears to require HNF4a activity (Tirona et ah, 2003; Urquhart et 
al, 2007).
1.6.8 Glucocorticoid Receptor (GR)
The glucocorticoid receptor (GR, NR3C1) has ubiquitous tissue expression and is 
involved in the up-regulation of the clinically important drug metabolising genes 
CYP2C9, CYP2B6, CYP3A4 and CYP3A5. GR is also implicated in the increased 
expression of PXR, FXR and CAR (Tirona et al., 2005). A detailed review of GR 
activation has not been included in this research.
1.7 Aims of the Thesis
The specific objectives of this research were two-fold. The first objective was to 
detennine direct effects of the Pis RTV and ATV on the metabolic NRs with a 
specific focus on the role of FXR, LXRa and PPARa in the metabolic complications 
associated with the use of these drugs. NR effects were detennined by in vitro 
methods which measured both the effects on specific and downstream target gene 
expression, and the differences in cellular transport of each PI. The effects on gene
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expression were further evaluated by evaluating the effects of antagonism and 
knockdown by small interfering RNA (siRNA) on gene expression. The second 
objective was to determine whether or not polymorphisms previously associated with 
metabolic complications in non-HIV infected cohorts influenced the changes in lipid 
outcomes of an Italian HIV patient cohort which had been switched from a boosted 
ATV regimen to an unboosted ATV regimen.
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2.1 Introduction
Nuclear receptors (NRs) are present in many tissues of the body including 
hepatocytes (Tirona et al., 2005; Urquhait et al, 2007). The protease inhibitors (Pis) 
ritonavir (RTV) and atazanavir (ATY) have been shown to be substrates 
for/activators of the NRs including the pregnane xenobiotic activated receptor (PXR) 
and the constitutive androstane receptor (CAR) (Dussault et al., 2001; Healan- 
Greenberg et al., 2008; Lehmann et al., 1998). Pis have also been shown to impact 
several molecular pathways key to lipid metabolism including intra-nuclear 
transcription factors and the nuclear proteasome (Lagathu et al, 2005; Mallon, 
2007). Previous studies have focused on the roles of PXR and CAR in the 
metabolism of RTV and ATV with limited investigation of the role of the metabolic 
NRs controlling lipid and bile homeostasis in response to PI exposure.
The famesoid X activated receptor (also known as the farnesoid X receptor, FXR) 
and the liver oxysterol activated receptor alpha (also referred to as the Liver 
oxysterol receptor alpha, LXRa) are master regulators of cholesterol homeostasis, 
and modulate the transcription of many key genes involved in drug and lipid 
metabolism including the sterol regulatory element binding protein-1c (SREBP-lc), 
the most abundant sterol regulatory binding protein (SREB) isoform in adult human 
liver and a key player in lipogenesis (Hui, 2003; Liang et al., 2001; Osborne, 2000). 
Details of the regulatory mechanisms and target genes for the metabolic NRs are 
outlined in Section 1.4 of this thesis. The complex nature of the metabolic NRs 
involved in bile acid metabolism and detoxification together with genes and 
transporters regulated by the activation of the NRs is outlined in Figure 2.1, below.
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Liver
Figure 2.1: Metabolic NRs involved in bile acid metabolism: Arrows = transcriptional up- 
regulation, barred lines = transcriptional suppression.
RTV is no longer used as a PI in highly active antiretroviral therapy (HAART) but it 
is currently used at low dose to boost the activity of other Pis through its inhibition 
of the cytochrome P450 (CYP) enzyme, CYP3A4. RTV has no intrinsic antiviral 
activity at low dose but it has been widely implicated in the aetiology of 
hypertriglyceridaemia (Kim et al, 2006b; Mallon, 2007; Purnell et ai, 2000). The 
pathogenesis of the RTV-induced effects has been linked to the effect of RTV on 
hepatic and adipocyte SREBs including SREBP-lc (Hui, 2003; Liang et al., 2001; 
Osborne, 2000). RTV has also been associated with enhancing the formation of very
Chapter 2
55
low density lipoproteins (VLDL). A study in the human adipocyte cell line, Simpson 
Golabi Behmel Syndrome (SGBS), and clinical trials have shown that the newer PI 
ATV is associated with fewer signs of the deleterious metabolic side effects linked to 
lipodystrophy (Barreiro et al., 2005; Flammer el al., 2009; Fuster et al., 2005; Kim el 
al., 2006b),
The direct toxicity attributed to long-term HAART together with the complex 
interactions with human immunodeficiency virus (HIV) infection and possible other 
factors, (e.g. genetic predisposition, enviromnental) influence the risk of developing 
HIV/HAART associated dyslipidaemic lipodystrophy (HADL). Successful regimens 
have greatly improved morbidity and mortality outcomes for HIV+ individuals but 
the onset of HADL greatly increases the risk of developing cardiovascular disease 
and associated metabolic complications (Kim et al, 2006b; Mallon, 2007). The 
development of newer antiretrovirals (ARVs) which both overcome the problem of 
viral resistance and exhibit improved safety profiles for long-term use in an aging 
HIV+ population is particularly important.
LXRa is highly expressed in the liver and is a regulator of cholesterol homeostasis in 
the liver and macrophages (Gronemeyer el al, 2004a; Kalaany et al, 2006; Pascussi 
et al, 2008). It facilitates the processing and storage of cholesterol by up-regulating 
the cytochrome P450 7A1 enzyme (CYP7A1) and is implicated in the increased 
expression of the ATP binding cassette proteins ABCA1, ABCG1, ABCG5 and 
ABCG8 (Eloranta et al, 2005; Pascussi et al, 2008; Tirona et al, 2005). The 
transcriptional activity of LXRa is induced by elevated levels of naturally occurring
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oxysterols and da-hydroxy bile acids (Eloranta et aL, 2005; Francis et al., 2003). 
LXRa is also abundant in adipose tissue, where its activation has been shown to 
increase basal glucose uptake and the incorporation of TGs into lipid droplets 
(Lehrke et al, 2005).
LXRa responds to high cholesterol levels by increasing fatty acid synthesis to 
increase the formation of cholesterol esters, rendering the excess cholesterol pool 
biologically inactive (Giguere, 1999; Pascussi et al, 2008; Urquhart et al, 2007). 
LXRa also facilitates efflux of cholesterol from the periphery, including 
macrophages, through the increased expression of ABC transporters. Induction of 
ABC transporters increases the transfer of cholesterol and phospholipids to 
apolipoprotein A-I (ApoA-I) containing lipoproteins. Furthermore, activation of 
LXRa decreases intestinal absoiption of cholesterol mediated through the induction 
of ABC transporters including ABCG5 and ABCG8 (Kalaany et al, 2006; Pascussi 
et al, 2008). The effects of LXRa on fatty acid synthesis are mediated through the 
increased expression of SREBP-lc, a stimulator of lipogenesis. SREBP-lc is a 
transcription factor which has been previously associated with PI induced 
lipodystrophy (Bastard et al, 2002; Telenti et al, 2002). Increased production of 
liver triglycerides alongside transient increases in plasma levels resulting from the 
up-regulation of SREBP-lc remains a hurdle to the development of therapeutic 
LXRa agonists.
FXR, the counterbalance of hepatic LXRa action, is activated by bile acid 
accumulation resulting from the LXRa mediated conversion of cholesterol to bile
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acids. High concentrations of bile acids can be toxic to the cell and FXR functions to 
minimise this by inhibiting further bile acid production. Inhibition of bile acid 
synthesis is achieved by FXR down regulating CYP7A1, the rate-limiting enzyme in 
bile acid synthesis, through indirect signalling involving the increased expression of 
the small heterodimer partner-1 (SHP-l)-liver receptor homologue-1 (LRH-1) 
pathway. SHP-1 represses CYP7A1 expression by binding to regulatory sequences 
and preventing further response element (RE) binding of activated LXRa (Eloranta 
et ah, 2005).
PPARs may regulate metabolic gene expression by the formation of a NR 
heterodimer with LXRa (Giguere, 1999). PPARs have been implicated in metabolic 
diseases such as hyperlipidaemia, insulin resistance, coronary artery disease, obesity, 
diabetes and the metabolic syndrome (Behrens et al., 2000; Blaschke et aL, 2006; 
Duval et al^ 2007; Lee et al, 2003). Metabolic syndrome is characterised by visceral 
fat accumulation, hyperlipidaemia, elevated triglycerides, elevated blood pressure 
and hyperglycaemia, symptoms similar to those in HADL (Francis et al, 2003; 
Giguere, 1999; Villarroya et al, 2007). PPARa directs lipids to the liver where it is 
involved in energy homeostasis, inflammatory responses and fatty acid catabolism. 
PPARa is expressed in the liver, kidney, heart, skeletal muscle, adipose tissue, 
monocytes and other metabolically active tissues (Francis et al, 2003; Pascussi et 
a/., 2008).
PPARa is activated by a wide range of endogenous and dietary fatty acids (FAs) and 
their derivatives including prostaglandins, leukotrienes and eicosanoid derivatives of
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the lipo-oxygenase or cyclo-oxygenase pathways, and non-steroidal anti­
inflammatory drugs (NSAIDs) (Francis et ah, 2003; Giguere, 1999; Gronemeyer et 
al, 2004a). PPARa enhances the uptake and transport of circulating fatty acids (FAs) 
through modulation of its target genes including apolipoprotein A-I (ApoA-I), fatty 
acid binding proteins and lipoprotein lipase (LPL) (Berger et aL, 2002; Lee et al.t 
2003). PPARa activation by dietary polyunsaturated fatty acids (PUFAs) and fibrates 
has been shown to have positive effects on circulating triglyceride levels and plasma 
lipid profiles (Adkins et al. \ Clarke, 2001; Tobin et al, 2006).
SREBP-lc is a natural stimulatory ligand of PPARy and is thus an inducer of PPARy 
mediated adipogenesis and adiponectin production (Lee et al, 2003). Pis have been 
shown to inhibit SREBP-lc and impact PPARy mediated glucose and lipid 
metabolism (Bastard et al., 2002; Telenti et al, 2002). At the molecular level, 
adiponectin expression is stimulated by the PPARy/SREBP-lc pathway. Adiponectin 
acts by enhancing the suppression of insulin-induced hepatic gluconeogenesis whilst 
increasing FFA p-oxidation and insulin-dependent transport in muscle (Iwaki et al, 
2003). Low levels of adiponectin and its mRNA expression have been shown in 
conditions associated with insulin resistance and fat redistribution, including HADL 
(Haque et al, 2002). The effect of RTV on PPARy has been associated with 
decreased adipogenesis, lipogenesis and increased lipolysis, which together with a 
decrease in adipocyte LPL mRNA levels have been implicated in the dyslipidaemia 
and insulin resistance mechanisms of HADL (Carr, 2000; Lenhard et al, 2000). The 
implications of FXR, LXRa, PPARa and PPARy in metabolic complications are 
summarised in Table 2.1 below.
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Peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-la) 
has been shown to play a critical role in xenobiotic metabolism (Pascussi et al.> 
2008). It has a key role in cellular energy metabolism through co-ordination of 
transcriptional programs of mitochondrial biogenesis, adaptive thennogenesis and 
FA p-oxidation and is involved in the co-activation of key transcription factors of 
hepatic gluconeogenesis (Glass, 2006; Pascussi et ctL, 2008). PGC-la affects the 
activity of multiple NRs (including PPARy, RXRa, FXR, LXRa, HNF4a, PXR and 
CAR) to fine tune the biological response to ligand receptor interaction and underpin 
the variability of gene responses to different ligands and metabolic environments 
(Francis et aL, 2003; Gronemeyer et aL, 2004a; Handschin et aL, 2003; Pascussi et 
al., 2008; Tirona etaL, 2005).
Table 2.1: Summary of NRs implicated in metabolic complications and their effects
FXR LXRa PPARa PPARy
TTHDL TTHDL THDL
JXDL |LDL
|TGs |TGs |TGs
iVLDL
l Insulin 
resistance
l Insulin 
resistance
i Insulin 
resistance
TFat TFFAs TFat
^Reverse
cholesterol
transport
TReverse
cholesterol
transport
TReverse
cholesterol
transport
TReverse
cholesterol
transport
The Hull? cell line is an immortal cell line of epithelial-like tumorigenic cells. The 
Huh? is a well differentiated cell line derived from a human carcinoma cell line
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originally derived from a hepatic tumour in a 57 year old Japanese male in 1982. 
Previous studies by the Liverpool HIV Pharmacology Group had considered the 
limitations of cell lines compared to primary hepatocytes and the implications of 
discrepancies reported between laboratories (Martin et al, 2007). Due consideration 
was given to the findings of this study when considering experimental design for the 
hepatic cell line model and comparative gene expression for the genes of interest was 
investigated prior to final selection of the preferred cell line, see Section 2.3.2 below. 
A stable cell line which could be sub-cultured in antibiotic free media was preferred. 
Ease of culture and reproducibility of data obtained from the immortalised cell lines 
favoured their use over primary hepatocytes. The Huh7 cell line was selected as the 
preferred experimental system for the gene expression studies as experience within 
the laboratory had revealed a better cell health profile for repeated sub-cultures in 
antibiotic free media compared to the widely used human hepatoma cell line HepG2.
Target genes for this thesis were selected on the basis of their involvement in fatty 
acid, cholesterol, lipid or triglyceride metabolism and based on previous reports as 
being regulated by the metabolic nuclear receptors FXR, LXRa and PPARa (Table 
2.2, below). PXR, CAR and PPARy were excluded as they have previously been 
extensively investigated (Feldman et aL, 2008; Guo et aL, 2006; Healan-Greenberg 
et aL, 2008; Kodama et aL, 2004; Lemoine et aL, 2006).
RTV was selected on the basis of its widespread use as a booster of PI activity in 
HAART and its previously reported involvement with the metabolic complications 
associated with Pis (Falutz, 2007; Kim et aL, 2006a; Mallon, 2007; Purnell et aL,
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2000). ATV was selected on the basis of it being a newer PI with fewer metabolic 
side effects (Kim et aL, 2006b). 22-(S)-hydroxycholesterol has previously been 
shown to bind LXRa without activation (Janowski et at., 1999) and was therefore 
considered a suitable LXRa antagonist to probe the involvement of LXRa in the 
metabolic NR response to RTV.
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Table 2.2: Human FXR, LXRa and PPARa target genes with their endogenous biological 
metabolic function and effects of induction shown.
Gene Name Abbrev.Name
Biological
Function
Regulation 
by FXR
Regulation 
by LXRa
Regulation 
by PPARa
Fatty acid 
transport protein FATP
Fatty acid 
metabolism Induced
Fatty acid 
translocase FAT
Fatty acid 
metabolism Induced
Apolipoprotein O 
III ApoC-III
TG
metabolism Repressed
Induced (via 
PPARa 
repression)
Repressed
Apolipoprotein A1 ApoA-I HDLmetabolism Repressed
Induced or 
Repressed Induced
Lipoprotein lipase LPL TGmetabolism
Induced (via 
ApoC-II 
induction)
Induced Induced
Apolipoprotein C- 
II ApoC-II
TG
metabolism Induced Induced Repressed
Apolipoprotein A2 ApoA2 HDLmetabolism Induced
Apolipoprotein AS ApoA5 HDLmetabolism Induced
Fatty acid synthase FAS Fatty acid metabolism
Induced or 
Repressed Induced Induced
Sterol Regulatory 
Element Binding 
Protein-1c
SREBP-
1c Lipogenesis
Repressed 
(via SHP-1 
induction)
Induced
Very Low Density 
Lipoprotein 
Receptor
VLDLR TGmetabolism Induced Repressed Induced
Cytochrome P450 
7A1 CYP7A1
Cholesterol
metabolism
Repressed 
(via SHP-1 
induction)
Induced Repressed
Solute Carrier 
Family 10 A1
SLC10A
1
Cholesterol 
and bile acid 
metabolism
Repressed Repressed
Peroxisome
Proliferator
Activated
Receptor-a
PPARa TGmetabolism Induced Repressed
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2.2 Aim
The aims of this research were to investigate the specific impact of the Pis RTV and 
ATV on gene expression in NRs involved in lipid metabolism identified in Section 
2.1 of this thesis, and on the gene expression of downstream targets in their 
metabolic pathways (Table 2.2); to establish if the differential effects in gene 
expression in the presence of RTV and ATV could be attributed to differences in the 
cellular accumulation of these drugs; and to determine the effect of an LXRa 
antagonist (22-(S)-hydroxycholesterol) on gene expression in RTV and ATV treated 
cells.
2.3 Materials and Methods
2.3.1 Materials
Normal liver RNA, normal intestinal RNA and the Huh? cell line were obtained 
from the European Collection of Cell Cultures (ECACC) (Salisbury, UK). HepG2 
and Caco-2 cell lines were obtained from American Type Culture Collection 
(Manassas, USA). Forward and reverse primers for in-house developed assays 
(HSP70, VDR, IBABP-L, and HNF4<x), Molecular Grade Ethanol, Molecular Grade 
Isopropanol, Molecular Grade Methanol, Sodium Dodecyl Sulphate (SDS), Ni,Ni- 
Dmimethylformamide (DMF), Thiazolyl Blue Tetrazolium Bromide, Hanks 
Balanced Salt Solution (HBSS), Dimethylsulphoxide (DMSO), Dulbecco’s modified 
Eagle’s medium (DMEM), RNAse free water, DNAse free water, newborn foetal 
calf serum (FCS), foetal bovine serum (FBS), Trypsin-EDTA xl, 2-mercaptoethanol, 
Chloroform, potassium chloride, HEPES free acid, magnesimn chloride, potassium 
hydroxide pellets, and Tri®Reagent RNA isolation reagent were purchased from 
Sigma Aldrich Co. Limited (Irvine, Ayrshire, UK). lOx Taqman PCR Buffer II,
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25mM MgCk, 5U/jj,1 Amplitaq Gold DNA Polymerase, lOOmM dNTPs, Taqman 
Reverse Transcription Reagents, Taqman Gene Expression inventoried Assays and 
Taqman Endogenous Control Gene Expression Plates were purchased from Applied 
Biosystems Limited (Warrington, UK). Absolute qPCR mix was purchased from 
ABgene Limited (Epsom, Surrey, UK). Nunc cell culture flasks, Nunclon Surface 96 
well plates, Nunclon Surface 48 well plates, Nunclon Surface 6 well plates and 
Nunclon Up-Cell 6 well plates were purchased from (Nunc A/S, Kamstrup, 
Demnark). PicoGreen dsDNA Quantitation Reagent was purchased from Invitrogen 
Limited (Paisley, UK). DNA Molecular Weight Marker XIV (lOObp ladder) was 
purchased from Roche Diagnostics Limited (Burgess Hill, UK). Ritonavir and 
Radiolabelled ritonavir (14C, 99.9% estimated purity) were kind gifts from Abbott 
Laboratories (North Chicago, USA). Atazanavir was a kind gift from Bristol-Myers 
Squibb (USA). Darunavir was a kind gift from Tibotec BVBA (Beerse, Belgium). 
Indinavir was a kind gift from Merck and Co. (New Jersey, USA). Radiolabelled 
atazanavir (3H, >99% estimated purity) was purchased from Moravek Biochemicals 
(California, USA). Ultima Gold Scintillation Fluid was purchased from Perkinn 
Elmer, (Boston USA). The DNA Engine Opticon 2 system was from MJ Research 
Inc. (USA).
2.3.2 Cells and Cell Maintenance
2.3.2.1 Huh?, HepG2 and Caco-2 Cell Lines
Huh? and HepG2 cells were maintained in DMEM supplemented with 10% FBS, 
incubated at 37°C and 5% CO2 and were sub-cultured every 2-3 days. Basal levels of 
all transcripts were quantified from passages 14-32 in Huh? cells and from passages 
16-20 in HepG2 cells.
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Caco-2 cells were maintained in DMEM supplemented with 15% PCS, incubated at 
37°C and 5% CO2 and were sub-cultured every 2-3 days. Basal levels of all 
transcripts were quantified from passages 28-52 in Caco-2 cells.
2.3.2.2 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoIium bromide (MTT) Cell 
Toxicity Assays
RTV, ATV, indinavir (IDV) and darunavir (DRV) were assayed for toxicity in Hub? 
by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay at 
final concentrations of O.Ol-lOOpM in DMSO against DMSO-treated controls, and 
at final concentrations of O.Ol-lOOpM in methanol against methanol-treated controls 
at 0.5% v/v for vehicles. The toxicity of 22-(S)-hydroxycholesterol was also 
determined by the MTT assay at final concentrations of O.Ol-lOOpM in methanol 
against methanol-treated controls at 0.5% v/v for vehicles. Incubation was for 120h 
at 37°C and 5% CO2 prior to assessment of cell death by fluorescence at 560nm via a 
GENios XFLU04 plate reader. Methanol was determined to be the preferred vehicle 
for toxicity and induction assays (see section 2.5.1). Drugs were determined to be 
toxic where the cell viability after 120h was below 85% compared to the untreated 
cells.
2.3.2.3 Cell Treatment
Cell lines were seeded at a density of 5xl06 per well into 10% FCS-supplemented 
DMEM medium, in Nunclon Surface 6 well plates and incubated at 37°C and 5% 
CO2 for 24h prior to the set-up of all expression experiments. The concentration- 
response experiments for RTV and ATV were conducted at final concentrations of 0, 
0.1, 1.0, and lOpM, determined by cell viability after 120h toxicity assays.
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Methanol-treated controls were used (0.5% v/v for vehicles). RTV and ATV treated 
Huh? cells were incubated at 37°C and 5% C02 and were sampled at 24h. The 
concentration-response experiments for RTV plus 22-(S)-hydroxycholesterol treated 
Huh7 cells were conducted at final concentrations of 0, 0.1,1.0, and lOpM RTV plus 
a fixed concentration of 20pM 22-(S)-hydroxycholesterol in each assay. The cells 
were incubated at 37°C and 5% C02 and were sampled at 24h.
2.3.2.4 RNA Isolation from Huh7 Cells
Isolation of RNA from untreated, RTV-treated, ATV-treated, and RTV plus 22-(S)- 
hydroxycholesterol-treated Huh7 cells was undertaken using the Tri®Reagent method 
in accordance with the manufacturer’s instructions. Briefly, cells were lysed directly 
from plate in Tri-Reagent by repetitive pipetting (1ml Tri/5-1 Ox 106 cells) and 
incubated for 5 minutes at room temperature prior to transfer to Eppendorf® tubes. 
200ul of chloroform were added to each tube. Each tube was shaken vigorously and 
incubated at room temperature for 2-3minutes. Samples were centrifuged at 12000 x 
g for 15 minutes at 2 C. The upper aqueous phase was transferred to a fresh tube, 
500ul isopropanol added, incubated at room temperature for 10 minutes, then 
centrifuged at 12000 x g for 10 minutes at 2°C. The supernatant was discarded, 1ml 
of 75% ethanol was added, tubes were vortexed and centrifuged at 7500 x g for 5 
minutes at 2 C. The supernatant was removed and the pellet air-dried for lOminutes. 
The RNA pellets were dissolved in 20pi ddH20 and incubated for 10 minutes at
o
60 C. The samples were analysed and quantified using a Thermo-Scientific® 
Nanodrop 1000 to assess quantity and purity of the RNA extracted. RNA is detected 
at 260nm (where 40gg/ml corresponds to an optical density [OD] of 1.00) and
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protein at 280mn, an A260/A280 ratio of over 1.8 indicated samples of sufficient purity 
to proceed with PCR.
2.3.2.S Production of cDNA
RNA was isolated as described above (2.2.2.4) and cDNA was synthesised in a total 
reaction volume of SOpl with the total RNA normalised to 2|u,g per 50pi reaction. The 
RNA to cDNA reverse transcription reactions were performed in 5pi of lOx Taqman 
PCR Buffer II, 1 Ipl of 25mM Mga2, lOpl of lOmM dNTPs, 2.5pl of 50pM random 
hexamers, Ipl of 20U/pl RNase inhibitor, L75pl of 50U/pI MuLV reverse 
transcriptase (Applied Biosystems Limited, Warrington, UK) and RNase free water 
up to 50pl volume. Reverse transcription was undertaken with the following cycling 
conditions: 10 minutes at 25°C, 30 minutes at 48°C and, 5 minutes at 95°C. Samples 
were analysed and quantified using a Thermo-Scientific® Nanodrop 1000 to assess 
quantity and purity of the cDNA.
DNA is detected at 260nm (where 40pg/ml corresponds to an optical density [OD] of 
1.00) and protein at 280nm, an A260/A280 ratio of over 1.7 indicated samples of 
sufficient purity to proceed with PCR. The concentration of each sample was 
normalised to 20ng/pl by the addition of DNAse free water.
Normal liver RNA, normal intestinal RNA (European Collection of Cell Cultures 
(ECACC) Salisbury, UK) was also reverse transcribed using the Taqman Reverse 
Transcription kit, analysed and quantified as described above.
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2.3.2.6 Cellular Accumulation of Ritonavir and Atazanavir
In order to assess the intracellular accumulation of RTV and ATV, Huh? cells at 
passage 14 were resuspended in media containing [3H]-ATV (0.02pCi mr1) or [l4C]- 
RTV (0.02pCi‘mL_1). The cells were incubated at 37°C/5% C02 for 30 minutes, 
centrifuged at 9000rpm for 1 minute at 2°C. 100pi aliquots of each supernatant
fraction were transferred to corresponding scintillation vials. The remaining 
supernatant was discarded and the pellets were washed three times in ice cold Hanks 
Balanced Salt Solution (HBSS), centrifuged at 9000rpm for 1 minute at 2°C and then 
dissolved in lOOpl water and transferred to corresponding scintillation vials. 
Scintillation fluid (4ml) was then added to both supernatant and pellet and the 
cellular accmnulation was calculated (ratio of radiolabelled drug associated with the 
cell pellets divided by that associated with media). A cell volume of 0.4pl was 
assumed. The accumulation of ATV and RTV was determined at Oh and 24h post 
incubation the drugs. Controls consisted of untreated Huh? incubated in media.
The results of the scintillation count were analysed in MS Excel 2010 by determining 
the cellular accumulation ratio (CAR) with the following calculation:
CAR = Intracellular associated radioactivity/Extracellular associated radioactivity.
2.3.2.? Development and Optimisation of In-House Gene Expression Assays
Single-stranded DNA primers were designed in accordance with established protocol 
laid down by primer manufacturers and the literature (Chou et aL, 1992; Jeffreys el 
al, 1988; Saiki et aL, 1988) and were validated in silico using the online NCBI 
Primer-BLAST system (NCBI-Primer-Blast, 2009; Sayers et al.\ Yu et al).
Chapter 2
69
Briefly, the primer sequences were designed to be 15 to 30 bases in length, did not 
complement within themselves or to each other; primer concentrations in the range 
of 0.2mM to 0.5mM were optimised for best results; the concentrations of MgCl2 
(Range 1.0 to 4.0mM), dNTPs (Range 0.2 to 0.8mM), DNA polymerase enzyme, 
annealing temperatures (Range 50°C to 70°C) and the number of PCR amplification 
cycles (Range 30 -50) were also varied during the optimisation process. Preferred 
conditions determined by optimisation are outlined in Sections 2.3.2.9 and 2.5.3 
below.
The effect of the variations was determined by examining the intensity and 
distribution of amplification products after electrophoresis on agarose gel followed 
by visualisation with ethidium bromide staining of the gel.
The in-house developed real time PCR gene expression assays for quantification by 
Pico-green relative to the expression of the housekeeping gene, p-2-microglobulin 
(P-2M), were then used to determine the gene expression of HSP70, IBABP-L, VDR 
and HNF4a. Relative expression of the transcripts against the expression of the P-2M 
was performed, in duplicate for all assays, in an Opticon2 Fluorescence Detector. 
Amplification was conducted in a 25pi reaction consisting of: 2.5pi 10 x Taqman 
Buffer II, 0.5 pi 0.5U/pl Amplitaq Gold, 1.25pl 25mM MgCl2, 2pl lOmM dNTPs, 
40ng cDNA (normalised to 20ng/pl), 0.5 pi PicoGreen (final concentration 1:5000) 
and 0.5pl 15pM forward and 0.5pl 15pM reverse primers (for each gene), and 
nuclease-free water was added to provide a final volume of 25 pi. Primer sequences 
and RT-PCR conditions for in-house developed gene expression assays are outlined 
in Table 2.4 below.
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2.3.2.S Identification of Controls by Gene Expression Assays in Untreated Cells
Normal liver RNA and normal intestinal RNA was reverse transcribed to cDNA as 
described previously (Owen et al.> 2004) and was normalised to 20ng/pl as described 
in 2.2.2.5 above. Gene expression was detennined in normal liver cDNA, normal 
intestinal cDNA, and untreated Huh? cell line cDNA for each assay using the 
Taqman inventoried gene expression assays (Table 2.3) and in-house developed gene 
expression assays (Table 2.4) below. Relative expression of each gene was 
determined by comparative CT (AACt) method against the normal liver control 
values for each experimental condition using Microsoft Office Excel 2010 for 
analysis.
2.3.2.9 RT-PCR Gene Expression
Taqman Gene Expression inventoried assays for RT-PCR (Applied Biosystems 
Limited, Warrington, UK, (Table 2.3)) were used for FXR, LXRa, ApoA-I, ApoC-II, 
ApoC-III, SREBP-1C, VLDLR, SLC10A1, PPARa, CYP7A1, GAPDH and [3-actin 
quantified against the housekeeping gene |32M. Amplification was conducted in a 
reaction consisting of 25 pi Taqman Gene Expression inventoried Assay kit, as 
supplied. Amplification was performed in an Opticon2 Fluorescence Detector (MJ 
Research, Bio-Rad, Hertfordshire, UK) at 95°C for 10 minutes then 50 cycles of 
95°C for 15 seconds and 60°C for 1 minute. In-house developed real time PCR gene 
expression assays for quantification relative to p2M (housekeeping gene) were 
performed on HSP70, IBABP-L, VDR and HNF4a.
Relative expression of the transcripts against the expression of the housekeeping 
gene was performed, in duplicate for all assays for a minimum of 4 biological
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replicates, in an Opticon2 Fluorescence Detector. Amplification was conducted in a 
reaction consisting of 25 pi Taqman Gene Expression inventoried Assay kit, as 
supplied; and for in-house developed assays: 2.5pi 10 x Taqman Buffer II, 0.5 pi 
0.5U/pl Amplitaq Gold, 1.25pl 25mM MgCl2, 2pl lOmM dNTPs, 40ng cDNA 
(normalised to 20ng/pl), 0.5 pi Pico Green (final concentration 1:5000) and 0.5pl 
15pM forward and 0.5pl 15pM reverse primers (for each gene), and nuclease-ffee 
water was added to provide a final volume of 25 pi. Primer sequences and RT-PCR 
conditions for in-house developed gene expression assays are outlined in Table 2.4 
below.
For each gene expression assay, amplification plots were generated by the Opticon 2 
software showing the increase in reporter dye fluorescence with each cycle of RT- 
PCR. The threshold cycle (Ct) values for each assay were determined where the PCR 
efficiency was at 100% and data was exported to Microsoft Office Excel 2010 for 
analysis. Calculations for relative mean gene expression were performed using the 
comparative (delta-delta) Ct methodology (AACt) (Bookout et aL, 2003). 
Expression values were normalised against the mean expression of the relative 
housekeeping gene and plotted against vehicle controls for each gene.
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Table 2.3: Taqman Gene Expression Assays for RT PCR
Taqman Assay ID Assay Gene
Hs00231968 ml FXR
Hs00231882 ml PPARa
Hs00167982 ml CYP7A1
HsOl 08869 l ml SREBP-lc
Hs03037356 ml APOC2 (ApoC-II)
HsOOl 63644jml APOC3 (ApoC-IIl)
Hs01045922 ml VLDLR
HsOOl 61820 ml SLC10A1 (NTCP)
HsOO 16364 l m 1 APOA-I (ApoA-I)
HsOOl 72885 ml LXRa
Hs99999907 ml P2M
Hs99999903 ml p-actin
Hs99999905_ml GAPDH
2.4. Statistical Analysis
Statistical analysis of all results was undertaken using StatsDirect Statistical software 
version 2.7.8. Spearman's Rank tests were performed on the untreated cells to 
determine correlation between cell line expression and normal tissue gene 
expression. Shapiro-Wilk W tests were performed to test for normality. Normal 
distribution of the data sets was confirmed so the Unpaired T-Test was performed on 
all data sets to determine the significance of the differences in gene expression at 
varying concentrations. A statistical trend was defined as a P value <0.1. Statistical 
significance was set at P<0.05.
2.5 Results
2.5.1 3-(4,5-dimethylthiazol-2-yl)-2,5-diplienyltetrazolium bromide (MTT) Cell 
Toxicity Assays
Results for the DMSO vehicle MTT toxicity assays are not shown as DMSO was 
rejected as the preferred vehicle due to precipitation of the drug in the DRV and
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ATV assays. The MTT toxicity assays using methanol as the drug vehicle for 4 
technical and 4 biological replicates were performed for each drug, including 22-(S)- 
hydroxycholesterol in Huh? cells. RTV was determined to be toxic in Huh? cells 
(n=4) at lOOpM, as shown in figure 2.2 below. IDV was also determined to be toxic 
in Huh? cells (n=4) at lOOpM, as shown in Figure 2.2 below. DRV was also 
determined to be toxic in Huh? cells 01=4) at lOpM and lOOpM, as shown in Figure 
2.2 below. ATV was detennined to be toxic in Huh? cells (n=4) at lOOpM as shown 
in Figure 2.2 below.
The antagonist 22-(S)-hydroxycholesterol was not found to be toxic in Huh? cells 
(n=4) in concentrations up to lOOpM, as shown in Figure 2.3 below.
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Ritonavir (RTV) Toxicity in Huh?
110 -|
[RTV] |iM
q Darunavir (DRV) Toxicity in 
Huh?
120 i
[DRV] MM
B Indinavir (IDV) Toxicity in Huh?
120
[IDV] HM
D Atazanavir (ATV) Toxicity in 
Huh?
120 -i
[ATV] JIM
Figure 2.2: MTT Assays in Huh? (passage =22) Cells: A= Incubated with ritonavir (RTV) for 
120h, n=4; B= Incubated with indinavir (IDV) for 120h, n=4; C= Incubated with darunavir 
(DRV) for 120h, n=4; and D= Incubated with atazanavir (ATV) for 120h, n=4
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22(S) Hydroxycholesterol Toxicity in Huh? Cells
cells 0.00 0.01 0.10 1.00 10.00 20.00 40.00 50.00 100.00
[22(S) Hydroxycholesterol] iiM
Figure 2.3: MTT Assay: Huh7 cells (passage 22) incubated with 22-(S)-hydroxycholesterol 
for 120h, n=4
2.5.2 Quantification of RNA and cDNA
The RNA extracted from Huh? cells (as described in Section 2.3.2.4), was analysed 
and quantified using a Thermo-Scientific® Nanodrop 1000 to assess its quantity and 
purity. The RNA had an A260/A280 ratio in the range of 1.85-2.01 (RTV samples), 
1.92-2.08 (RTV + 22-(S)-hydroxycholesterol samples) and 1.94-2.15 (ATV samples) 
indicating sufficient purity to proceed to cDNA construction for RT PCR. RNA 
samples were frozen at -80°C following cDNA construction.
The cDNA for all conditions had A260/A280 ratios in the range of 1.98-2.13 indicating 
sufficient purity to proceed to construction of normalised (20ng/pl) cDNA working 
stocks. Master and working stock cDNA samples were frozen at -20°C until used in 
gene expression assays.
Chapter 2
76
2.5.3 Optimisation of In-House Gene Expression Assays
RNA was isolated by the Tri®Reagent method as described in 2.2.2.4 above and 
reverse transcribed to cDNA as described previously in 2.2.2.5. Single-stranded 
DNA primers were designed and validation was performed as outlined in Section 
2.3.2.7. Each validation reaction contained 40ng cDNA (normalised to 20ng/pl).
Optimum final primer concentrations were detennined to be 0.3pM forward and 
0.3pM reverse (for each gene) in a final reaction volume of 25pi. The optimum 
polymerase enzyme was detennined as 0.25U/pl Amplitaq Gold per reaction. The 
optimum final concentrations for the remaining variables outlined in 2.3.2.7 were 
1.25mM MgCb, 0.8mM dNTPs, and 1:5000 PicoGreen (final concentration). Primer 
sequences and cycle thresholds for annealing and extension in RT-PCR conditions 
for in-house developed gene expression assays are outlined in Table 2.3 below. The 
presence of amplification products was confirmed by electrophoresis on agarose gel 
followed by visualisation of the product by ethidium bromide staining of the gel. 
Figure 2.4 below shows the validation of VDR gene expression by PicoGreen and 
the presence of the P-2M and VDR amplicons on the agarose gel, similar validations 
were performed for HNF4a, HSP70 and IBABP-L (not shown). The gene expression 
of IBABP-L was below the detection threshold even after 50 cycles, so it was 
excluded from the research, it was originally included as a potential negative control 
for the assays, but HSP70 expression was more robust and it was therefore a 
preferred candidate.
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VDR Gene Expression with PicoGreen (1:5000)
- * -
MWM
P-2M
ISjiM 15 nM 1.5 1.5 nM
VDR
15 nM 1.5 nM 1.5|iM
Figure 2.4: Opticon Trace: Representative VDR Gene expression against (3-2M control in 
Huh7 Cells for in-house developed PicoGreen assay, n=2, with validation of amplicon 
products by electrophoresis. (MWM= Molecular weight marker).
Primer sequences and RT-PCR conditions for in-house developed gene expression 
assays are outlined in Table 2.4 below.
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Table 2.4: In-House Developed Primers for RT PCR Gene Expression Assays Quantified by 
Pico-green.
Gene
Name
Forward Primer 
S’-S*
Reverse Primer S’-S’ RT-PCR Conditions
HNF4a TTGAGTGGGCCAAGTACATC
TACGGATGGAGTTT
CGGTAG
95°C- 10 minutes
40 cycles:
95°C -15 s, 60°C -45 s, 72°C -45 s; 
72°C - 5 minutes
VDR
TGCCTGACCCT
GGAGACTTTG
ACC
CATCATGCCGATGT
CCACACAGCG
95°C -10 minutes
50 cycles:
95°C -20 s, 65°C -30 s, 72°C -45 s; 
72°C - 5 minutes
HSP70 CCGAGAAGGACGAGTTTGAG
GCAGCAAAGTCCTT
GAGTCC
95°C — 10 minutes
45 cycles:
95°C -15 s, 65°C -60 s, 72°C -60 s; 
72°C - 5 minutes
IBABP-L
ACATGGGTGA
GCCGGAAAGG
AGAC
CCGGAGTAGTGCTG
GGACCAAGTGAAGT
95°C -10 minutes
50 cycles:
95°C -15 s, 65°C -60 s, 72°C -60 s; 
72°C - 5 minutes
2.5.4 Identification of Controls by Gene Expression Assays in Untreated Cells
Gene expression was determined in normal liver cDNA, normal intestinal cDNA, 
and untreated Huh? cell line cDNA for each assay using the Taqman inventoried 
gene expression assays (Table 2.3) and in-house developed primers for PicoGreen 
gene expression assays (Table 2.4) above. Relative expression of each gene was 
detennined by comparative Ct (AACt) method against the normal liver control 
values for each experimental condition (Bookout et aL, 2003). Figure 2.5 below 
outlines the representative expression of the genes assayed by Taqman inventoried 
gene expression assays against the 0-2M housekeeping control gene in normal liver 
controls (n=T).
Figures 2.6 - 2.8 show the relative mean expression of FXR, SREBP-lc, ApoAl, 
PPARa, VLDLR, VDR, LXRa, ApoC-II, ApoC-III and HNF4<x expressed in each of
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the cell lines and normal intestine with relative expression compared to the normal 
liver controls. Figure 2.9 shows HSP70 relative mean expression against normal liver 
controls for each of the cell lines. Gene expression analysis was confirmed the target 
genes of interest were present in normal liver controls and Huh7 cell lines, however, 
the regulation of CYP7A1, IBABP-L and SLC10A1 were below the detection 
threshold of the assays used (in the cell lines) and further refinement of these assays 
was not undertaken as part of this research.
Huh7 was selected as the preferred cell line for gene expression analysis following 
evaluation of the results of the toxicity and untreated cell assays. This cell line 
selection was consistent with the requirements for a stable cell culture in antibiotic 
free media as discussed in Section 2.1 above.
Figure 2.5: Opticon Trace: Representative Gene expression of FXR, SREBP-lc, ApoA1, 
PPARa, VLDLR, LXRa, ApoC-ll, ApoC-lll, SLC10A1, CYP7A1, GAPDH, and (3-actin against 
(3-2M housekeeping control in normal liver controls for Taqman gene expression assays, n=1
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fa FXR Mean Expression
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Figure 2.6: A= FXR Gene Expression Assay in untreated Huh7, HepG2 and Caco-2 cells 
with normal liver and normal intestinal controls; B = SREBP1-C Gene Expression Assay 
untreated Huh7, HepG2 and Caco-2 cells with normal liver and normal intestinal controls;
= ApoA1 Gene Expression Assay in untreated Huh7, HepG2 and Caco-2 cells with normal 
liver and normal intestinal controls; D = PPARa Gene Expression Assay in untreated Huh7, 
HepG2 and Caco-2 cells with normal liver and normal intestinal controls; n=4 for all assays.
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Figure 2.7: A = VLDLR Gene Expression Assay in untreated Huh7, HepG2 and Caco-2 cells 
with normal liver and normal intestinal controls; B = VDR Gene Expression Assay in 
untreated Huh7, HepG2 and Caco-2 cells with normal liver and normal intestinal controls; C 
= LXRa Gene Expression Assay in untreated Huh7, HepG2 and Caco-2 cells with normal 
liver and normal intestinal controls; and D = ApoC-ll Gene Expression Assay in untreated 
Huh7, HepG2 and Caco-2 cells with normal liver and normal intestinal controls; n=4 for all 
assays.
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HNF4ct Mean ExpressionA ApoC-Ill Mean Expression B
14 1.6
Figure 2.8: A = ApoC-Ill Gene Expression Assay in untreated Huh7, HepG2 and Caco-2 
cells with normal liver and normal intestinal controls; and B = .HNF4a Gene Expression 
Assay in untreated Huh7, HepG2 and Caco-2 cells with normal liver and normal intestinal 
controls; for all assays.
Figure 2.9: HSP70 Gene Expression Assay in untreated Huh7, HepG2 and Caco-2 cells with 
normal liver controls, n=4.
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Cellular Accumulation of Ritonavir and Atazanavir
Cellular accumulation of RTV and ATV was determined as described above (2.3.2.6) 
in Huh? cells at passage 14. The accumulation of ATV and RTV was determined at Oh 
and 24h post incubation with the drugs. Controls consisted of untreated Huh? incubated 
in media. The results of the scintillation count were analysed to detennine the cellular 
accumulation ratio (CAR) as described in Section 2.3.2.6.
The results showed that the cellular accumulation ratio (CAR) for ATV was 2 fold 
greater than it was for RTV (Figure 2.10, below).
Figure 2.10: The comparative cellular accumulation (shown by cellular accumulation ratio 
(CAR)) of ritonavir (RTV) and atazanavir (ATV) in Huh? cells (passage no. = 14), n=4.
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2.5.6 Gene Expression in Ritonavir, Atazanavir and 22(S)-HydroxycholesteroI/ 
Ritonavir Treated Huh 7 Cells
Maximal induction and repression by both RTV and ATV was observed after 24h 
incubation. After 48h the induction and repression observed in the 24h RTV and 
ATV assays had diminished to return to basal expression levels. Consequently all 
assays were optimised for 24h incubation with drug treatments. The gene expression 
assay for FXR was evaluated for both the effects of RTV and ATV treatments, and to 
determine whether 22-(S)-hydroxycholesterol, an antagonist of LXRa, had regulated 
the FXR gene expression in the presence of RTV. As 22-(S)-hydroxycholesterol had 
been confirmed as not toxic in the range O.OlpM to lOOpM (Section 2.5.2), a fixed 
concentration of 20pM was selected for the antagonist, as it had previously been 
shown to bind LXRa without activation at this concentration (Janowski et al.t 1999). 
HSP70 gene expression was stable across all concentrations of RTV, RTV plus 22- 
(S)-hydroxycholesterol and ATV in Huh7 cells (n=4) and was therefore selected as 
the negative control for the drug incubation experiments (Figure 2.11 below).
All results were quantified by calculating the relative mean expression of each gene 
and condition for each of the duplicates (n=4) against the relative mean expression of 
the housekeeping gene and plotted against the mean expression of each gene of the 
vehicle controls as previously described in Section 2.3.2.9.
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HSP70 - Expression in Huh7 (p24) Cells - 24h Induction
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Figure 2.11: HSP70 Gene Expression Assay in Huh7 cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20pM 22(S)-Hydroxycholesterol and atazanavir (ATV) for 24h, 
n=4.
Significant induction of ApoA-I by RTV was observed at concentrations of 0.1 pM 
(2.7 fold increase compared to vehicle control, P=<0.0001), l.OpM (3.6 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (5.6 fold increase compared to 
vehicle control, P=<0.0001) in Huh7 cells (n=4). Figure 2.12 below. The statistically 
significant induction of ApoA-I by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM was abolished in the presence of 20pM 22-(S)-hydroxycholesterol, 
Figure 2.12 below. Significant induction of ApoA-I by ATV was also observed at a 
concentrations of 0.1 pM (1.2 fold increase compared to vehicle control, P=0.0013), 
l.OpM (1.4 fold increase compared to vehicle control, P=<0.0001) and lOpM (1.6 
fold increase compared to vehicle control, P=<0.0001) in Huh7 cells (n=4), however, 
this was less marked than that which was observed for RTV, Figure 2.12 below.
ApoC-Il was significantly induced by RTV at 0.1 pM (1.7 fold increase compared to 
vehicle control, P=<0.0001), l.OpM (3 fold increase compared to vehicle control.
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P=<0.0001) and lOjiM (9 fold increase compared to vehicle control, P=<0.0001) in 
Huh7 cells (n=4). Figure 2.12 below. The statistically significant induction of ApoC- 
II by RTV observed at concentrations of 0.1 pM, 1.0pM and lOpM was abolished in 
the presence of 20pM 22-(S)-hydroxycholesterol, Figure 2.12 below. ApoC-II was 
significantly repressed by ATV at concentrations of 0.1 pM (4.4 fold decrease 
compared to vehicle control, P=<0.0001), l.OpM (2 fold decrease compared to 
vehicle control, P=<0.0001) and lOpM (2.6 fold decrease compared to vehicle 
control, P=<0.0001) in Huh7 cells (n=4). Figure 2.12 below.
Significant induction of ApoC-III at 0.1 pM (1.2 fold increase compared to vehicle 
control, P=<0.0001), l.OpM (1.3 fold increase compared to vehicle control, 
P=<0.0001) and lOpM RTV was observed (5 fold increase compared to vehicle 
control, P=<0.0001) in Huh7 cells (n^), Figure 2.12 below. The use of 22-(S)- 
hydroxy cholesterol abolished the significant induction of ApoC-III at 0.1 pM, l.OpM 
and lOpM RTV, Figure 2.12 below. ApoC-III gene expression was also significantly 
increased at O.lpM (1.1 fold increase compared to vehicle control, P=0.0009), 
l.OpM (1.1 fold increase compared to vehicle control, P^cO.OOOl) and lOpM ATV 
(1.1 fold increase compared to vehicle control, P=0.0022) in Huh7 cells (n=4), 
however, this was less marked than that which was observed for RTV, Figure 2.12 
below.
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Figure 2.12: Gene expression assays in Huh7 cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20pM 22(S)-Hydroxycholesterol and atazanavir (ATV) for 24h: A 
ApoA-l; B = ApoC-ll; and C = ApoC-lll, n=4 for all assays. *** denotes P=<0.0001, ** 
denotes P=0.001 * denotes P=<0.01.
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PPARa gene expression was significantly repressed by RTV at concentrations of 
0.1 pM (2.6 fold decrease compared to vehicle control, P=<0.0001), 1.0pM (5.1 fold 
decrease compared to vehicle control, P=<0.0001) and IGpM (6.2 fold decrease 
compared to vehicle control, P=<0.0001) in Huh? cells (n=4), Figure 2.13 below. 
The repression of PPARa by RTV at concentrations of O.lpM (2.6 fold decrease), 
l.OpM (5.1 fold decrease) and lOpM (6.2 fold decrease) was abolished by the LXRa 
antagonist 22-(S)-hydroxycholesterol in Hull? cells (n=4). Figure 2.13 below. 
PPARa gene expression was significantly down-regulated by ATV at the lOpM 
concentration only (1.1 fold decrease compared to vehicle control, P=<0.0001). At 
ATV concentrations of O.lpM and 1.0pM there was no significant change in the 
expression of PPARa compared to the vehicle control. Figure 2.13 below.
Significant induction of SREBP-lc at O.lpM (1.3 fold increase compared to vehicle 
control, P=<0.0001), l.OpM (2.1 fold increase compared to vehicle control, 
P=<0.0001) and lOpM RTV was observed (3.2 fold increase compared to vehicle 
control, P=<0.0001) in Huh? cells (^=4), Figure 2.13 below. The statistically 
significant induction of SREBP-lc at O.lpM (1.3 fold increase), l.OpM (2.1 fold 
increase) and lOpM (3.2 fold increase) observed after 24h treatment with RTV was 
abolished by the addition of 20pM 22-(S)-hydroxycholesterol at each of the RTV 
concentrations. Figure 2.13 below. Significant repression of SREBP-lc by ATV at 
concentrations of O.lpM (1.3 fold decrease compared to vehicle control, p=<0.0001), 
l.OpM (1.6 fold decrease compared to vehicle control, P=<0.0001) and lOpM (1.8 
fold decrease compared to vehicle control, P^O.OOOl) was observed after 24h 
induction in Huh? cells (n=4). Figure 2.13 below.
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VLDLR was significantly repressed by RTV at concentrations of 0.1 pM (7.7 fold 
decrease compared to vehicle control, P=<0.0001), l.OpM (15.8 fold decrease 
compared to vehicle control, P=<0.0001) and lOpM (10.9 fold decrease compared to 
vehicle control, P=<0.0001), in Huh7 cells (n=4). Figure 2.13 below. The significant 
repression of VLDLR by RTV at concentrations of 0.1 pM (7.7 fold decrease), 
LOpM (15.8 fold decrease) and lOpM (10.9 fold decrease), was also abolished by 
the addition of 20pM 22-(S)-hydroxycholesterol at each RTV concentration, Figure 
2.13 below. VLDLR was significantly induced by ATV at concentrations of 0.1 pM 
(1.3 fold increase compared to vehicle control, P=0.0015), LOpM (1.6 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (3.9 fold increase compared to 
vehicle control, P=<0.0001) in Huh7 cells (n=4). Figure 2.13 below.
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Figure 2.13: Gene expression assays in Huh7 cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20pM 22(S)-Hydroxycholesterol and atazanavir (ATV) for 24h: A= 
PPARa; B = SREBP-1c; and C = VLDLR, n=4 for all assays. *** denotes P=<0.0001, ** 
denotes P=0.001t ‘denotes P=<0.01.
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LXRa was also significantly induced by RTV concentrations of 0.1 (3.8 fold
increase compared to vehicle control, P=<0.0001), l.OpM (6.7 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (16.7 fold increase compared to 
vehicle control, P=<0.0001) in Huh7 cells (n=4), Figure 2.14 below. The addition of 
20pM 22-(S)-hydroxycholesterol to each of the RTV concentrations abolished its 
significant induction of effects on LXRa in Huh7 cells (n=4). Figure 2.14 below. 
LXRa was significantly induced by ATV concentrations of 0.1 pM (1.1 fold increase 
compared to vehicle control, P=0.042), l.OpM (1.2 fold increase compared to vehicle 
control, P=0.0384) and lOpM (1.3 fold increase compared to vehicle control, 
P=0.0005) in Huh7 cells (n=4), however, this was less marked than that which was 
observed for RTV, Figure 2.14 below.
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Figure 2.14: LXRa Gene Expression Assay in Huh7 cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20pM 22(S)-Hydroxycholesterol and atazanavir (ATV) for 24h, 
n=4. *** denotes P=<0.0001, ** denotes P=<0.001, * denotes P=<0.05.
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HNF4a was significantly repressed by RTV at concentrations of 0.1 pM (1.4 fold 
decrease compared to vehicle control, P=<0.0001), l.OpM (2.8 fold decrease 
compared to vehicle control, P-<0.0001) and lOpM (5.3 fold decrease compared to 
vehicle control, P=<0.0001) in Huh? cells (n=4), Figure 2.15 below. HNF4a, 
however, was also significantly repressed by RTV in the presence of 20fiM 22-(S)~ 
hydroxycholesterol at concentrations of 0.1 pM (1.3 fold decrease compared to 
vehicle control, P=0.0035), l.OpM (2.8 fold decrease compared to vehicle control, 
P=<0.0001) and lOpM (5.1 fold decrease compared to vehicle control, P=<0.0001) 
in Huh? cells (n=4). Figure 2.15 below. HNF4a was significantly induced by ATV at 
concentrations of 0.1 pM (2.2 fold increase compared to vehicle control, P=0.0009), 
l.OpM (2.5 fold increase compared to vehicle control, P=<0.0001) and lOpM (4 fold 
increase compared to vehicle control, P=<0.0001) in Huh? cells (n=4), Figure 2.15 
below.
FXR was significantly induced by RTV concentrations of 0.1 pM (1.5 fold increase 
compared to vehicle control, P=<0.0001), l.OpM (2,1 fold increase compared to 
vehicle control, P=<0.0001) and lOpM (1.5 fold increase compared to vehicle 
control, P=<0.0001) in Huh? cells (n=4). Figure 2.15 below. FXR was also 
significantly induced by RTV in the presence of 20pM 22-(S)-hydroxycholesterol at 
concentrations of 0.1 pM (1.4 fold increase compared to vehicle control, P=<0.0001), 
l.OpM (2 fold increase compared to vehicle control, P=<0.0001) and lOpM (1.5 fold 
increase compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 2.15 
below. Significant repression of FXR gene expression was observed at ATV 
concentrations of 0. IpM (1.8 fold decrease compared to vehicle control, P^O.OOOl),
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l.OfaM (1.8 fold decrease compared to vehicle control, P=<0.0001) and lOpM (2.1 
fold decrease compared to vehicle control, P=<0.0001) in Huh7 cells (n=4). Figure 
2.15 below.
VDR was significantly induced by RTV concentrations of 0.1 pM (1.5 fold increase 
compared to vehicle control, P=<0.0001), 1.0pM (2 fold increase compared to 
vehicle control, P^cO.OOOl) and lOpM (7.3 fold increase compared to vehicle 
control, P=<0.0001) in Huh7 cells (0=4), Figure 2.15 below. VDR was also 
significantly induced by RTV in the presence of 20pM 22-(S)-hydroxycholesterol at 
concentrations of 0. IpM (1.5 fold increase compared to vehicle control, P=<0.0001), 
1.0pM (2.1 fold increase compared to vehicle control, P=<0.0001) and lOpM (7.6 
fold increase compared to vehicle control, P=<0.0001) in Huh7 cells (n=4), Figure 
2.15 below. VDR was significantly induced by ATV concentrations of 0.1 pM (1.3 
fold increase compared to vehicle control, P=0.0005), l.OpM (1.6 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (1.6 fold increase compared to 
vehicle control, P=<0.0001) in Huh7 cells (n=4), however, this was less marked than 
that which was observed for RTV, Figure 2.15 below.
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HNF4a Expression in Huh7 (p24) Cells - 24h Induction
* 2.0
[Drug] iiM
B FXR Expression in Huh? (p24) Cells - 24h Induction
[Drug] uM
VDR Expression in Huh? (p24) Cells - 24h Induction
5 6.0
cc 1.0
[Drug]
Figure 2.15: Gene expression assays in Huh? cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20|jM 22(S)-Hydroxycholesterol and atazanavir (ATV) for 24h: A= 
HNF4a; B = FXR; and C = VDR, n=4 for all assays. *** denotes P=<0.0001, ** denotes 
P=0.001, ‘denotes P=<0.01.
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2.6 Discussion
This Chapter investigated the specific impact of the Pis RTV and ATV on gene 
expression in NRs involved in lipid metabolism which were identified in Section 2.1 
of this thesis, and on the gene expression of downstream targets in their metabolic 
pathways (Table 2.2). It considered whether the differential effects in gene 
expression in the presence of RTV and ATV could be attributed to differences in the 
cellular accumulation of these drugs. Finally it determined the effect of an LXRa 
antagonist (22-(S)-hydroxycholesterol) on gene expression in RTV and ATV treated 
Huh? cells.
Cellular accumulation assays of RTV and ATV in the hepatic cell line, Huh?, 
indicated that the deleterious side effects associated with RTV were not due to higher 
intracellular accumulation of this drug. The results (Section 2.5.5) demonstrated that 
ATV intracellular accumulation was 2 fold greater than it was for RTV. It was 
concluded, therefore, that intracellular accumulation was not influencing the 
contrasting metabolic profiles of these drugs.
Gene expression analysis was conducted using Taqman Gene Expression inventoried 
assays for RT-PCR (Applied Biosystems Limited, Warrington, UR) and in-house 
developed real time PCR gene expression assays for quantification by Pico-green. 
The Taqman Gene Expression inventoried assays for RT-PCR (Table 2.3) were used 
for FXR, LXRa, ApoA-I, ApoC-II, ApoC-III, SREBP-1C, VLDLR, SLC10A1, 
PPARa, CYP7A1, GAPDH and [3-actin. The in-house developed real time PCR gene 
expression assays for quantification by Pico-green were used to determine the gene 
expression of HSP70, IBABP-L, VDR and HNF4a. Development and optimisation
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of these assays was as described in Sections 2.S.2.7 and 2.5.3. All gene expression 
was quantified against the housekeeping gene, (3-2-microglobulin ((3-2M), a Taqman 
inventoried Gene Expression assay.
FXR activation improves serum lipid profiles through suppression of hepatic 
triglyceride synthesis via repression of SREBP-lc and increased expression of lipid 
metabolism genes including PLTP, LCAT and ApoC-II (Fiorucci et al,, 2007). The 
observed significant up-regulation of ApoC-II (P=<0.0001 at 0.1 pM, IpM and 
lOpM) and significant down-regulation of HNF4a (P=<0.0001 at 0.1 pM, IpM and 
lOpM) gene expression was consistent with the expected outcome of the significant 
induction of FXR (P=<0.0001 at 0.1 pM, IpM and lOpM) by RTV. The addition of 
the LXRa antagonist 22(S)-hydroxycholesterol to the RTV induction experiments 
did not knock-out the up-regulation of FXR or the down-regulation of HNF4a by 
RTV. The up-regulation of ApoC-II by RTV was, however, completely abolished in 
the presence of the LXRa antagonist suggesting that more than one mechanism is 
involved in its up-regulation, FXR was significantly down-regulated in response to 
ATV induction studies (P=<0.0001 at O.lpM, IpM and lOpM) whilst HNF4a gene 
expression was significantly up-regulated by ATV (P=0.0009 at O.lpM, and 
P=<0.0001 at IpM and lOpM) suggesting that down-regulation of FXR may be the 
mechanism involved with this response. This was not investigated further in this 
thesis as ATV has a better lipid profile than RTV and the focus of this research was 
directed towards the metabolic target genes where the observed effect was 
inconsistent with regulation by FXR. ApoC-II, a mediator of TG metabolism, was 
significantly down-regulated by all concentrations of ATV induction ((P=<0.0001 at
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0.1 |jM, IjjM and IOjjM with a maximal 4.4 fold decrease compared to vehicle 
control at O.lpM), which may be attributed to regulation by PPARcc. Again this was 
not further investigated during this research due to the contrasting lipid profile of 
ATY which is better than that of RTV, with the focus remaining on the deleterious 
metabolic side effects of the latter.
SREBP-lc is a target gene of FXR via a SHP-1 dependent pathway. The 
consequence of FXR down-regulation of SREBP-lc in vivo would be the repression 
of hepatic triglyceride and fatty acid synthesis (Zhang et aL, 2008). Although FXR 
mediated inhibition of fatty acid synthesis may be transient. Prolonged exposure to 
high levels of bile acids or potent agonists does not appear to have the same 
beneficial effects as short term exposure on plasma lipids. SHP-1 mediated 
suppression of SREBP-lc via FXR activation appears to be overcome through the 
direct activation of fatty acid synthase (FAS) by FXR which is necessary for 
sufficient fatty acid synthesis under states of cholesterol and bile acid excess to avoid 
cholesterol toxicity (Fiorucci et aL, 2007). The up-regulation of FXR by RTV should 
therefore have resulted in the inhibition of SREBP-lc via SHP-1, if this pathway was 
dominating the regulation of this gene.
The RTV induction assays resulted in a significant up-regulation of SREBP-lc 
(P=<0.0001 at 0.1 pM, IjjM and IOjjM). When this is compared to a concentration 
dependent significant increase in FXR expression, it suggests another mechanism 
was involved with SREBP-lc up-regulation. There is evidence that the effects of 
LXRa on fatty acid synthesis are mediated through the increased expression of
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SREBP-l c, and that the latter is a transcription factor which has been associated with 
PI induced lipodystrophy (Telenti et al., 2002). As activated LXRa stimulates 
lipogenesis by inducing SREBP-lc and other lipogenic genes (Handschin et al, 
2005), and significant up-regulation of LXRa was observed at all RTV 
concentrations (P=<0.0001 at 0.1 pM, IpM and lOpM, with maximal 16.7 fold up- 
regulation at 10jrM RTV), it is likely that LXRa mediated the up-regulation of 
SREBP-lc in these assays. LXRa chemical antagonism using 22(S)- 
hydroxycholesterol abolished the induction effects of RTV on both LXRa and 
SREBP-lc supporting this hypothesis. Furthennore SREBP-lc gene expression was 
significantly down-regulated at all concentrations of ATV (P=<0.0001 at 0.1 pM, 
IpM and lOpM) suggesting a potential explanation for the contrasting lipid profiles 
of ATV and RTV.
LXRa has been shown to inhibit PPARa signalling (Miyata et al, 1996). PPARa 
was significantly down-regulated at all concentrations (P=<0.0001 at 0.1 pM, IpM 
and lOpM) in the RTV assays. LXRa inhibition with 22(S)-hydroxycholesterol also 
abolished the effects of RTV on PPARa supporting the hypothesis that LXRa is a 
key player in the regulation of PPARa. At 0.1 pM and IpM ATV there was no 
significant change in PPARa gene expression from vehicle controls. The significant 
down-regulation of PPARa by ATV observed at lOpM (maximal decrease of 1.1 fold 
compared to vehicle, P=<0.0001) was to a lesser magnitude than observed in the 
RTV experiments (maximal decrease of 6.2 fold compared to vehicle observed at 
10pM RTV). This may reflect the magnitude of difference between the increase in 
LXRa expression by ATV (maximal increase of 1.3 fold compared to vehicle
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observed at 10|aM, P=0.0005) compared to the increase in LXRa expression by RTV 
(maximal increase of 16.7 fold compared to vehicle observed at lOpM, P=<0.0001).
The induction of ABC transporters by LXRa increases the transfer of cholesterol and 
phospholipids to ApoA-I containing lipoproteins (Kalaany et al, 2006; Pascussi et 
al., 2008). The observed significant induction of VDR, like FXR, by RTV should 
result in repression of ApoA-I activity, but significant induction was observed at all 
RTV concentrations (P=<0.0001 at 0.1|uM, IpM and 1 OpM). This supports the 
theory that up-regulation of LXRa target genes may be the mechanism involved with 
the significant up-regulation of ApoA-I, supported by the abolition of this up- 
regulation when the LXRa antagonist, 22(S)-hydroxycholesterol was co-incubated 
with RTV. The significant up-regulation of ApoA-I by ATV (maximal increase of 
1.6 fold compared to vehicle observed at lOgM ATV, P=<0.0001) was to a much 
lesser magnitude than observed in the RTV experiments (maximal increase of 5.6 
fold compared to vehicle observed at lOpM RTV, P=<0.0001). This also may be 
attributed to the magnitude of difference between the increase in LXRa expression 
by ATV (maximal increase of 1.3 fold compared to vehicle observed at 1 OpM) 
compared to the increase in LXRa expression by RTV (maximal increase of 16.7 
fold compared to vehicle observed at IOjuM).
PPARa induction leads to the repression of ApoC-III (Duval et al, 2007; Feldman et 
ctL, 2008; Yamada et al, 2007). In the RTV assays, the significant down-regulation 
of PPARa may have contributed to the significant induction of ApoC-III, (a 5 fold 
increase compared to the vehicle control at lOpM RTV, P=<0.0001), as LXRa
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induces ApoC-III through its repression of PPARa which was significantly down- 
regulated at all RTV concentrations. Furthermore the inhibition of LXRa by 22(S)- 
hydroxycholesterol abolished the effects of RTV on ApoC-III (and PPARa) 
supporting the hypothesis that LXRa is a key player in the regulation of both ApoC- 
III and PPARa. ApoC-III gene expression was significantly up-regulated by a 
magnitude of 1.1 fold at all ATV concentrations (P=0.0009 at 0.1 pM, P=<0.0001 at 
l.OpM and P=0.0022 at lOpM) which may be a contributory factor in the 
mechanisms involved with the contrasting lipid profiles of ATV and RTV.
LXRa also represses VLDLR (Scotti et al.) which was significantly down-regulated 
at all RTV concentrations (P=<0.0001 at O.lpM, IpM and lOpM) with the maximal 
15.8 fold decrease compared to vehicle seen at l.OpM RTV. Inhibition of LXRa with 
22(S)-hydroxycholesterol abolished the effects of RTV on VLDLR supporting the 
hypothesis that LXRa was regulating VLDLR. The statistically significant up- 
regulation of VLDLR by all concentrations of ATV (P=0.0015 at 0.1 pM, and 
P=<0.0001 at IpM and lOpM, with the maximal increase of 3.9 fold compared to 
vehicle observed at 1 OpM) is consistent with the regulation of this gene by FXR and 
by PPARa regulation. This may again underpin the different mechanisms involved in 
the contrasting lipid profiles of ATV and RTV.
The use of RTV at low doses in combination with other Pis exploits its role as a 
pharmacoenhancer to inhibit their metabolism (Foisy et al^ 2008). RTV is no longer 
used at therapeutic doses due to its high toxicity and the availability of other Pis with 
more attractive lipid profiles (Foisy et aL, 2008) including ATV (Barreiro et al.
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2005). The beneficial effects of RTV as a pharmacoenhancer also make it a notorious 
mediator of drug-drug interactions and toxological effects due to non-clearance of 
these drugs (Barreiro et al, 2005; Foisy el al, 2008). Pis boosted by RTV still carry 
a high pill burden as part of twice daily regimens and the probability of treatment 
interruption due to drug induced toxicity is 2 fold greater with RTV than with ATV. 
Furthennore patients taking a RTV boosted regimen have incurred significant 
increases in total cholesterol and triglyceride levels after 48 week trials whereas the 
same parameter in the ATV cohort were unchanged (Barreiro et al., 2005). The 
differences in the cellular accumulation of RTV and ATV shown in Section 2.5.5 are 
important as it proves the hypothesis that the differential metabolic effects observed 
in the RTV assays were not due to higher intracellular accumulation and supports the 
hypothesis that these drugs target different genes in the lipid metabolism complex.
Current research continues to examine the role and impact of individual and multiple 
NR “knockdown” on the induction profile of the target genes of the metabolic NRs, 
thereby determining the relative contribution of FXR, LXRa and PPARa in both a 
drug-specific and tissue-specific manner. Chapter 3 of this thesis will discuss the 
comparative effects of biological knockout of LXRa on the differing gene expression 
profiles associated with RTV and ATV in the Huh? cell line, in an effort to confirm 
the specific influence of LXRa in these findings.
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CHAPTER 3
THE INFLUENCE OF SIRNA KNOCKDOWN OF LIVER 
OXYSTEROL RECEPTOR ALPHA (LXRot) IN 
RITONAVIR TREATED HEPATIC CELLS
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3.1 Introduction
Chapter 2 of this thesis outlined the role of the metabolic NRs together with the role 
of the Pis RTV and ATV as substrates for/activators of these NRs (Dussault et ai, 
2001; Healan-Greenberg et al, 2008; Lehmann et al, 1998). Chapter 2 also 
discussed the impact that Pis have been shown to have on several molecular 
pathways key to lipid metabolism including intra-nuclear transcription factors and 
the nuclear proteasome (Lagathu et aL, 2005; Mallon, 2007). The regulatory 
mechanisms and target genes for the metabolic NRs have been outlined in Chapter 1 
- General Introduction of this thesis and the complex nature of the metabolic NRs 
involved in bile acid metabolism and detoxification together with genes and 
transporters regulated by the activation of the NRs is outlined in Figure 2.1, (Chapter 
2). In Chapter 2 the role of FXR and LXRa as master regulators of cholesterol 
homeostasis, and modulators of the transcription of many key genes involved in drug 
and lipid metabolism including SREBP-lc, a key player in lipogenesis (Hui, 2003; 
Liang et aL, 2001; Osborne, 2000) was discussed. This Chapter continues to 
investigate the role of the metabolic NRs in regulating lipid and bile homeostasis in 
response to PI metabolism.
In Chapter 2, the LXRa antagonist 22-(S)-hydroxycholesterol was used to 
chemically inhibit LXRa gene expression. An antagonist reduces the effects of an 
agonist, which may be an endogenous ligand or a drug, by either competing for the 
receptor binding site to stop the agonist binding thereby reducing any potential 
agonist effects. This may be reversible or irreversible binding, the former being 
concentration dependent and the latter due to covalent bind to the receptor. Other
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antagonists may be non-competitive (binding an alternate site to block the agonist 
binding the receptor) or functional, exerting the opposite effect to the agonist, by 
binding an alternate site and through which it actions as an agonist, and reducing the 
effect of the agonist at the first receptor. 22-(S)-hydroxycholesterol has previously 
been shown to bind LXRct without activation (Janowski el aL, 1999) and was 
therefore considered a suitable LXRa antagonist to determine the involvement of 
LXRa in the metabolic NR response to RTV. The use of a chemical antagonist to 
validate the effects of RTV on LXRct gene expression and its regulation of target 
gene expression has limitations even for the best characterised ligands as it is unwise 
to ignore the possibility that RTV and/or the antagonist may be influencing this gene 
expression through promiscuity at more than one target.
Biological knockdown of a gene by siRNA causes a transient knockdown of gene 
expression by degradation of the mRNA transcript responsible for protein synthesis 
(Dykxhoom et aL, 2006). The effects are transient because new protein can be 
synthesised when new mRNA is transcribed. The duration of the knockdown will 
vary between genes so it is necessary to validate the knockdown at both the gene 
expression and protein levels.
Chapter 2 also discussed the observed impact of RTV up-regulation of FXR gene 
expression on its target genes ApoC-II (significantly up-regulated) and HNMa 
(significantly down-regulated) It contrasted these findings with the reported role of 
FXR activation in the improvement of serum lipid profiles through repression of 
SREBP-lc and increased expression of PLTP, LCAT and ApoC-II (Fiorucci et aL,
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2007). RTV effects on HNF4a were not influenced by co-incubation with the LXRa 
antagonist 22(S)-hydroxycholesterol, supporting the hypothesis of FXR influencing 
its regulation. The up-regulation of ApoC-II by RTV was, however, completely 
abolished in the presence of the LXRa antagonist, supporting the hypothesis that 
both FXR and LXRa influence the regulation of ApoC-II. This chapter further 
investigates the influence of LXRa inhibition on ApoC-II gene expression in the 
presence of RTV.
In Chapter 2, it was hypothesised that LXRa had mediated the up-regulation of 
SREBP-lc, as the LXRa antagonist 22(S)-hydroxycholesterol abolished the 
induction effects of RTV on both LXRa and SREBP-lc. In this Chapter, knockdown 
of LXRa by small interfering RNA (siRNA) is used to probe the findings of Chapter 
2 and to further assess the influence of RTV on the previously identified target genes 
of LXRa and FXR. It was also hypothesised that LXRa inhibits PPARa gene 
expression as this was significantly down-regulated in the RTV assays and these 
effects were abolished in when RTV was co-incubated with the LXRa antagonist 
22(S)-hydroxycholesterol. The use of siRNA knockdown of LXRa will seek to 
validate this.
It has been reported that PPARs may regulate metabolic gene expression by the 
fonnation of a NR heterodimer with LXRa (Giguere, 1999). PPARa induction leads 
to the repression of ApoC-III (Duval et al, 2007; Feldman et a!., 2008; Yamada et 
al., 2007). In the RTV assays. Chapter 2, the observed significant down-regulation of 
PPARa may have influenced the significant up-regulation of ApoC-III, as LXRa
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induces ApoC-III through its repression of PPARa. Co-incubation with LXRa 
antagonist, 22(S)-hydroxycholesterol, abolished the effects of RTV on ApoC-III (and 
PPARa) supporting the hypothesis that LXRa is involved in the regulation of both 
these genes. It is further hypothesised VLDLR gene expression which was 
significantly down-regulated at all RTV concentrations was inhibited via LXRa up- 
regulation as co-incubation with LXRa antagonist 22(S)-hydroxycholesterol 
abolished the effects of RTV on VLDLR.
The observed significant induction of VDR, like FXR, by RTV in Chapter 2 should 
have resulted in the down-regulation of ApoA-I expression, but the opposite effect 
was observed at all RTV concentrations. It is hypothesised that the up-regulation of 
LXRa target genes may be influencing the significant up-regulation of ApoA-I, a 
theory supported by the abolition of this up-regulation when the LXRa antagonist, 
22(S)-hydroxycholesterol was co-administered with RTV.
Current research continues to examine the role and impact of individual and multiple 
NRs on the induction profile of the target genes, thereby detennining the relative 
contribution of FXR, LXRa and PPARa in both a drug-specific and tissue-specific 
manner. This Chapter will discuss the comparative effects of biological knockout of 
LXRa by siRNA on the gene expression profiles associated with RTV in the Huh7 
cell line, in an effort to confinn the specific influence of LXRa in these findings.
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3.2 Aim
The aims of this research were to further investigate the specific impact of the PI 
RTV on gene expression in NRs involved in lipid metabolism identified in Section
2.1 of this thesis, and on the gene expression of downstream targets in their 
metabolic pathways (Table 2.2); to confirm the differential effects in gene expression 
in the presence of RTV and RTV plus 22(S)-hydroxycholesterol seen in Section 
2.5.6 and to establish the effect of using siRNA knockdown of LXRa on gene 
expression in RTV treated cells.
3.3 Materials and Methods
3.3.1 Materials
As previously described in Section 2.3.1 above. CelLytic M and Protease Inhibitor 
Cocktail were purchased from Sigma Aldrich Co. Limited (Irvine, Ayrshire, UK). 
Lipofectamine 2000 Transfection Reagent and Novex Western Protein Kit including 
NuPage Precast Gels and iBlot kits were purchased from Invitrogen Limited 
(Paisley, UK). LXRa, GAPDH and non-Targeting small interfering RNAs (siRNAs) 
were purchased from Dhannacon-Thermo Scientific (Epsom, UK). Monoclonal 
mouse anti-human antibody for GAPDH was purchased from Abeam PLC 
(Cambridge, UK). Monoclonal mouse anti-human antibodies for LXRa and (3-actin, 
and goat anti mouse secondary antibody were purchased from R and D Systems 
Europe Limited (Abingdon, Oxon, UK).
3.3.2 Cells and Cell Maintenance
3.3.2.1 Huh7 Cell Line
As previously described in Section 2.3.2.1 above.
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3.3.2.2 MTT Cell Toxicity Assays
As previously described in Section Z3.2.2 of this thesis.
3.3.2.3 Cell Treatment
The Huh7 cell line was seeded at a density of 2.5xl06 per well into 10% FCS- 
supplemented DMEM medium, in Nunclon Up-Cell Surface 6 well plates and 
incubated at 37°C and 5% CO2 for 24h prior to the set-up of all biological 
knockdown experiments. The concentration-response experiments for RTV, ATV 
and analysis of methanol treated controls were conducted as previously described in 
Section 2.3.2.3 above. The concentration-response experiments for RTV in the 
biological knockdown treated Huh7 cells were conducted at final concentrations of 0, 
0.1, 1.0, and lOpM RTV following an initial 24h knockdown by siRNA. The cells 
were incubated at 37°C and 5% C02 and were sampled at 24h.
3.3.2.4 RNA Isolation from Huh7 Cells
Isolation of RNA from untreated, RTV-treated, ATV-treated and siRNA treated 
Huh7 cells was undertaken using the Tri®Reagent method as described in 2.3.2.4.
3.3.2.5 Production of cDNA
The cDNA was synthesised as previously described in Section 2.3.2.5 above.
3.3.2.6 Identification of Preferred Housekeeping Control by Gene Expression Assay
Selection of suitable candidate housekeeping controls was determined by gene 
expression analysis in Huh7 cells (n=3) in three conditions: untreated cells, mock 
transfections (Lipofectamine 2000 vehicle with siRNA vehicle only) and siRNA 
knockdown of LXRct using Taqman Endogenous Control Plates. The results of the
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initial analysis revealed five potential candidates: Glyceraldehyde Phosphate 
Dehydrogenase (GAPDH); p-actin; Hydroxymethyl-bilane Synthase (HMBS); and 
60S Acidic Ribosomal Protein (also known as human Large Ribosomal Protein, 
RPLPO) Figure 3.1, below; and p-2-microglobulin (P-2M, Figure 3.2). Large volume 
endogenous control assays were not available for all individual Taqman inventoried 
assays so further analysis was perfonned on p-actin and p-2M across all treatments 
in Huh? cells.
3.3.2.? Optimisation of LXRot Knockdown in the Huh? Cell Line
LXRtx was identified as a target for biological knockdown to facilitate further 
investigation of its regulation of gene expression in response to 24h exposure to 
RTV. GAPDH was identified as a suitable positive control for siRNA knockdown as 
it had previously been determined to have stable gene expression levels 24h exposure 
to RTY and RTV plus 20pM 22-(S)-hydroxycholesterol, and in untreated Huh? cells. 
The negative control of Dharmacon Non-Targeting siRNA was selected on the basis 
of previous experience within the Liverpool HIV Pharmacology Group (LHPG).
Lipofectamine 2000 (Invitrogen, UK) was used to transfect Huh? cells using a matrix 
of Lipofectamine 2000 (0.5pl, l.Opl and 1.5pi) and siRNA concentrations (OnM, 
5nM, 10nM, 15nM and 20nM) in 48 well plates to optimise the conditions for 
maximal knockdown at the mRNA level over 3 time periods: 24h, 48h and 72h in 
accordance with the manufacturer’s instructions. Each reaction was set up with 4 
biological and 4 technical replicates. Controls were set up for each time period as 
untreated cells and vehicle controls with 0.5j.il, l.Opl and 1.5pi Lipofectamine plus 
2 5 pi of 1 x siRNA buffer (prepared in accordance with Dhannacon instructions) per
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reaction. Transfections were performed in accordance with the manufacturer’s 
standard protocol for Lipofectamine 2000 (Invitrogen, UK). Briefly, the day prior to 
transfection 2x105 Huh? (at passage 22) cells were plated in 250pl 10% FCS/DMEM 
culture medium so that at transfection they would be 30-50% confluent. The culture 
media was replaced by pre-wanned (37°C) serum free DMEM media on the day of 
transfection. LXRet, GAPDH (positive control) and non-targeting (negative control) 
siRNAs were diluted in lx siRNA buffer (25pi) (prepared in accordance with 
Dharmacon instructions) to provide concentrations to give final reaction 
concentrations in the range 5nM to 20nM, and incubated for 5 minutes at room 
temperature whilst the diluted Lipofectamine 2000 in serum free DMEM (25pi) 
media was prepared. Following incubation the dilute siRNA and dilute 
Lipofectamine 2000 were combined and incubated at room temperature for a further 
20 minutes. The siRNA/Lipofectamine 2000 complexes were added to the 
appropriate wells containing cells and were mixed gently by rocking the plate. Each 
well volume was made up to 200p! by the addition of a further 150pl serum free 
DMEM media. The plates were incubated at 37°C/5% CO2 for 4 hours. Following 4 
hour incubation the siRNA/Lipofectamine 2000 complex containing media was 
completely aspirated and replaced by pre-wanned (37°C) 10% FCS/DMEM media 
prior to further incubation at 37°C/5% C02 for 24h, 48h or 72h, until ready for 
analysis of gene knockdown efficiency by RT-PCR.
Following optimisation confinnation of the preferred conditions for maximum 
efficiency mRNA knockdown, the transfections were repeated scaled-up in 
accordance with the manufacturer’s instractions to facilitate optimisation of protein
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knockdown. Briefly, Lipofectamine 2000 was used to transfect 2.5xl06 Huh? (at 
passage 23) cells plated in 2.5ml (final volume) media using 5j.il Lipofectamine 2000 
and LXRa siRNA (15nM), GAPDH (20nM) and non-targeting siRNA (20nM) final 
concentrations in 6 well Nunclon Up-Cell plates to optimise the conditions for 
maximal knockdown at the protein and mRNA levels over 3 time periods: 24h, 48h 
and 72h as described above. Nunclon Up-Cell 6 well plates (for temperature sensitive 
release of adherent cells) were used for scaled up assays as they facilitated protein 
and RNA extraction from the same lysate. Efficiency of the siRNA knockdown was 
detennined by RT-PCR.
Protein was extracted using CelLytic M and protease inhibitor cocktail in accordance 
with the manufacturer’s standard protocol (Sigma Aldrich, UK). Briefly, the growth 
medium was removed from the cells, then the cells were rinsed once with phosphate 
buffered saline (PBS), and PBS discarded. 150pl CelLytic M reagent containing 
1:100 protease inhibitor cocktail (Sigma Aldrich, UK) were added. Cells were 
incubated for 15 minutes on a shaker and the lysed cells collected. The lysed cells 
were centrifuged for 15 minutes at 12000 x g to pellet the cellular debris. The 
protein-containing supernatant was removed to a chilled tube. Unused lysate was 
stored at -80°C
Protein was quantified against a BSA standard curve and normalised to 50pg per 
reaction for analysis of the efficiency of the protein knockdown by Western blot 
analysis. Western blot was performed in accordance with the manufacturer’s 
instructions (Invitrogen Limited, Paisley, UK). Briefly, 50pg total protein was
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combined with an equal volume of NuPage LDS loading buffer and 10% Nupage 
reducing agent, samples were heated to 70°C for 10 minutes, cooled and loaded onto 
NuPage Novex Bis-Tris Mini Gels, and run in a XCell Surelock™ Mini Cell at 200V 
for 50 minutes, the gel was then washed with distilled water and transferred to iBlot 
nitrocellulose for 7 minutes at 23 volts. The membrane was blocked with 10% non­
fat dried milk in 0.1% T-TBS (Tween 20 and Tris buffered saline) overnight at 4°C. 
The membrane was washed 3 times and the primary antibody added in 2% non-fat 
dried milk in 0.1% T-TBS for 2 hours at 4°C, washed a further 4 times and the 
secondary antibody added in 2% non-fat dried milk in 0.1% T-TBS for 1 hour at 
4°C. The membrane was washed a further 12 times, blotted and enhanced 
chemiluminescence perfonned, exposed to light sensitive film, developed and fixed. 
Protein bands were validated against Novex Sharp Standards (Invitrogen Limited, 
Paisley, UK).
3.3.2.8 LXRa Knockdown in the Huh7 Cell Line
Huh7 cells (at passage 22) were transfected with 5pi Lipofectamine 2000/15nM 
siRNA final concentration (LXRa) and 20nM siRNA GAPDH (positive control) and 
Non-Targeting (negative control) final concentrations in 6 well Nunclon® Up-Cell® 
plates for 24h in accordance with the optimised methodology outlined in 3.2.2.7 
above. Briefly, the day prior to transfection 2.5xl06 cells were plated in 2.5ml 10% 
FCS/DMEM culture medium so that at transfection they would be 30-50% confluent. 
The culture media was replaced by pre-wanned (37°C) serum free DMEM media on 
the day of transfection. LXRa, GAPDH (positive control) and non-targeting 
(negative control) siRNAs were diluted in lx siRNA buffer (25pl) (prepared in 
accordance with Dhannacon instructions) to provide concentrations to give final
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reaction concentrations at 15nM (LXRa) and 20nM (positive and negative controls), 
and incubated for 5 minutes at room temperature whilst the diluted Lipofectamine 
2000 in serum free DMEM (25pi) media was prepared. Following incubation the 
dilute siRNA and dilute Lipofectamine 2000 were combined and incubated at room 
temperature for a further 20 minutes. The siRNA/Lipofectamine 2000 complexes 
were added to the appropriate wells containing cells and were mixed gently by 
rocking the plate. Each well volume was made up to 2.5ml by the addition of a 
further 2ml serum free DMEM media. The plates were incubated at 37°C and 5% 
C02 for 4 hours. Following 4 hour incubation the siRNA/Lipofectamine 2000 
complex containing media was completely aspirated and replaced by pre-warmed 
(37°C) 10% FCS/DMEM media prior to further incubation at 37°C and 5% CO2 for 
24h until ready for analysis of gene knockdown efficiency by RT-PCR. Efficiency 
of the protein knockdown was determined by western blot analysis, as described in 
332.1.
3.3.2.9 RT-PCR Gene Expression
Taqman Gene Expression inventoried assays for RT-PCR (Applied Biosystems 
Limited, Warrington, UK, (Table 2.3)) were used for FXR, LXRa, ApoA-I, ApoC-II, 
ApoC-III, SREBP-1C, VLDLR, PPARa, GAPDH and p-actin quantified against the 
housekeeping gene p-2-microglobulin (P2M). Amplification was perfonned as 
previously described in Section 2.3.2.9 above.
3.4. Statistical Analysis
Statistical analysis of all results was undertaken using StatsDirect Statistical software 
version 2.7.8 as previously described in Section 2.4 above.
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3.5 Results
3.5.1 MTT Toxicity Assays
Results for the MTT toxicity assays are shown in 2.5.1 of this thesis.
3.5.2 Selection of Preferred Housekeeping Control by Gene Expression Assay 
Selection of suitable candidate housekeeping controls was determined by gene 
expression analysis in Huh? ceils (n=3) in three conditions: untreated cells, mock 
transfections (Lipofectamine 2000 vehicle with siRNA vehicle only) and siRNA 
knockdown of LXRa using Taqman Endogenous Control Plates. The results of the 
initial analysis revealed five potential candidates: GAPDH, which had been 
identified as a positive control for the siRNA knockdown experiments so was not the 
preferred housekeeping control; (l-actin; HMBS; and RPLPO, Figure 3.1 below; and 
[3-2-microglobulin (|3-2M, Figure 3.2). HMBS and RPLPO were not available as 
large volume endogenous controls in individual Taqman inventoried assays so 
further analysis was performed using (3-actin and P-2M across all treatments in Huh? 
cells, p-actin showed greater variance in Gr values across the RTV treated Huh? cells 
(Figure 3.3) consequently P-2M (Figure 3.4) was selected as the preferred 
housekeeping control.
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Figure 3.1: Endogenous Control Gene Expression Assay in untreated Huh7, Mock 
Transfection and siRNA LXRa Knockdown Huh7 cells (p23) n=3 for all assays: A = GAPDH; 
B = p-actin; C = HMBS; D = RPLPO.
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(32M Comparative Gene Expression (n=3)
Cells Mock siLXRa
Figure 3.2: (3-2-microglobulin Endogenous Control Gene Expression Assay in untreated 
Huh7, Mock Transfection and siRNA LXRa Knockdown Huh7 cells (p23) n=3.
(5-actin Mean Expression in Huh7 (p24) Cells
2.5
•5 2
£ 1.5
c■V
Z 1 0*
I 0.5 -I
c ^ ^ Jt>v 4.^ 4w 4>v 4.^ .J? 4^ 4T 4T 4.^ 4T 4^^ ^ ^ ^ ST <S^ £ 4 CS^ .cjy
<*- v
zVVV/>V^ z zV>iv A? X>
S*r yp X®/zz
[Drug] (iM
Figure 3.3: p-actin Endogenous Control Gene Expression Assay relative to GAPDH in Huh7 
(p24) Cells all conditions (n=4). (Mock Transfection = 5.0pl Lipofectamine 2000/25pl 1 x 
siRNA buffer (vehicle only) per reaction).
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Figure 3.4: (32M Endogenous Control Gene Expression Assay relative to GAPDH in Huh7 
(p24) Cells all conditions (n=4). (Mock Transfection = 5.0pl Lipofectamine 2000/25pl 1 x 
siRNA buffer (vehicle only) per reaction).
3.5.3 Quantification of RNA and cDNA
The RNA extracted from Huh? cells all conditions as described in Section 3.3.2.4 
above, was analysed and quantified using a Thermo-Scientific® Nanodrop 1000 to 
assess its quantity and purity. The RNA had an A260/A280 ratio in the range of 1.85- 
2.01 (RTV samples), 1.94-2.15 (ATV samples) and 1.85-1.97 (siRNA samples) 
indicating sufficient purity to proceed to cDNA construction for RT PCR. RNA 
samples were frozen at -80°C following cDNA construction.
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The cDNA for all conditions had A260/A280 ratios in the range of 1.98-2.13 indicating 
sufficient purity to proceed to construction of normalised (20ng/pl) cDNA working 
stocks. Master and working stock cDNA samples were frozen at -20°C until used in 
gene expression assays.
3.5.4 Optimisation of LXRa Knockdown in Huh? Cell Line
Optimal conditions for siRNA knockdown of LXRa} siRNA knockdown of GAPDH 
(positive control) and non-targeting siRNA (negative control) in Huh? (passage = 22) 
cells were determined by evaluating knockdown efficiency of each gene over three 
time periods: 24h, 48h and 72h> as described in 3.3.2.? above (Figure 3.5, below). 
RNA was isolated by the Tri®Reagent method as described in 3.3.2.4 above and 
reverse transcribed to cDNA as described previously in 3.3.2.5.
Optimum conditions for knockdown were determined to be l.Opl Lipofectamine 
2000 with 15nM LXRa siRNA in 48 well plates at the mRNA level over 24h (Figure 
3.5 below) and 48h (Figure 3.5 below), with evidence of recovery at the mRNA level 
observed after 72h (Figure 3.5 below). Optimal conditions for siRNA knockdown of 
GAPDH siRNA (Positive control; Figure 3.5 below) and stability of the non­
targeting siRNA (negative control; Figure 3.5 below) were determined to be 1.5pl 
Lipofectamine 2000 with 20nM GAPDH siRNA and l,5pl Lipofectamine 2000 with 
20nM non-targeting siRNA in 48 well plates at the mRNA level over 24h and 48h, 
mRNA recovery was again observed after 72h.
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Protein was extracted in accordance with the CelLytic standard protocol and 
quantified against a BSA standard curve (Figure 3.6, below) as described in 3.3.2.7 
above.
Figure 3.6: Standard Curve of BSA absorbance at 560nm for protein quantification.
Optimal conditions for scaled up siRNA knockdown of LXRa in Huh7 (passage = 
23) cells were determined to be 5.0pl Lipofectamine 2000 with 15nM final 
concentration LXRa siRNA in 6 well N unci on® Up-Cell® plates at the mRNA level 
over 24h (Figure 3.7 below). Optimal conditions for siRNA knockdown of GAPDH 
(Positive control; Figure 3.7 below) and non-targeting siRNAs (negative control; 
Figure 3.7 below) were determined to be 5.0pl Lipofectamine 2000 with 20nM final 
concentration GAPDH siRNA and 5.0pl Lipofectamine 2000 with 20nM final 
concentration non-targeting siRNA in 6 well N unci on® Up-Cell® at the mRNA level 
over 24h.
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LXRa 24h knockdown - Scaled up Optimisation in Huh7 (p23) Cells
■ LXRa in 24h Knockdown ■ GAPDH in 24h Knockdown
1.5 n
co
Cells 5nl/0nM 5ul/15nM Pos Control Neg Control
5ul/20nM 5|il/20nM
Lipofectamine2000 volume per reaction pl/siRNA Concentration nM n=4
Figure 3.7: Gene Expression Assay in Huh7 cells (passage no. = 23) for optimisation of 24h 
scaled up siRNA knockdown of LXRa and GAPDH (positive control) in 6 well plates, n=4.
The siRNA knockdown of LXRa and GAPDH at the protein level was confirmed at 
24h by Western Blot analysis, see Figure 3.8 below.
Figure 3.8: Representative GAPDH (Positive Control) and LXRa Protein Expression in 24h 
siRNA knockdown in Huh7 cells (at passage 23). A = Mock transfection (5pl Lipofectamine 
2000/0nM siRNA); B = LXRa Knockdown (5pl Lipofectamine 2000/15nM LXRa siRNA); C = 
GAPDH Knockdown (5pl Lipofectamine 2000/20nM GAPDH siRNA); D = Negative Control 
(5pl Lipofectamine 2000/20nM Non-Targeting siRNA); E = Untreated Huh7 Cells.
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3.5.5 Gene Expression in Ritonavir Treated LXRa Knockdown Huh? Cells
Optimal conditions for siRNA knockdown of LXRa in Huh? cells were determined 
to be 5.0pl Lipofectamine 2000 with 15nM final concentration LXRa siRNA in 6 
well plates at the mRNA and protein levels over 24h (3.3.6 above). Optimal 
conditions for siRNA knockdown of GAPDH (Positive control) and stable 
expression of non-targeting siRNA (negative control) were determined to be 5.0pl 
Lipofectamine 2000 with 20nM GAPDH siRNA and 5.0pl Lipofectamine 2000 with 
20nM non-targeting siRNA in 6 well plates at the mRNA and protein levels over 24h 
(3.5.4 above).
HSP70 gene expression was stable across all concentrations of RTV and ATV in 
Huh? cells (n=4), as previously shown in 2.5.6, it was consequently selected as the 
negative control for the RTV incubation experiments in the siRNA knockdown cells 
(Figure 3.9 below). There were no statistically significant differences in the HSP70 
mean expression values across all conditions compared to vehicle controls. Figure 
3.9 below.
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HSP70 - Expression in siRNA Knockdown Huh7 (p24) Cells - 24h Induction
I I
gj 0.80
« 0.60 -
•2 0.40 -
[Drug] pM
Figure 3.9: HSP70 Gene Expression Assay in Huh7 cells (passage no. = 24) (relative to 
housekeeping control f3-2M) incubated for 24h with ritonavir (RTV), RTV in Mock 
Transfection Huh7 cells and RTV in 24h siRNA knockdown Huh7 cells, n=4.
Significant up-regulation of ApoA-I by RTV was observed at concentrations of 
0.1 pM (2.7 fold increase compared to vehicle control, P^O.0001), l .OpM (3.6 fold 
increase compared to vehicle control, P=<0.0001) and lOpM (5.6 fold increase 
compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 3.10 below. 
The statistically significant up-regulation of ApoA-I by RTV was also observed in 
the Mock Transfection plus RTV incubations at concentrations of 0.1 pM RTV (2.7 
fold increase compared to vehicle control, P=<0.0001), l.OpM RTV (3.8 fold
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increase compared to vehicle control, P=<0.0001) and IOjiM RTV (5.6 fold increase 
compared to vehicle control, P=<0.0001), Figure 3.10 below. The expression of 
ApoA-I in siRNA LXRa knockdown cells without RTV was not significantly altered 
from basal expression in vehicle controls. Figure 3.10 below. The statistically 
significant up-regulation of ApoA-I by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM RTV with and without mock transfection was abolished in the 
siRNA LXRa knockdown samples at concentrations of 0.1 pM, l .OpM and lOpM 
RTV, Figure 3.10 below.
APOA1 Expression in siRNA Knockdown Huh7 (p24) 
Cells - 24h Induction
| 3.0 -
[Drug] iiM
Figure 3.10: APOA Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
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ApoC-II was significantly up-regulated by RTV at 0.1 pM (1.7 fold increase 
compared to vehicle control, P^cO.OOOl), l.OpM (3 fold increase compared to 
vehicle control, P=<0.0001) and lOpM (9 fold increase compared to vehicle control, 
P=<0.0001) in Huh7 cells (n=4). Figure 3.11 below. The statistically significant up- 
regulation of ApoC-II by RTV was also observed in the Mock Transfection plus 
RTV incubations at concentrations of 0.1 pM RTV (1.8 fold increase compared to 
vehicle control, P=<0.0001), l.OpM RTV (3.3 fold increase compared to vehicle 
control, P=<0.0001) and lOpM RTV (8,2 fold increase compared to vehicle control, 
P=<0.0001), Figure 3.11 below. ApoC-II expression in siRNA LXRa knockdown 
cells without RTV was not significantly altered from basal expression in vehicle 
controls, Figure 3.11 below. The statistically significant up-regulation of ApoC-II by 
RTV observed at concentrations of 0. IpM, l.OpM and lOpM RTV with and without 
mock transfection was abolished in the siRNA LXRa knockdown samples at 
concentrations of 0.1 pM, 1 .OpM and lOpM RTV, Figure 3.11 below.
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Figure 3.11: ApoC-ll Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
Significant up-regulation of ApoC-III at 0.1 pM (1.2 fold increase compared to 
vehicle control, P=<0.0001), l.OpM (1.3 fold increase compared to vehicle control, 
P=<0.0001) and lOpM RTV was observed (5 fold increase compared to vehicle 
control, P=<0.0001) in Huh7 cells (n=4), Figure 3.12 below. The significant up- 
regulation of ApoC-III by RTV was also observed in the Mock Transfection plus 
RTV incubations at concentrations of 0.1 pM RTV (1.2 fold increase compared to 
vehicle control, P=<0.0001), l.OpM RTV (1.3 fold increase compared to vehicle 
control, P=<0.0001) and lOpM RTV (5 fold increase compared to vehicle control.
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P=<0.0001), Figure 3.12 below. ApoC-III gene expression in the siRNA LXRa 
knockdown cells without RTV was not significantly altered from basal expression in 
vehicle controls. Figure 3.12 below. The statistically significant up-regulation of 
ApoC-III by RTV observed at concentrations of 0.IpM, l.OpM and lOpM RTV with 
and without mock transfection was abolished in the siRNA LXRa knockdown 
samples at concentrations of O.lpM, l.OpM and 10|iM RTV, Figure 3.12 below.
APOC-III Expression in siRNA Knockdown Huh7 (p24) Cells - 24h Induction
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Figure 3.12: ApoC-III Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
PPARa gene expression was significantly down-regulated by RTV at concentrations 
of 0.1 pM (2.6 fold decrease compared to vehicle control, P=<0.0001), l .OpM (5.1
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fold decrease compared to vehicle control, P=<0.0001) and lOpM (6.2 fold decrease 
compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 3.13 below. A 
statistically significant down-regulation of PPARa gene expression by RTV was also 
observed in the Mock Transfection plus RTV incubations at concentrations of 0.1 pM 
RTV (2.4 fold decrease compared to vehicle control, P=<0.0001), l.OgM RTV (4.9 
fold decrease compared to vehicle control, P=<0.0001) and lOpM RTV (6.3 fold 
decrease compared to vehicle control, P=<0.0001), Figure 3.13 below. The 
expression of PPARa in the siRNA LXRa knockdown cells without RTV was not 
significantly altered from basal expression in vehicle controls. Figure 3.13 below. 
The statistically significant down-regulation of PPARa gene expression by RTV 
observed at concentrations of 0.IpM, l.OpM and lOpM RTV with and without mock 
transfection was abolished in the siRNA LXRa knockdown samples at 
concentrations of O.lpM, l.OpM and lOpM RTV, Figure 3.13 below.
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PPARa Expression in siRNA Knockdown Huh7 (p24) Cells - 24h Induction
Figure 3.13: PPARa Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
Significant up-regulation of SREBP-lc at 0.1 pM (1.3 fold increase compared to 
vehicle control, P=<0.0001), l.OpM (2.1 fold increase compared to vehicle control, 
P=<0.0001) and lOpM RTV was observed (3.2 fold increase compared to vehicle 
control, P=<0.0001) in Huh? cells (n=4). Figure 3.14 below. The statistically 
significant up-regulation of SREBP-lc by RTV was also observed in the Mock 
Transfection plus RTV incubations at concentrations of 0.1 pM RTV (1.3 fold 
increase compared to vehicle control, P=0.0003), l.OpM RTV (2 fold increase 
compared to vehicle control, P=<0.0001) and lOpM RTV (3.2 fold increase
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compared to vehicle control, P=<0.0001), Figure 3.14 below. The expression of 
SREBP-lc in the siRNA LXRa knockdown cells without RTV was not significantly 
altered from basal expression in vehicle controls. Figure 3.14 below. The statistically 
significant up-regulation of SREBP-lc by RTV observed at concentrations of 0.1 juM, 
l.OpM and lOpM RTV with and without mock transfection was abolished in the 
siRNA LXRa knockdown samples at concentrations of 0.1 pM, l .OpM and 10|iM 
RTV, Figure 3.14 below.
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Figure 3.14: SREBP-1c Gene Expression Assay in Huh7 cells (passage no. = 24) incubated 
for 24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001, ** denotes P=<0.001.
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VLDLR was significantly down-regulated by RTV at concentrations of 0.1 gM (7.7 
fold decrease compared to vehicle control, p=<o.0001), l.OpM (15.8 fold decrease 
compared to vehicle control, P=<0.0001) and lOpM (10.9 fold decrease compared to 
vehicle control, P=<0.0001), in Huh7 cells (n=4), Figure 3.15 below. The statistically 
significant down-regulation of VLDLR gene expression by RTV was also observed 
in the Mock Transfection plus RTV incubations at concentrations of 0.1 pM RTV 
(8.2 fold decrease compared to vehicle control, P=<0.0001), l.OpM RTV (14.6 fold 
decrease compared to vehicle control, P=<0.0001) and lOpM RTV (13 fold decrease 
compared to vehicle control, P=<0.0001), Figure 3.15 below. The expression of 
VLDLR in the siRNA LXRa knockdown cells without RTV was not significantly 
altered from basal expression in vehicle controls. Figure 3.15 below. The statistically 
significant down-regulation of VLDLR gene expression by RTV observed at 
concentrations of 0.1 pM, 1.0pM and lOpM RTV with and without mock transfection 
was diminished in the siRNA LXRa knockdown samples at concentrations of 
0.1 pM, LOpM and lOpM RTV but remained statistically significant. At 
concentrations of 0.1 pM RTV in the siRNA LXRa knockdown cells (1.2 fold 
decrease (reduced from 8.2 fold decrease in mock transfection) compared to vehicle 
control, P=0.0008), LOpM RTV in the siRNA LXRa knockdown cells (1.2 fold 
decrease (reduced from 14.6 fold decrease in mock transfection) compared to 
vehicle control, P=0.0002) and lOpM RTV in the siRNA LXRa knockdown cells 
(1.2 fold decrease (reduced from 13 fold decrease in mock transfection) compared to 
vehicle control, P=0.0004) in Huh7 cells (n=4). Figure 3.15 below.
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Figure 3.15: VLDLR Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001, ** denotes P=<0.001.
LXRa was also significantly up-regulated by RTV concentrations of 0. IpM (3.8 fold 
increase compared to vehicle control, P=<0.0001), l.OpM (6.7 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (16.7 fold increase compared to 
vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 3.16 below. The statistically 
significant up-regulation of LXRa by RTV was also observed in the Mock 
Transfection plus RTV incubations at concentrations of 0.1 pM RTV (4.5 fold 
increase compared to vehicle control, P=<0.0001), l .OpM RTV (6.9 fold increase 
compared to vehicle control, P=<0.0001) and lOpM RTV (16.9 fold increase
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compared to vehicle control, P=<0.0001), Figure 3.16 below. The expression of 
LXRa in the siRNA LXRa knockdown cells without RTV was significantly 
decreased from basal expression (8 fold decrease compared to vehicle control, 
P=<0.0001), Figure 3.16 below. The statistically significant up-regulation of LXRa 
gene expression by RTY obseived at concentrations of 0.1 pM, 1.0pM and lOpM 
RTV with and without mock transfection was completely diminished in the siRNA 
LXRa knockdown samples at concentrations of 0.1 pM, LOpM and lOpM RTV. 
However, LXRa gene expression levels remained repressed compared to vehicle 
controls at all RTV concentrations in the siRNA LXRa knockdown cells. This 
repression of LXRa gene expression was statistically significant at concentrations of 
0.1 pM RTV in the siRNA LXRa knockdown cells (4.5 fold decrease compared to 
vehicle control, P=<0.0001), LOpM RTV in the siRNA LXRa knockdown cells (4.2 
fold decrease compared to vehicle control, P=<0.0001) and lOpM RTV in the siRNA 
LXRa knockdown cells (3.8 fold decrease compared to vehicle control, P=<0.0001) 
in Huh? cells (n=4). Figure 3.16 below.
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Figure 3.16: LXRa Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
HNF4a was also significantly down-regulated by RTV at concentrations of 0.1 pM 
(1.4 fold decrease compared to vehicle control, P=<0.0001), l.OpM (2.8 fold 
decrease compared to vehicle control, P=<0.0001) and lOpM (5.3 fold decrease 
compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 3.17 below. 
HNF4a, however, was also significantly down-regulated by RTV in the Mock 
Transfection plus RTV incubations at concentrations of 0.1 pM RTV (1.4 fold 
decrease compared to vehicle control, P=<0.0001), l.OpM RTV (2.5 fold decrease 
compared to vehicle control, P=<0.0001) and lOpM RTV (5.4 fold decrease 
compared to vehicle control, P=<0.0001), Figure 3.17 below. The expression of
Chapter 3
136
HNF4a in the untreated siRNA LXRa knockdown cells was not significantly altered 
from basal expression levels in the vehicle controls. Figure 3.17 below. The 
statistically significant down-regulation of HNF4a by RTV observed at 
concentrations of O.lpM, l.OpM and lOpM RTV with and without mock transfection 
was also observed in the siRNA LXRa knockdown samples at concentrations of 
0.1 pM RTV (1.3 fold decrease compared to vehicle control, P=<0.0001), l.OpM 
RTV (2.7 fold decrease compared to vehicle control, P=<0.0001) and lOpM RTV 
(5.1 fold decrease compared to vehicle control, P=<0.0001), Figure 3.17 below.
HNF4a Expression in siRNA Knockdown Huh7 (p24) Ceils - 24h Induction
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Figure 3.17: HNF4a Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
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FXR was also significantly up-regulated by RTV concentrations of 0.1 pM (1.5 fold 
increase compared to vehicle control, P=<0.0001)} l.OpM (2.1 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (1.5 fold increase compared to 
vehicle control, P=<0.0001) in Huh? cells (ir=4). Figure 3.18 below. The statistically 
significant up-regulation of FXR by RTV was also observed in the Mock 
Transfection plus RTV incubations at concentrations of 0.1 pM RTV (1.5 fold 
increase compared to vehicle control, P=<0.0001), 1.0pM RTV (2.1 fold increase 
compared to vehicle control, P=<0.0001) and lOpM RTV (1.9 fold increase 
compared to vehicle control, P=<0.0001), Figure 3.18 below. The expression of FXR 
in the siRNA LXRcc knockdown cells without RTV was not significantly altered 
from basal expression in vehicle controls, Figure 3.18 below. The statistically 
significant up-regulation of FXR by RTV observed at concentrations of 0.1 pM, 
1.0pM and lOpM RTV with and without mock transfection was also observed in 
siRNA LXRtx knockdown samples at concentrations of 0.1 pM RTV (1.6 fold 
increase compared to vehicle control, P=<0.0001), LOpM RTV (2 fold increase 
compared to vehicle control, P=<0.0001) and lOpM RTV (1.7 fold increase 
compared to vehicle control, P=<0.0001) in Huh? cells (n=4), Figure 3.18 below.
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FXR Expression in siRNA Knockdown Huh7 (p24) Cells - 24h Induction
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Figure 3.18: FXR Gene Expression Assay in Huh7 cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh7 cells and RTV in 24h siRNA 
knockdown Huh7 cells, n=4. *** denotes P=<0.0001.
VDR was also significantly up-regulated by RTV concentrations of 0.1 pM (1.5 fold 
increase compared to vehicle control, P=<0.0001), l.OpM (2 fold increase compared 
to vehicle control, P=<0.0001) and lOpM (7.3 fold increase compared to vehicle 
control, P=<0.0001) in Huh? cells (n=4). Figure 3.19 below. The statistically 
significant up-regulation of VDR by RTV was also observed in the Mock 
Transfection plus RTV incubations at concentrations of 0.1 pM RTV (1.6 fold 
increase compared to vehicle control, P=<0.0001), l .OpM RTV (2.1 fold increase 
compared to vehicle control, P=<0.0001) and lOpM RTV (7.9 fold increase
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compared to vehicle control, P—<0.0001), Figure 3.19 below. The expression of 
VDR in siRNA LXRa knockdown cells without RTV was not significantly altered 
from basal expression in vehicle controls. Figure 3.19 below. The statistically 
significant up-regulation of VDR by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM RTV with and without mock transfection was also observed in the 
siRNA LXRa knockdown samples at concentrations of 0.1 pM RTV (1.5 fold 
increase compared to vehicle control, P=<0.0001), l.OpM RTV (2.1 fold increase 
compared to vehicle control, P=<0.0001) and lOpM RTV (8.5 fold increase 
compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 3.19 below.
VDR Expression in siRNA Knockdown Huh7 (p24) Cells - 24h Induction
q n
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Figure 3.19: VDR Gene Expression Assay in Huh? cells (passage no. = 24) incubated for 
24h with ritonavir (RTV), RTV in Mock Transfection Huh? cells and RTV in 24h siRNA 
knockdown Huh? cells, n=4. *** denotes P=<0.0001.
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3.6 Discussion
The inhibition of LXRa gene expression by a chemical antagonist was discussed in 
Chapter 2. The implications the inhibition of LXRa gene expression had on 
downstream target genes was also discussed together with the hypothesis that LXRa 
functions as a master regulator of this downstream gene expression. In this chapter, 
the findings of Chapter 2 were further probed to validate the role of LXRa and to 
confirm this hypothesis. The specific focus of this chapter was to determine the 
impact of the PI RTV on gene expression in NRs involved in lipid metabolism 
identified in Section 2.1 of this thesis, and on the gene expression of downstream 
targets in their metabolic pathways (Table 2.2), thereby detennining the influence of 
LXRa. Probing the influence of LXRa knockdown by siRNA on its own gene 
expression and that of its target genes confirmed the effects of LXRa on gene 
expression in the presence of RTV and RTV plus 22(S)-hydroxycholesterol seen in 
Section 2.5.6 and validated the observed role of LXRa on gene expression in 
response to RTV.
The observed significant up-regulation of ApoC-II (P=<0.0001 at 0.1 pM, IpM and 
lOpM) and significant down-regulation of HNF4a (P=<0.0001 at 0.1 pM, IpM and 
lOpM) gene expression was consistent with the expected outcome of the significant 
induction of FXR (P=<0.0001 at 0.1 pM, IpM and lOpM) by RTV. As previously 
seen in Section 2.5.6, the addition of the LXRa antagonist 22(S)-hydroxycholesterol 
did not knock-out the up-regulation of FXR or the down-regulation of HNF4a by 
RTv Bi0i0gica| knockdown of LXRa by siRNA in the RTV incubation experiments
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did not knock-out the up-regulation of FXR or the down-regulation of HNF4a by 
RTV, which confirmed the earlier findings and supported the hypothesis that LXRa 
is not a master regulator of these genes. The up-regulation of ApoC-II by RTV was, 
however, completely abolished in the biological knockdown of LXRa samples, 
confirming the observed results with the LXRa antagonist. Section 2.5.6. This 
supported the hypothesis that more than one mechanism is involved in the up- 
regulation of ApoC-II and that LXRa is a key regulator of its gene expression.
The RTV incubation assays resulted in significant up-regulation of SREBP-lc 
(P=<0.0001 at 0.1 jjM, Ij-iM and lOpM), This was inconsistent with the concentration 
dependent significant increase in FXR expression, which suggested another 
mechanism was involved with SREBP-lc up-regulation. It has previously been 
reported that the effects of LXRa on fatty acid synthesis are mediated through 
increased expression of the transcription factor , SREBP-lc, and that SREBP-lc has 
been associated with PI induced lipodystrophy (Telenti et al., 2002). As significant 
up-regulation of LXRa was observed at all RTV concentrations (P=<0,0001 at 
0.1 pM, IpM and lOpM, with maximal 16.7 fold up-regulation at lOpM RTV), it is 
likely that LXRa mediated the up-regulation of SREBP-lc in these assays. The 
inhibition of LXRa by the antagonist 22(S)-hydroxycholesterol and the abolition of 
its effects on SREBP-lc were demonstrated in Section 2.5.6. These findings were 
confirmed by biological knockdown of LXRa by siRNA which also abolished the 
induction effects of RTV on both LXRa and SREBP-lc and supported this 
hypothesis. Biological knockdown by siRNA of LXRa actually resulted in down- 
regulation of LXRa gene expression in the presence of all RTV concentrations
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(P=<0.0001 at 0.1 (iM, IpM and with maximal 4.5 fold down-regulation at
0.1 jxM RTV). This could provide a potential future therapeutic mechanism for the 
inhibition of LXRa in vivo, as interest develops in the use of siRNA for gene therapy 
for complex metabolic disorders. This opportunity is discussed further in Chapter 7.
It is hypothesised that LXRa is involved in the down-regulation of PPARa gene 
expression which was significantly down-regulated at all concentrations (P=<0.0001 
at 0.1 pM, IpM and lOpM) in the RTV assays. In Chapter 2, inhibition of LXRa by 
the chemical antagonist 22(S)-hydroxycholesterol was shown to abolish these 
effects. The use of siRNA to biologically knockdown LXRa confinned the 
hypothesis that LXRa is a key player in the regulation of PPARa as the effects of 
RTV on PPARa were also abolished in these assays.
In Chapter 2, the expected outcome of significant up-regulation of VDR, like FXR, 
by RTV was discussed. The up-regulation of these two genes should have resulted in 
down-regulation of ApoA-I gene expression, but significant up-regulation was 
observed at all RTV concentrations (p=<0.0001 at 0.1 pM, IpM and lOpM). This 
supported the hypothesis that up-regulation of LXRa target genes may have been the 
mechanism involved with the up-regulation of ApoA-I. When RTV was co-incubated 
with the LXRa antagonist, 22(S)-hydroxycholesterol, the up-regulation of ApoA-I 
was abolished. This was confirmed in the assays incubated with RTV following 
biological knockdown of LXRa by siRNA, supporting the hypothesis.
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It has been reported that PPARa induction leads to the repression of ApoC-III (Duval 
et al., 2007; Feldman et al, 2008; Yamada et al, 2007). In the RTV assays, the 
observed significant down-regulation of PPARa may have contributed to the 
significant induction of ApoC-III, (a 5 fold increase compared to the vehicle control 
at 10pM RTV, p=<0.0001), as LXRa induces ApoC-III through its repression of 
PPARa, which was significantly down-regulated at all RTV concentrations. 
Chemical inhibition of LXRa by 22(S)-hydroxycholesterol was shown to abolish the 
effects of RTV on ApoC-III in Section 2.5.6 in support of the hypothesis. This was 
validated by biological knockdown of LXRa by siRNA which also abolished the 
effects of RTV on ApoC-III (and PPARa) confirming the hypothesis that LXRa is a 
key player in the regulation of both ApoC-III and PPARa.
LXRa also inhibits VLDLR gene expression which was significantly down-regulated 
at all RTV concentrations (P=<0.0001 at 0.1 juM, IpM and lOpM) with the maximal 
15.8 fold decrease compared to vehicle seen at l.OpM RTV. These effects can be 
abolished by the inhibition of LXRa the chemical antagonist 22(S)- 
hydroxycholesterol as shown in Section 2.5.6, which supported the hypothesis that 
LXRa was regulating VLDLR. The biological knockdown of LXRa by siRNA 
underpinned this hypothesis as the impact of RTV on VLDLR gene expression was 
diminished to a 1.2 fold decrease at all RTV concentrations compared to vehicle 
controls, although this decrease in VLDLR expression remained statistically 
significant, suggesting that other mechanism may be involved in the regulation of 
VLDLR by RTV.
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The Liverpool HIV Pharmacology Group is researching the interplay between 
intracellular accumulation of ARVs and metabolism, and its relevance to the 
induction of drug disposition genes in HIV therapy with a specific focus on the role 
of FXR, LXRa and PPARa in the metabolic complications associated with the use of 
these drugs. This thesis has principally focussed on the role of LXRa in these 
complications. Polymorphisms in LXRa and key metabolic target genes were also 
investigated to establish the clinical relevance of these findings (Chapters 5 and 6).
In summary, this chapter has described the comparative effects of biological 
knockout of LXRa on the differing gene expression profiles associated with RTV, 
identified in Chapter 2, in the Huh? cell line. It has confirmed the specific influence 
of LXRa in these results and discussed the implications of regulation by LXRa on 
the downstream gene expression of its metabolic targets, including SREBP-lc which 
has previously been implicated in PI induced lipodystrophy (Telenti et ai, 2002). 
This chapter has also hypothesised the role of multiple NRs, including LXRa, FXR, 
VDR, HNF4a and PPARa, controlling regulation of key downstream metabolic 
targets and discussed the specific role of LXRa in their regulation. Finally it has 
discussed the potential future clinical role for inhibition of LXRa as it has been 
shown that LXRa agonists have disruptive effects on a cascade of metabolic genes 
and downstream targets. Inhibition of LXRa has demonstrated that some of these 
downstream effects can be modified.
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CHAPTER 4
THE IMPACT OF LIVER OXYSTEROL RECEPTOR 
ALPHA (LXRa) MODULATION BY RITONAVIR AND 
ATAZANAVIR ON TRANSPORTERS IN THE 
CHOLESTEROL METABOLISM PATHWAY
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4.1 Introduction
LXRa is a master regulator of cholesterol homeostasis, bile acid metabolism, and 
modulates the transcription of many key genes involved in drug and lipid metabolism 
(Hui, 2003; Liang et al.> 2001; Osborne, 2000). LXRa has also been shown to have 
positive effects on glucose metabolism (Cha et al, 2007; Kalaany et al, 2006). In 
Chapters 2 and 3 of this thesis the impact of the Pis RTV and ATV on NR gene 
expression and the role played by LXRa in this was investigated and discussed. This 
Chapter will focus on the impact of RTV and ATV on key transporters in cholesterol, 
bile acid and glucose metabolism where LXRa has previously been implicated in 
regulation of gene expression.
Cholesterol occupies the spaces between the polar head-groups of the phospholipid 
bilayer of cell membranes where it reduces the fluidity of the membrane. It is also 
the precursor molecule for the synthesis of bile salts, vitamin D and steroid hormones 
(Charlton-Menys et al., 2008). It can be derived from the diet or synthesised within 
the body by the liver and central nervous system (CNS). It can be lost from the body, 
as part of a daily faecal loss as fractions of bile salts and unabsorbed intestinal 
cholesterol, and in sebum (Charlton-Menys et al., 2008; Levy et al, 2007). Bile salts 
are detergents synthesised by the liver, from cholesterol, and released with bile into 
the duodenum. Bile salts emulsify fats via their hydrophilic polar carboxyl and 
hydroxyl groups, and their lipophilic hydrocarbon rings which interface with lipids 
(Charlton-Menys et al, 2008). Cholesterol circulates as lipoproteins, principally as 
chylomicrons, LDL, VLDL and HDL (Charlton-Menys et al, 2008; Lusis, 2000; 
Williams et al, 2007).
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4.1.1 Transporters Involved in Cholesterol Homeostasis, Bile Acid and Glucose 
Metabolism
Members of the ABC transporter family are transmembrane proteins which transport 
a wide variety of endogenous substrates and xenobiotics across extracellular and 
intracellular membranes. ABCB1 (P-glycoprotein, P-gp, multidrug resistance protein 
1), ABCC1 and ABCC2 (the multidrug resistance associated proteins 1 and 2, 
respectively) have previously been implicated in modulating the levels of anti­
retroviral drugs, including RTV and ATV, in cells and tissues (Ho et al.t 2005; 
Telenti et aL, 2002; Telenti et aL, 2008). ABCB1 has a critical role in drug 
absorption, biliary excretion, renal secretion and central nervous system (CNS) entry 
of a wide range of hydrophobic xenobiotics (Faber et at., 2003; Ho et at., 2005).
ABCB1 has previously been shown to be involved in the transport of both RTV and 
ATV, (Perloff et aL, 2005; Solon et ai, 2002). RTV and ATV have both been shown 
to be substrates for ABCB1 and ABCC1 (Janneh et at.) rendering these transporters 
suitable positive controls for this research.
ABCB1 and ABCC1 are mainly located in the plasma membrane of the epithelium 
and endothelium of the liver (Ho et al, 2005; Pan et al, 2007; Urquhart et at., 2007). 
ABCC2 is a drug efflux transporter expressed in the liver and its primary function is 
the excretion of organic anions from Phase II drug metabolism reactions, e.g. 
glutathione, glucuronide and sulphate conjugates, from hepatocytes into bile. 
ABCC2 is involved in the transport of endogenous substrates including bilirubin and 
bile salts (Urquhart et at, 2007). Sections 1.6.2 and 1.6.3 discussed the control of
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ABCC2 expression by the NRs PXR, FXR and CAR. ABCC2 gene expression has 
been implicated in the metabolic disorder Dubin-Johnson Syndrome (Stefkova et al, 
2004).
FXR has also been implicated in the up-regulation of ABCB11 (the bile salt export 
pump, BSEP) (Eloranta et al, 2005; Thomas et al, 2008). Defects in ABCB11 have 
been linked to metabolic diseases including progressive familial intrahepatic 
cholestasis type 2 (Stefkova et al, 2004). LXRa has been shown to be the 
counterbalance of FXR regulation (Berkenstam et al, 2005; Edwards et al, 2002; 
Kalaany et al, 2006; Rader, 2007). LXRa has been implicated in the regulation of 
ABCA1 (Edwards et al, 2002; Eloranta et al, 2005), ABCG1, ABCG4, ABCG5 and 
ABCG8, key genes in cholesterol transport (Bradley et al, 2005; Edwards et al, 
2002; Joseph et al, 2003; Rader, 2007). Defects in the ABCA1 (cholesterol efflux 
regulatory protein, CERP) gene have been linked to the metabolic disorders Tangier 
disease and familial hypoapoproteinaemia (Stefkova et al, 2004). Polymorphisms in 
ABCG5 and ABCG8 genes have been implicated in the metabolic disease 
sitosterolaemia (Stefkova et al, 2004). ABCB2, is a half-ABC transporter, which 
functions as a peptide transporter involved in pumping degraded cytosolic peptides 
across the endoplasmic reticulum. It is a key player in bile acid transport. Mutations 
in ABCB2 have been associated with immune deficiencies including ankylosing 
spondylitis, coeliac disease and insulin dependent diabetes mellitus (Stefkova et al, 
2004).
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GLUT4 (SLC2A4), a key gene involved in glucose metabolism, has been shown to 
be a direct target of LXRa (Mitro et al., 2007; Zelcer et al.t 2006). Sections 2.5 and 
2.6 of this thesis have already discussed the up-regulation of FXR and LXRa gene 
expression by RTV and the consequential effects on the downstream target SREBP- 
1c, where up-regulation by LXRa was seen to be the predominant consequence of 
incubation with RTV. SREBP-lc is a key player in the regulation of hepatic 
triglyceride and fatty acid synthesis (Zhang et al, 2008) and a target of both LXRa 
and FXR, key players in cholesterol and bile acid homeostasis (Edwards et aL, 2002; 
Kalaany et al., 2006). The different regulation of FXR and LXRa gene expression by 
RTV and ATV led to the hypothesis that cholesterol and bile acid metabolism and 
transport may also be disrupted through downstream regulation of transporter gene 
expression.
4.2 Aim
The aims of this chapter were to investigate the specific impact of the Pis RTV and 
ATV on the gene expression of transporters involved in cholesterol homeostasis and 
bile acid metabolism; and on the gene expression of the glucose transporter GLUT4; 
and to establish whether LXRa influences the gene expression of these transporters 
in the presence of RTV.
4.3 Materials and Methods
4.3.1 Materials
As previously described in Sections 2.3.1 and 3.3.1 above. Nunclon Surface 48 well 
plates were purchased from (Nunc A/S, Kamstrup, Denmark).
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4.3.2 Cells and Cell Maintenance
4.3.2.1 Huh7 Cell Line
As previously described in Section 2.3.2.1 above.
4.3.2.2 3-(4,5-dimethyltliiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) Cell 
Toxicity Assays
The toxicity of RTV, ATV and 22-(S)-hydroxycholesterol was determined by the 
MTT assay at final concentrations as previously described in Section 2.3.2.2 of this 
thesis. Drugs were determined to be toxic where the cell viability after 120h was 
below 85% compared to the untreated cells.
4.3.2.3 Cell Treatment
Cells were seeded as previously described in Sections 2.3.2.3 and 3.3.2.3 above. The 
concentration-response experiments for RTV in the biological knockdown treated 
Huh? cells were conducted at final concentrations of 0, 0.1, 1.0, and lOpM RTV 
following an initial 24h knockdown by siRNA, optimised as described in section 
3.3.2.7 and set up as described previously in Section 3.3.2.8. The cells were 
incubated at 37°C and 5% CO2 and were sampled at 24h.
4.3.2.4 RNA Isolation from Huh? Cells
Isolation of RNA from untreated, RTV-treated, ATV-treated and RTV plus 22-(S)- 
hydroxycholesterol-treated Huh? cells was as previously described in Section 2.3.2.4 
of this thesis.
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4.3.2.5 Production of cDNA
RNA was isolated as described above (2.3.2.4) and cDNA was synthesised in a total 
reaction volume of 50j.il with the total RNA normalised to 2jig per 50j.il reaction, as 
previously described in Section 2.3.2.5 of this thesis.
4.3.3 RT PCR - Gene Expression
Taqman Gene Expression inventoried assays for RT-PCR (Applied Biosystems 
Limited, Warrington, UK, (Table 4.1)) were used for ABCA1, ABCB1, ABCB2, 
ABCB11, ABCC1, ABCC2, ABCG1, ABCG4, ABCG5, ABCG8 and GLUT4 
quantified against the housekeeping gene (32M. Relative expression of the transcripts 
against the expression of the housekeeping gene was performed, in duplicate for all 
assays as previously described in Section 2.3.2.9 above.
Table 4.1: Taqman Gene Expression Assays for RT PCR
Taqman Assay ID Assay Gene
Hs01059118 ml ABCA1
HsOO184491 ml ABCB1
Hs00388682 ml ABCB2
HsOO 184824 ml ABCB11
Hs00219905 ml ABCC1
Hs00166123 ml ABCC2
Hs01555189 ml ABCG1
Hs00223446 ml ABCG4
Hs03037375 ml ABCG5
Hs02880035 ml ABCG8
Hs99999907 ml (32M
HsOO 168966 ml GLUT4
4.4 Statistical Analysis
Statistical analysis of all results was undertaken using StatsDirect Statistical software 
version 2.7.8 as previously described in Section 2.4 above.
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4.5 Results
4.5.1 3-(4,5-dimethylthiazol-2-yl)-2,5-(liphenyltetrazolium bromide (MTT) Toxicity 
Assays
Results for the MTT toxicity assays are shown in Section 2.5.1 of this thesis.
4.5.2 Quantification of RNA and cDNA
RNA was extracted from Huh? cells, analysed and quantified, as previously 
described in Section 43.2.4 above. The RNA had an A260/A280 ratio in the range of 
1.85-2.01 (RTV samples), 1.94-2.15 (ATY samples), 1.92-2.08 (RTV + 22-(S)- 
hydroxycholesterol samples) and 1.85-1.97 (siRNA samples) indicating sufficient 
purity to proceed to cDNA construction for RT PCR. RNA samples were frozen at - 
80°C following cDNA construction.
The cDNA for all conditions had A260/A280 ratios in the range of 1.98-2.13 indicating 
sufficient purity to proceed to construction of normalised (20ng/pl) cDNA working 
stocks. Master and working stock cDNA samples were frozen at -20°C until used in 
gene expression assays.
4.5.3 Gene Expression in Ritonavir, Atazanavir and 22(S)-Hydroxycholesterol/ 
Ritonavir Treated Huh 7 Cells
In the optimisation experiments in Sections 2.5.6 and 3.5.5, maximal up-regulation 
and down-regulation of gene expression by both RTV and ATV was observed after 
24h incubation, so the same incubation period was utilised for the transporter gene 
expression assays.
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Optimal conditions for siRNA knockdown of LXRa in Huh? cells were determined 
to be 5.0fxl Lipofectamine 2000 with 15nM final concentration LXRa siRNA in 6 
well plates at the mRNA and protein levels over 24h (Section 3.5.5). Optimal 
conditions for siRNA knockdown of GAPDH (Positive control) and stable 
expression of non-targeting siRNA (negative control) were determined to be 5.0pi 
Lipofectamine 2000 with 20nM GAPDH siRNA and 5.0pl Lipofectamine 2000 with 
20nM non-targeting siRNA in 6 well plates at the mRNA and protein levels over 24h 
(Section 3.5.4).
4.5.3.1 ABCA1
Significant up-regulation of ABCA1 gene expression by RTV was observed at 
concentrations of O.lpM (1.9 fold increase compared to vehicle control, P=<0.0001), 
LOpM (2.0 fold increase compared to vehicle control, P=<0.0001) and lOpM (3.4 
fold increase compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 
4.1 below. In the presence of 20pM 22-(S)-hydroxycholesterol, the statistically 
significant up-regulation of ABCA1 by RTV observed at concentrations of O.lpM, 
LOpM and lOpM was abolished and replaced with significant down-regulation of 
ABCA1 gene expression by 1.6 fold compared to vehicle controls at each RTV 
concentration (P=<0.0001 at concentrations of O.lpM, LOpM and lOpM RTV plus 
20pM 22-(S)-hydroxycholesterol), Figure 4.1 below. ABCA1 gene expression was 
not significantly altered in the presence of 0,1 pM ATV, however, significant down- 
regulation of ABCA1 was observed at concentration of LOpM (1.9 fold decrease 
compared to vehicle control, P=<0,0001) and lOpM ATV (2.3 fold decrease 
compared to vehicle control, P=<0.0001), Figure 4.1 below. Significant up- 
regulation of ABCA1 gene expression by RTV was observed in the mock
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transfections (5.Oj.il Lipofectamine 2000/0nM siRNA) at concentrations of 0.1 pM 
(1.9 fold increase compared to vehicle control, P=<0.0001), l.OpM (2.0 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (2.7 fold increase compared to 
vehicle control, P=<0.0001), Figure 4.1 below. The expression of ABCA1 in siRNA 
LXRa knockdown cells without RTV was not significantly altered from basal 
expression in vehicle controls. Figure 4.1 below. The statistically significant up- 
regulation of ABCA1 gene expression by RTV observed at concentrations of 0.1 pM, 
1.0 pM and lOpM RTV with and without mock transfection was abolished and 
replaced with significant down-regulation of ABCA1 gene expression by 2.7 fold 
compared to vehicle controls at O.lpM RTV (P=<0.001), by 1.9 fold compared to 
vehicle controls at l.OpM (P=<0.0001) and by 1.8 fold at lOpM (P=<0.001), in the 
siRNA LXRa knockdown samples. Figure 4.1 below.
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Figure 4.1: ABCA1 Gene expression assays in Huh7 cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, 
RTV in 24h siRNA knockdown cells and atazanavir (ATV) for 24h: n=4 for all assays. *** 
denotes P=<0.0001, ** denotes P=0.001* denotes P=<0.01.
4.S.3.2 ABCB1, ABCB2 and ABCB11
ABCB1 gene expression was significantly down-regulated by RTV at 0.1 pM (8.2 
fold decrease compared to vehicle control, P=<0.0001), l.OpM (47.2 fold decrease 
compared to vehicle control, P=<0.0001) and lOpM (9.3 fold decrease compared to 
vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 4.2 below. The statistically 
significant down-regulation of ABCB1 observed at all RTV concentrations was 
abolished and replaced with significant up-regulation of ABCB1 gene expression in 
the presence of 20pM 22-(S)-hydroxycholesterol, at 0.1 pM RTV (1.7 fold increase 
compared to vehicle controls P=<0.0001), l.OpM (1.8 fold increase compared to
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vehicle controls P=0.0034), and 10|iM (1.6 fold increase compared to vehicle 
controls P^O.0018), Figure 4.2 below. ABCB1 gene expression was down-regulated 
by ATV at all concentrations, at 0.1 pM there was a significant 1.6 fold decrease 
compared to vehicle controls, (P=0.0046), but at l.OpM there was only a 1.1 fold 
decrease compared to vehicle controls, which was not statistically significant 
(P=0.5182) and at lOpM ATV there was a significant 1.3 fold decrease compared to 
vehicle controls, (P=0.0103) in Huh? cells (n=4). Figure 4.2 below. Highly 
significant down-regulation of ABCB1 gene expression by RTV was observed in the 
mock transfections (5.0pl Lipofectamine 2000/0nM siRNA) at RTV concentrations 
of 0.1 pM (2.3 fold decrease compared to vehicle control, P=<0.0001), l.OpM (4.5 
fold decrease compared to vehicle control, P=<0.0001) and lOpM (8.4 fold decrease 
compared to vehicle control, P=<0.0001), Figure 4.2 below. The expression of 
ABCB1 in siRNA LXRa knockdown cells without RTV was not significantly altered 
from basal expression in vehicle controls. Figure 4.2 below. The statistically 
significant down-regulation of ABCB1 gene expression by RTV observed at 
concentrations of 0. IpM, 1.0pM and lOpM RTV with and without mock transfection 
was abolished and replaced with a highly significant up-regulation of ABCB1 gene 
expression by 1.9 fold compared to vehicle controls at 0.1 pM RTV (P=<0.0001), by 
1.8 fold compared to vehicle controls at l.OpM (P^cO.OOOl) and by 1.6 fold at lOpM 
(P^O.OOOS), in the siRNA LXRa knockdown samples. Figure 4.2 below.
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Figure 4.2: ABCB1 Gene expression assays in Huh7 cells (passage no. = 24) incubated with 
ritonavir (RTV), RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, 
RTV in 24h siRNA knockdown cells and atazanavir (ATV) for 24h: n=4 for all assays. *** 
denotes P=<0.0001, ** denotes P=0.001* denotes P=<0.01.
A highly significant up-regulation of ABCB2 gene expression by RTV was observed 
at concentration of 0.1 pM (1.9 fold increase compared to vehicle control, 
P=<0.0001), however, at higher RTV concentrations a down-regulation of ABCB2 
gene expression was observed. At l.OpM RTV a statistically significant 1.1 fold 
decrease compared to vehicle controls, P=0.0371 was observed and at lOpM RTV a 
highly significant 2 fold decrease in ABCB2 expression compared to vehicle controls 
was seen, (P=0.0002) in Huh7 cells (n=4). Figure 4.3 (A) below. In the presence of 
20pM 22-(S)-hydroxycholesterol, the statistically significant up-regulation of 
ABCB2 by RTV observed at 0.1 pM was abolished and replaced with significant
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dowii-regulation of ABCB2 gene expression by 1.1 fold compared to vehicle 
controls (P~0.0225). At l.OpM RTV plus 20pM 22-(S)-hydroxycholesterol the 
regulation was unaltered from the same concentration RTV alone assay, down- 
regulation was 1.1 fold compared to vehicle controls with a significance at P=0.0404, 
Figure 4.3 (A) below. At lOpM RTV plus 20pM 22-(S)-hydroxycholesterol there 
was no significant difference in ABCB2 gene expression compared to vehicle 
controls. Figure 4.3 (A) below. ABCB2 gene expression was significantly down- 
regulated by ATV at all concentrations, at 0.1 pM there was a significant 8 fold 
decrease compared to vehicle controls, (P-O.OOOl), at 1.0pM there was a 2.3 fold 
decrease compared to vehicle controls, (P=<0.0001) and at lOpM ATV there was a 
significant 1.3 fold decrease compared to vehicle controls, (P=0.0053) in Huh? cells 
(n=4). Figure 4.3 (A) below. Significant up-regulation of ABCB2 gene expression by 
RTV was observed in the mock transfections (5.0pl Lipofectamine 2000/0nM 
siRNA) at 0.1 pM (1.8 fold increase compared to vehicle control, P=0.0017), 
furthermore at 1,0 pM RTV (1.1 fold decrease compared to vehicle control, 
P=<0.0001) and lOpM a 2.1 fold decrease in ABCB2 expression compared to 
vehicle control was observed, (P=<0.0001), Figure 4.3 (A) below. The expression of 
ABCB2 in siRNA LXRa knockdown cells without RTV was not significantly altered 
from basal expression in vehicle controls, Figure 4.3 (A) below. The statistically 
significant up-regulation and down-regulation of ABCB2 gene expression by RTV 
observed at concentrations of 0.1 pM and l.OpM RTV with and without mock 
transfection was abolished in the siRNA LXRa knockdown samples, at lOpM RTV a 
significant down-regulation of ABCB2 gene expression by 1.3 fold compared to
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vehicle controls (P=0.006), was observed in the siRNA LXRa knockdown samples, 
Figure 4.3 (A) below.
Significant up-regulation of ABCB11 gene expression by RTV was observed at 
0.1 pM (2.9 fold increase compared to vehicle control, P=<0.0001), however, highly 
significant down regulation of ABCB11 gene expression was observed at 
concentrations of 1.0pM RTV (1.9 fold decrease compared to vehicle control, 
P=<0.0001) and lOpM (2.9 fold decrease compared to vehicle control, P=<0.0001) 
in Huh? cells (n=4). Figure 4.3 (B) below. In the presence of LXRa antagonist, 
20pM 22-(S)-hydroxycholesterol, the statistically significant up-regulation and 
down-regulation of ABCB11 expression by RTV was reversed. At 0.1 pM RTV in 
the presence of the antagonist ABCB11 gene expression was down-regulated 1.2 fold 
compared to vehicle controls (P=<0.0001), at 1.0pM and lOpM RTV, in the 
presence of the antagonist, ABCB11 expression was significantly up-regulated by 
1.2 and 1.3 fold respectively compared to vehicle controls (P=<0.0001 at both LOpM 
and lOpM RTV plus 20pM 22-(S)-hydroxycholesterol), Figure 4.3 (B) below. 
ABCB11 gene expression was significantly up-regulated in the presence of O.lpM 
(1.3 fold increase compared to vehicle controls, P=0.0002) and LOpM ATV (1.2 fold 
increase compared to vehicle controls, P=0.0002), however, significant down- 
regulation of ABCB11 was observed at concentration of lOpM ATV (1.4 fold 
decrease compared to vehicle control, P=0.0011), Figure 4.3 (B) below. Significant 
up-regulation of ABCB11 gene expression by RTV was observed in the mock 
transfections (5.0pl Lipofectamine 2000/0nM siRNA) at O.lpM RTV (2.8 fold 
increase compared to vehicle control, P=0.0002). Significant down-regulation of
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ABCB11 was observed in the mock transfections at 1.0|aM RTV (2.3 fold decrease 
compared to vehicle control, P=<0.0001) and lOpM (2.4 fold decrease compared to 
vehicle control, P=<0.0001), Figure 4.3 (B) below. The expression of ABCB11 in 
siRNA LXRa knockdown cells without RTV was not significantly altered from basal 
expression in vehicle controls, Figure 4.3 (B) below. The statistically significant up- 
regulation of ABCB11 gene expression by RTV observed at 0.1 pM with and without 
mock transfection was abolished and replaced with significant down-regulation of 
ABCB11 gene expression by 1.2 fold compared to vehicle controls, (P=0.0019). The 
down-regulation observed at 1.0 pM and lOpM RTV with and without mock 
transfection was still evident although at lesser levels with 1.3 fold decreases 
compared to vehicle controls at both l.OpM RTV (P=0.0065) and lOpM RTV 
(P=0.0043), in the siRNA LXRa knockdown samples. Figure 4.3 (B) below.
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Figure 4.3: Gene expression assays in Huh7 cells (passage no.=24) incubated with ritonavir 
(RTV), RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, RTV in 
24h siRNA knockdown cells and atazanavir (ATV) for 24h: A= ABCB2; and B= ABCB11, n=4 
for all assays. ***denotes P=<0.0001, **denotes P=<0.001 ‘denotes P=<0.01.
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4.S.3.3 ABCC1 and ABCC2
Highly significant down-regulation of ABCC1 gene expression by RTV was 
observed at concentrations of 0.1 pM (7 fold decrease compared to vehicle control, 
P=<0.0001), l.OpM (9 fold decrease compared to vehicle control, P=<0.0001) and 
lOpM (4.5 fold decrease compared to vehicle control, P=<0.0001) in Huh? cells 
(n=4). Figure 4.4 (A) below. In the presence of 20pM 22-(S)-hydroxycholesterol, the 
statistically significant down-regulation of ABCC1 by RTV observed at 
concentrations of 0.1 pM, 1.0pM and lOpM RTV was abolished at 0.1 pM RTV plus 
20 pM 22-(S)-hydroxycholesterol and had diminished down-regulation of ABCC1 
expression at 1.0pM (1.9 fold decrease compared to vehicle controls, P=<0.0001) 
and lOpM (2.3 fold decrease compared to vehicle controls, P=<0.0001), Figure 4.4 
(A) below. ABCC1 gene expression was also significantly down-regulated in the 
presence of all concentrations of ATV. At 0.1 pM ATV ABCC1 gene expression was 
down-regulated 12.7 fold compared to vehicle controls, (P=<0.00001), at l.OpM 
ATV there was a 3.1 fold decrease compared to vehicle controls, (P=<0.0001) and at 
lOpM ATV ABCC1 gene expression was significantly down-regulated by 3.5 fold 
compared to vehicle controls, (P=<0.0001), Figure 4.3 (A) below. Significant down- 
regulation of ABCC1 gene expression by RTV was observed in the mock 
transfections (5.0pl Lipofectamine 2000/0nM siRNA) at concentrations of 0.1 pM 
(6.3 fold decrease compared to vehicle control, P=<0.0001), l.OpM (9.5 fold 
decrease compared to vehicle control, P=<0.0001) and lOpM (4.7 fold decrease 
compared to vehicle control, P=<0.0001), Figure 4.4 (A) below. The expression of 
ABCC1 in siRNA LXRa knockdown cells without RTV was not significantly altered 
Rom basal expression in vehicle controls, Figure 4.4 (A) below. The statistically
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significant down-regulation of ABCC1 gene expression by RTV observed at 
concentrations of 0.1 pM, 1 .OpM and 10pM RTV with and without mock transfection 
was diminished but still significant down-regulation of ABCC1 by LI fold compared 
to vehicle controls at 0.1 pM RTV (P=<0.0001), by 2.1 fold compared to vehicle 
controls at LOpM (P=0.0008) and by 2.4 fold at lOpM (P=<0.0001), in the siRNA 
LXRa knockdown samples. Figure 4.4 (A) below.
Significant up-regulation of ABCC2 gene expression by RTV was observed at 
concentrations of O.lpM (4.6 fold increase compared to vehicle control, P=<0.0001), 
and LOpM (2.1 fold increase compared to vehicle control, P=<0.0001), however, 
significant down-regulation of ABCC2 expression was observed at lOpM RTV (1.2 
fold decrease compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 
4.4 (B) below. In the presence of 20pM 22-(S)-hydroxycholesterol, the statistically 
significant up-regulation of ABCC2 by RTV observed at 0.1 pM, l.OpM and lOpM 
was diminished to 1.1. fold, 1.3 fold and 1.1 fold increases in expression 
respectively, (P=<0.0001 at 0.1 pM and 1.0pM and P=0.0035 at lOpM), Figure 4.4 
(B) below. ABCC2 gene expression was significantly down-regulated in the presence 
of 0.1 pM ATV (4.1 fold decrease compared to vehicle controls, P=<0.0001), and at 
LOpM ATV (1.8 fold decrease compared to vehicle controls, P=<0.0001), however, 
up-regulation of ABCC2 was observed at concentration of lOpM ATV (1.02 fold 
increase compared to vehicle control, P=0.0428), Figure 4.4 (B) below. Significant 
up-regulation of ABCC2 gene expression by RTV was observed in the mock 
transfections (5.0pl Lipofectamine 2000/0riM siRNA) at concentrations of 0.1 pM 
(4.6 fold increase compared to vehicle control, P=<0.0001) and LOpM (2.6 fold
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increase compared to vehicle control, P=<0.0001), however, at lOpM there were no 
significant differences from basal expression levels, Figure 4.4 (B) below. The 
expression of ABCC2 in siRNA LXRa knockdown cells without RTV was not 
significantly altered from basal expression in vehicle controls. Figure 4.3 (B) below. 
The statistically significant up-regulation of ABCC2 gene expression by RTV 
observed at concentrations of 0.1 pM and 1.0pM RTV, together with the significant 
down-regulation evidenced at lOpM RTV with and without mock transfection was 
again diminished at all RTV concentrations, ABCC2 gene expression was up- 
regulated by 1.1 fold compared to vehicle controls at 0.1 pM RTV (P=0.0002), by 1.2 
fold compared to vehicle controls at l.OpM (P=0.0041) and down-regulated by 1.1 
fold at lOpM (P=<0.0003), in the siRNA LXRa knockdown samples. Figure 4.4 (B) 
below.
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Figure 4.4: Gene expression assays in Huh7 cells (passage no.=24) incubated with RTV, 
RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, RTV in 24h 
siRNA knockdown cells and ATV for 24h: A= ABCC1; and B= ABCC2, n=4 for all assays, 
denotes P=<0.0001, ** denotes P=<0.001 * denotes P=<0.01.
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4.S.3.4 ABCG1, ABCG4, ABCG5 and ABCG8
Significant up-regulation of ABCG1 gene expression by RTV was observed at 
concentrations of 0.1 pM (3.4 fold increase compared to vehicle control, P=0.0024), 
l.OpM (3.9 fold increase compared to vehicle control, P=<0.0001) and lOpM (4.5 
fold increase compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 
4.5 (A) below. In the presence of 20pM 22-(S)-hydroxycholesterol, the statistically 
significant up-regulation of ABCG1 by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM was diminished to 1.5 fold increase compared to vehicle controls 
at 0.1 pM RTV (P=0,0008) at l.OpM to a 2.5 fold increase compared to vehicle 
controls (P=<0.0001) and at lOpM RTV plus 20pM 22-(S)-hydroxycholesterol to a 
3.1 fold increase compared to vehicle controls (P=0.0012), Figure 4.5 (A) below. 
ABCG1 gene expression was significantly down-regulated in the presence of all 
ATV concentrations, at 0.1 pM ATV there was a 2.4 fold decrease in ABCG1 
expression compared to vehicle controls, (P=0.0007), and at l.OpM ATV a 4.5 fold 
decrease compared to vehicle controls was evident, (P=<0.0001), and at lOpM ATV 
a 4.1 fold decrease in expression compared to vehicle controls was observed, 
P=<0.0001), Figure 4.5 (A) below. Significant up-regulation of ABCA1 gene 
expression by RTV was observed in the mock transfections (5.Op! Lipofectamine 
2000/0nM siRNA) at concentrations of 0. IpM (2.4 fold increase compared to vehicle 
control, P=0.0001), l.OpM (3.9 fold increase compared to vehicle control, 
P=<0.0001) and lOpM (5.7 fold increase compared to vehicle control, P=<0.0001), 
Figure 4.5 (A) below. The expression of ABCG1 in siRNA LXRa knockdown cells 
without RTV was not significantly altered from basal expression in vehicle controls. 
Figure 4.5 (A) below. The statistically significant up-regulation of ABCG1 gene
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expression by RTV observed at concentrations of 0,1 pM, 1.0pM and lOpM RTV 
with and without mock transfection was diminished to a 1.6 fold increase compared 
to vehicle controls at 0.1 pM RTV (P=0.0016), to a 1.6 fold increase compared to 
vehicle controls at l.OpM (P=0.0059) and to a 1.9 fold increase at lOpM (P=<0.001), 
in the siRNA LXRa knockdown samples. Figure 4.5 (A) below.
Significant up-regulation of ABCG4 gene expression by RTV was observed at 
concentrations of 0.1 pM (1.6 fold increase compared to vehicle control, P=<0.0001), 
l.OpM (3.3 fold increase compared to vehicle control, P=<0.0001) and lOpM (6,9 
fold increase compared to vehicle control, P=<0.0001) in Huh? cells (n=4). Figure 
4.5 (B) below. In the presence of 20pM 22~(S)-hydroxycholesterol, the statistically 
significant up-regulation of ABCG4 by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM was diminished to a 1.1 fold increase compared to vehicle controls 
at 0.1 pM RTV (P=<0.0001)5 and was abolished and replaced with a significant 
down-regulation of ABCG4 gene expression at l.OpM (1.1 fold decrease compared 
to vehicle controls, (P=<0.0001)) and lOpM (1.1 fold decrease compared to vehicle 
controls, (P=<0.0001)) RTV plus 20pM 22-(S)-hydroxycholesterol, Figure 4.5 (B) 
below. ABCG4 gene expression was significantly altered at all ATV concentrations, 
in the presence of 0.1 pM ATV a 1.5 fold increase in gene expression compared to 
vehicle controls was observed, (P^O.OOOl), however, significant down-regulation of 
ABCG4 expression was observed at concentrations of l.OpM (1.1 fold decrease 
compared to vehicle control, p=<0.0001) and lOpM ATV (3.1 fold decrease 
compared to vehicle control, P=<0.0001), Figure 4.5 (B) below. Significant up- 
regulation of ABCG4 gene expression by RTV was observed in the mock
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transfections (5.Oj.il Lipofectamine 2000/0nM siRNA) at concentrations of 0.1 pM 
(1.8 fold increase compared to vehicle control, P^O.OOOS), 1.0pM (3.6 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (6,8 fold increase compared to 
vehicle control, P=<0.0001), Figure 4.5 (B) below. The expression of ABCG4 in 
siRNA LXRa knockdown cells without RTV was not significantly altered from basal 
expression in vehicle controls. Figure 4.5 (B) below. The statistically significant up- 
regulation of ABCG4 gene expression by RTV observed at concentrations of 0.1 pM, 
1.0pM and lOpM RTV with and without mock transfection was abolished and 
replaced with significant down-regulation of ABCG4 gene expression by 1.4 fold 
compared to vehicle controls at 0.1 pM RTV (P=0.0005), by 1.3 fold compared to 
vehicle controls at l.OpM (P=0.0003) and by 1.1 fold at lOpM (P^O.0305), in the 
siRNA LXRa knockdown samples. Figure 4.5 (B) below.
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Figure 4.5: Gene expression assays in Huh7 cells (passage no.=24) incubated with RTV, 
RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, RTV in 24h 
siRNA knockdown cells and ATV for 24h: A= ABCG1; and B= ABCG4, n=4 for all assays, 
denotes P=<0.0001, ** denotes P=<0.001 * denotes P=<0.01.
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Significant up-regulation of ABCG5 gene expression by RTV was observed at 
concentrations of 0.1 pM (2.2 fold increase compared to vehicle control, P=0.0003), 
l.OpM (4.8 fold increase compared to vehicle control, P=0.0002) and lOpM (8.5 fold 
increase compared to vehicle control, P=<0.0001) in Huh? cells (n=4), Figure 4.6 
(A) below. In the presence of 20 pM 22-(S)-hydroxycholesterol, the statistically 
significant up-regulation of ABCG5 by RTV observed at concentrations of 0.1 pM 
and lOpM was diminished and at 1.0 pM was abolished. ABCG5 gene expression at 
0.1 pM and lOpM RTV in the presence of 20pM 22-(S)-hydroxycholesterol was 
diminished to a 1.1 fold increase compared to vehicle controls at 0.1 pM (P=0.0009) 
and at lOpM a 1.2 fold increase compared to vehicle controls was observed, 
(P=0.0242), Figure 4.6 (A) below. ABCG5 gene expression was significantly down- 
regulated at all ATV concentrations, in the presence of 0.1 pM ATV a 3.5 fold 
decrease in gene expression compared to vehicle controls was observed, 
(P=<0.0001), at l.OpM a 14.4 fold decrease in ABSG5 expression compared to 
vehicle control was observed, (P=<0.0001) and at lOpM ATV a 26.8 fold decrease 
compared to vehicle control was seen, (P^cO.OOOl), Figure 4.6 (A) below. 
Significant up-regulation of ABCG5 gene expression by RTV was observed in the 
mock transfections (5.0pl Lipofectamine 2000/0nM siRNA) at concentrations of 
0.1 pM (2.1 fold increase compared to vehicle control, P=<0.0001), l.OpM (4.3 fold 
increase compared to vehicle control, P=0.0005) and lOpM (8.3 fold increase 
compared to vehicle control, P=<0.0001), Figure 4.6 (A) below. The expression of 
ABCG5 in siRNA LXRa knockdown cells without RTV was not significantly altered 
from basal expression in vehicle controls, Figure 4.6 (A) below. The statistically 
significant up-regulation of ABCG5 gene expression by RTV observed at
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concentrations of 0.1 |iM, 1.0|iM and 10|iM RTV with and without mock transfection 
was abolished at 0.1 (iM and diminished at l.O^iM and IOjiM to a 1.1 fold increase 
compared to vehicle controls at LOpM (P=0.0107) and to a 1.3 fold increase at 
10pM (P=<0.0001), in the siRNA LXRa knockdown samples. Figure 4.6 (A) below.
Significant up-regulation of ABCG8 gene expression by RTV was observed at 
concentrations of 0.1 pM (2 fold increase compared to vehicle control, P=<0.0001)5 
l.OpM (3.7 fold increase compared to vehicle control, P=<0.0001) and lOpM (7.1 
fold increase compared to vehicle control, P=<0,0001) in Huh7 cells (n=4). Figure 
4.6 (B) below. In the presence of 20pM 22-(S)-hydroxycholesterol, the statistically 
significant up-regulation of ABCG8 by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM was diminished to a 1.9 fold increase in ABCG8 gene expression 
compared to vehicle controls at both 0.1 pM and l.OpM RTV concentrations 
(P=<0.0001 for both) and to a 1.7 fold increase compared to vehicle controls at 
lOpM RTV plus 20pM 22-(S)-hydroxycholesterol, (P=<0.0001), Figure 4.6 (B) 
below. ABCG8 gene expression was significantly up-regulated in the presence of 
0.1 pM ATV a 1.2 fold increase compared to vehicle controls (P=0.0012), however, 
significant down-regulation of ABCG8 was observed at concentration of l.OpM (1.1 
fold decrease compared to vehicle control, P=0.0004) and lOpM ATV (1.1 fold 
decrease compared to vehicle control, P=0.0104), Figure 4.6 (B) below. Significant 
up-regulation of ABCG8 gene expression by RTV was observed in the mock 
transfections (5.0pl Lipofectamine 2000/0nM siRNA) at concentrations of 0.1 pM (2 
fold increase compared to vehicle control, P=<0.0001), l.OpM (4.2 fold increase 
compared to vehicle control, P=0.0003) and lOpM (9.5 fold increase compared to
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vehicle control, P^cO.OOOl), Figure 4.6 (B) below. The expression of ABCG8 in 
siRNA LXRa knockdown cells without RTV was not significantly altered from basal 
expression in vehicle controls. Figure 4.6 (B) below. The statistically significant up- 
regulation of ABCG8 gene expression by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM RTV with and without mock transfection was abolished and 
replaced with significant down-regulation of ABCG8 gene expression by 1.1 fold 
compared to vehicle controls at 0.1 pM RTV (P=0.0099), and diminished to a 1.1 
fold increase compared to vehicle controls at 1.0pM (PA).0287) and to a 1.3 fold 
increase at lOpM (PA).0002), in the siRNA LXRa knockdown samples, Figure 4.6 
(B) below.
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Figure 4.6: Gene expression assays in Huh7 cells (passage no.=24) incubated with RTV, 
RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, RTV in 24h 
siRNA knockdown cells and ATV for 24h: A= ABCG5; and B= ABCG8, n=4 for all assays, 
denotes P=<0.0001l ** denotes P=<0.001 * denotes P=<0.01.
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4.S.3.5 GLUT4
Significant up-regulation of GLUT4 gene expression by RTY was observed at 
concentrations of 0.1 pM (1.6 fold increase compared to vehicle control, P=0.0022), 
l.OpM (1.6 fold increase compared to vehicle control, P=<0.0001) and lOpM (2.5 
fold increase compared to vehicle control, P=<0,0001) in Huh? cells (n=4). Figure 
4.7 below. In the presence of 20pM 22-(S)-hydroxycholesterol, the statistically 
significant up-regulation of GLUT4 by RTV observed at concentrations of 0.1 pM, 
l.OpM and lOpM was diminished at O.lpM and lOpM, and abolished at l.OpM. At 
0.1 pM RTV in the presence of 20pM 22-(S)-hydroxycholesterol GLUT4 gene 
expression was diminished to a 1.03 fold increase compared to vehicle controls, 
(P^O.0243) and at lOpM RTV plus 20pM 22-(S)-hydroxycholesterol) GLUT4 gene 
expression diminished to a 1.2 fold increase compared to vehicle controls, 
(P=<0.0001) Figure 4.7 below. GLUT4 gene expression was significantly down- 
regulated in the presence of all concentrations of ATV. At 0.1 pM ATV, an 8 fold 
decrease in gene expression was observed compared to vehicle controls, (P^cO.OOOl) 
significant down-regulation of GLUT4 was also observed at l.OpM ATV a 4 fold 
decrease compared to vehicle controls, (P=<0.0001) and at lOpM ATV a 4.8 fold 
decrease compared to vehicle controls, (P^O.OOOl), Figure 4.7 below. Significant 
up-regulation of GLUT4 gene expression by RTV was observed in the mock 
transfections (5.0pl Lipofectamine 2000/0nM siRNA) at concentrations of O.lpM 
(2.1 fold increase compared to vehicle control, P=<0.0001), l.OpM (2 fold increase 
compared to vehicle control, P=<0.0001) and lOpM (2.4 fold increase compared to 
vehicle control, P=<0,0001), Figure 4.7 below. The expression of GLUT4 in siRNA 
LXRa knockdown cells without RTV was not significantly altered from basal
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expression in vehicle controls. Figure 4.6 below. The statistically significant up- 
regulation of GLUT4 gene expression by RTV observed at concentrations of 0.1 pM 
and l.OpM with and without mock transfection was abolished and replaced with 
down-regulation of GLUT4 gene expression by 1.1 fold decrease compared to 
vehicle controls at 0.1 pM RTV (P=0.0334), and by 1.1 fold decrease compared to 
vehicle controls at l.OpM (P=0.0586, not significant). At lOpM RTV in the siRNA 
LXRa knockdown samples, a diminished significant up-regulation of GLUT4 gene 
expression was observed at a 1.1 fold increase compared to vehicle controls, 
(P=0.0006), Figure 4.7 below.
GLUT4 (SLC2A4) Expression in Huh7 (p24)
3.0
* * * * * *
[Drug] *iM
Figure 4.7: GLUT4 Gene expression assays in Huh7 cells (passage no.=24) incubated with 
RTV, RTV plus 20pM 22(S)-Hydroxycholesterol, RTV in Mock Transfection cells, RTV in 24h 
siRNA knockdown cells and ATV for 24h, n=4 for all assays. *** denotes P=<0.0001, ** 
denotes P=<0.001 * denotes P=<0.01
Chapter 4
178
4.6 Discussion
Chapter 2 and Chapter 3 of this thesis have demonstrated that LXRa is involved in 
the differing target gene expression profiles associated with the Pis RTV and ATV. 
This thesis has also demonstrated that antagonism of LXRa and biological 
knockdown by siRNA can be used to demonstrate the role of LXRa in the response 
to RTV. The endogenous role of LXRa is as a master regulator of cholesterol 
homeostasis in the liver and macrophages (Gronemeyer et ai, 2004a; Kalaany et aL, 
2006; Pascussi et al, 2008). It facilitates the processing and storage of cholesterol by 
up-regulating the cytochrome P450 7A1 enzyme (CYP7A1) and has been implicated 
in the increased expression of the ATP binding cassette proteins ABCA1, ABCG1, 
ABCG5 and ABCG8, key players in cholesterol transport and metabolism (Eloranta 
et aL, 2005; Pascussi et al, 2008; Tirona et aL, 2005). FXR, provides the 
counterbalance of hepatic LXRa action. It is activated by bile acid accumulation 
resulting from the conversion of cholesterol to bile acids, itself regulated by LXRa. 
Inhibition of bile acid synthesis is achieved by FXR down regulating CYP7A1, 
through indirect signalling involving the increased expression of the small 
heterodimer partner-1 (SHP-l)-liver receptor homologue-1 (LRH-1) pathway. SHP-1 
represses CYP7A1 expression by binding to promoter sequences and preventing 
further RE binding of activated LXRa (Eloranta et at, 2005).
Transcriptional activity of LXRa is induced by elevated levels of naturally occurring 
oxysterols and 6a-hydroxy bile acids (Eloranta et aL, 2005; Francis et aL, 2003). 
LXRa is also abundant in adipose tissue, where its activation has been shown to 
increase basal glucose uptake and the incorporation of TGs into lipid droplets
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(Lehrke et al, 2005). LXRa regulates cholesterol homeostasis by responding to high 
cholesterol levels and by increasing fatty acid synthesis to increase the formation of 
cholesterol esters, rendering the excess cholesterol pool biologically inactive 
(Giguere, 1999; Pascussi et al, 2008; Urquhart et al, 2007). The effects of LXRa on 
fatty acid synthesis are mediated through the increased expression of SREBP-lc, a 
stimulator of lipogenesis. SREBP-lc is a transcription factor which has been 
previously associated with PI induced lipodystrophy (Bastard et al, 2002; Telenti et 
al, 2002). Chapters 2 and 3 of this thesis have already discussed the impact of LXRa 
gene expression on SREBP-lc so it will not be discussed further in this chapter.
This chapter has focused on key hepatic transporters involved in cholesterol 
homeostasis, bile acid metabolism and in glucose transport, although some of these 
transporters also play key metabolic roles in the periphery and the intestine. This 
chapter also hypothesises the relative impact that LXRa regulation has on cholesterol 
and bile acid transport with the intention to further probe its contribution in the 
deleterious metabolic complications associated with PI based HAART regimens.
ABCA1 is a mediator of the efflux of cholesterol and phospholipids to lipid poor 
apolipoproteins for the formation of nascent HDL-cholesterol (HDL-c) (Borst et al, 
2002). ABCA1 is a direct target of LXRa (Edwards et al, 2002) the up-regulation of 
its gene expression by RTV was in line with the predicted outcome. Furthermore, it 
had been anticipated that this up-regulation could be blocked by antagonism of 
LXRa, as was observed in the RTV plus 22-(S)-hydroxycholesterol assays, 
supported by similar results in the biological knockdown (siRNA LXRa) assays.
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Interestingly, the significant down-regulation of ABCA1 gene expression in the RTV 
plus 22-(S)-hydroxycholesterol assays provided an insight into other mechanisms 
regulating the gene and showed LXRa to be a primary regulator of ABCA1 gene 
expression. It is hypothesised that the co-repressor molecules NCoR and SMRT may 
be implicated in the down-regulation of ABCA1 expression in the presence of the 
LXRa antagonist, a regulatoiy role for these co-repressors has already been reported 
(Kalaany et aL, 2006). ABCA1 gene expression was not significantly altered in the 
presence of 0.1 pM ATV, but at higher ATV concentrations significant down- 
regulation of ABCA1 which may be due to the involvement of SREBP-lc gene 
expression levels as it was established in Section 2.5.6 of this thesis that SREBP-lc 
expression is altered by both ATV and RTV incubations. Both FXR and LXRa 
regulate SREBP-lc and it had previously been implicated in the metabolic side 
effects due to PI use (Bastard et al,, 2002; Hui, 2003; Liang et at, 2001; Osborne, 
2000; Telenti et al, 2002).
ABCB1 has previously been shown to be involved in the transport of both RTV and 
ATV, (Perloff et al., 2005; Solon et al., 2002). The down-regulation of ABCB1 gene 
expression by RTV at all concentrations and the increased gene expression in the 
. presence of LXRa antagonism and knockdown suggests that LXRa may have been 
involved in ABCB1 gene regulation. It was hypothesised that LXRa may compete 
with other NRs, including may compete with other nuclear receptors, which may 
include PXR and HNF4a (Pascussi et al, 2008; Tirona et al, 2005), at the ABCB1 
binding site. This would explain, in part, the differential gene expression response in 
the presence of known PXR agonists (including RTV and ATV), and LXRa agonists
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(including RTV, as shown in these experiments) and the LXRa antagonist (22-(S)- 
hydroxycholesterol), although further investigations which were outside the scope of 
this current research would be required to probe this hypothesis. The current results 
suggested that there may be some merit in investigating the effects of PXR 
knockdown on the transporter response and to look at the effects of dual receptor 
knockdown for both PXR and LXRa on the gene expression of ABCB1 in the 
presence of RTV. Due to the time available for completion of this thesis this 
interesting further investigation is outside the scope of this thesis. The results from 
the current research suggest an inhibitory role for LXRa in respect of ABCB1 gene 
expression. ABCB1 was down-regulated by ATV at all concentrations, albeit to a 
lesser extent than the down-regulation observed in the RTV assays. As ATV has a 
more favourable lipid profile than RTV it did not warrant further investigation at this 
stage (Barreiro el aL, 2005; Feldt et aL, 2005; Flammer et aL, 2009).
The variable significant up-regulation and down-regulation of ABCB2, a key player 
in bile acid transporter, by RTV suggested that more than one mechanism was 
involved with its regulation. At 0.1 pM RTV ABCB2 was significantly up-regulated 
but at higher RTV concentrations, ABCB2 gene expression was down-regulated. At 
lower RTV concentrations, the up-regulation of ABCB2 could be blocked by the use 
of the LXRa antagonist and by biological knockdown of LXRa, which implicated a 
role for ABCB2 regulation by LXRa. At higher RTV concentrations biological 
knockdown and chemical antagonism of LXRa resulted in only small differences in 
the regulation of ABCB2 suggesting that although LXRa may play a role in the 
regulation of this transporter it is not the master regulator of this gene.
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ABCB11, the bile salt efflux pump, is regulated by FXR (Edwards et al, 2002; 
Kalaany et al, 2006). Significant up-regulation of ABCB11 gene expression by RTV 
was observed at 0.1 pM (2.9 fold increase, P=<0.0001), which may be consistent with 
the observed significant up-regulation of FXR by RTV and its previously reported 
role in ABCB11 regulation (Edwards et al, 2002; Kalaany et aL, 2006). Further 
probing of the role of FXR in this regulation would be required to confirm this 
hypothesis but this was outside the scope of this research. At higher concentrations 
of RTV, however, highly significant down-regulation of ABCB11 gene expression 
was evident at 1.0pM (1.9 fold decrease, P=<0.0001) and lOpM RTV (2.9 fold 
decrease, P=<0.0001). Furthermore the LXRa antagonist, 20 pM 22-(S)- 
hydroxycholesterol, reversed the effects of RTV on ABCB11 suggesting that LXRa 
may also play a key role in the regulation of this gene. This hypothesis is further 
supported by the results of the siRNA LXRa knockdown assays which also 
diminished the effects of RTV on ABCB11.
Highly significant down-regulation of ABCC1 gene expression by RTV was 
observed at all RTV concentrations. In the presence of 20pM 22-(S)- 
hydroxycholesterol and the siRNA knockdown of LXRa, this down-regulation of 
ABCC1 gene expression by RTV was abolished at O.ljaM RTV plus 20pM 22-(S)- 
hydroxycholesterol, and diminished at higher RTV concentrations and in the siRNA 
samples in a concentration dependent manner. ABCC1 gene expression was also 
significantly down-regulated in the presence of all concentrations of ATV, 
suggesting a complex array of mechanisms involved in ABCC1 regulation.
Chapter 4
183
Significant up-regulation of ABCC2 gene expression by RTV was observed at 
0.1 pM and l.OpM, however, significant down-regulation was observed at lOpM 
RTV. These effects were diminished in the assays using the LXRa antagonist, 22- 
(S)-hydroxycholesterol, and in the biological knockdown assays. This suggests that 
LXRa may be a key regulator in the xenobiotic response of this gene, but that it was 
not the primary regulator of this gene which involves other NRs including PXR and 
FXR (Ho et al, 2005; Wang et al, 2008).
ABCG1, a key player in cholesterol transport, was significantly up-regulated by all 
concentrations of RTV. This up-regulation was diminished in the presence of the 
LXRa antagonist 22-(S)-hydroxycholesterol, and in the biological knockdown assays 
suggesting a role for LXRa in die regulation of ABCG1 gene expression. 
Furthermore another key player in cholesterol transport, ABCG4, was also 
significantly up-regulated by all concentrations of RTV, effects which could be 
diminished in the presence of 22-(S)-hydroxycholesterol and by biological 
knockdown of LXRa. This regulation by LXRa could provide an insight into some 
of the metabolic complications associated with HADL as genes on the pathways for 
both bile acid transport and cholesterol transport were up-regulated simultaneously is 
these assays.
Significant up-regulation of ABCG5 and ABCG8 gene expression was also observed 
in the RTV assays at all RTV concentrations. The effects of which could be 
abolished or diminished in the presence of 22-(S)-hydroxycholesterol or siRNA 
knockdown of LXRa. Both of these transporters have previously been cited as under 
the regulatory control of LXRa (Francis et al., 2003). These experiments confirmed
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that the gene expression of these metabolic transporters differs in response to RTV 
and ATV and that the actions of RTV can be blocked through modulation of LXRa 
gene expression. The results also provide further insight into the complex 
mechanisms by which LXRa regulates its targets in response to a RTV stimulus. 
This may provide valuable clues in the design of future ARVs and other drugs, as 
agonism of LXRa may result in the disruption of a cascade of metabolic genes and 
downstream targets. In Chapter 3, the observed effects of biological knockdown by 
siRNA of LXRa resulted in a down-regulation of LXRa gene expression in the 
presence of all RTV concentrations. This suggested a potential future therapeutic 
mechanism for antagonism of LXRa in vivo, if the issues which have previously 
been associated with increased production of liver triglycerides by LXRa agonists 
can be eliminated. This is discussed in more detail in Chapter 7, General Discussion. 
The results from the transporter assays also support this hypothesis.
Up-regulation of GLUT4 gene expression was observed at all concentrations of 
RTV. In the presence of 20pM 22-(S)-hydroxycholesterol, this was diminished at 
0.1 pM and lOpM RTV, and abolished at l.OpM. The biological knockdown of 
LXRa confirmed these results implying a role for LXRa in the regulation GLUT4 
gene expression. Although caution should be exercised when interpreting the GLUT 
4 results as the overall basal and experimental expression levels of the gene were low 
in the Huh? cells.
In summary, this chapter has described the specific impact of the Pis RTV and ATV 
on the gene expression of transporters involved in cholesterol homeostasis and bile 
acid metabolism, with specific focus on the role of LXRa in this regulation. It has
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also discussed the impact of LXRa on the gene expression of the glucose transporter 
GLUT4; and its influence on the regulation of gene expression of this transporter in 
the presence of RTV. This chapter has hypothesised the role of multiple NRs, 
including LXRa, FXR, HNF4a and PXR, controlling regulation of key transporters, 
including ABCB1, and the need to consider whether future drugs act as LXRa 
agonists due to the disruptive effects it has on a cascade of metabolic genes and 
downstream targets. Inhibition of LXRa does show that some of these downstream 
effects can be modified.
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CHAPTER 5
THE INFLUENCE OF A SINGLE NUCLEOTIDE 
POLYMORPHISM IN THE LIVER OXYSTEROL 
RECEPTOR-a (LXRa) GENE IN A HIV COHORT
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5.1 Introduction
Dyslipidaemia and its related complications, including the increased risk of coronary 
artery disease, are growing public health concerns in both the HIV+ and HIV 
negative (HIV-) populations and an association with a genetic predisposition has 
been established (Alaynick, 2008; Dahlman et al, 2006; Maes et aL, 1997; 
Pushpakom et al.). Long-tenn treatment with HA ART is widely implicated with 
direct toxicity, which when associated with the complex interactions with HIV 
infection and combined with other factors, (including genetic predisposition, 
enviromnental) influence the risk of developing HADL. Morbidity and mortality 
outcomes for HIV+ individuals have greatly improved with successful treatment 
regimens but the onset of HADL significantly increases the risk of developing 
cardiovascular disease and associated metabolic complications (Kim et al., 2006b; 
Mallon, 2007).
NRTIs are strongly associated with lipoatrophy and fat wasting, which is exacerbated 
by dual NRTI therapy (Mallal et al, 2000; Mallon et al, 2003). Insulin resistance is 
commonly associated with Pis and NRTIs (Falutz, 2007; Giguere, 1999; Lagathu et 
al, 2005). Pis have been shown to impact several molecular pathways key to lipid 
metabolism including intra-nuclear transcription factors and the nuclear proteasome 
(Lagathu et al, 2005; Mallon, 2007). There is a need for the development of newer 
ARVs, which overcome the problem of viral resistance, with improved safety 
profiles for long-term use in an aging HIV+ population, and reduced risk of HADL 
onset. Research into metabolic disorders, including HADL, has included
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investigations into the role ofNRs including LXRtx (Cha et aL, 2007; Edwards et at, 
2002; Fiorucci etaL, 2007; Francis etal^ 2003; Tobin etal, 2006).
In Chapters 2 and 3 of this thesis the impact of the Pis RTV and ATV on NR gene 
expression and the role played by LXRa in this was investigated and discussed. 
Chapter 2 discussed the implications of inhibition of LXRa gene expression by a 
chemical antagonist had on downstream target genes together with the hypothesis 
that LXRa functions as a master regulator of this downstream gene expression. 
Chapter 3 validated die role of LXRa by probing the influence of LXRa knockdown 
by siRNA, in the presence of RTV, on its own gene expression and that of its target 
genes to confinn the hypothesis. In these chapters the role of LXRa as an inducer of 
the gene expression of SRERP-lc, ApoA-I, ApoC-II and ApoC-III, although the 
latter may have been through an indirect mechanism via PPARa, was confirmed. 
LXRa was also confirmed as a down-regulator of PPARa and VLDLR gene 
expression.
5.1.1 Liver Oxysterol Activated Receptor-a (LXRa)
LXRa is expressed in the liver ([highest]), intestine, kidney, adipose tissue, 
macrophages, ovary, brain, lung and spleen. LXRa plays a critical role in cholesterol 
and bile acid homeostasis (Cha et aL, 2007; Hu et aL, 2003; Kalaany et at, 2006). 
LXRa is involved in the up-regulation of CYP7A1 and is implicated in the increased 
expression of ABCA1, ABCG1, ABCG5 and ABCG8 (Eloranta et aL, 2005; 
Pascussi et aL, 2008; Tirana et aL, 2005). There is evidence that the effects of LXRa 
on fatty acid synthesis are mediated through the increased expression of SREBP-lc 
(Legry et aL, 2008), a transcription factor which has been previously associated with
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PI induced lipodystrophy (Bastard et al, 2002; Telenti et al, 2002). LXRa agonists 
have been implicated in glucose homeostasis and metabolism (Cao et al, 2003; 
Dahlman et al, 2009; Grefhorst et al.t 2005). LXRa also represses PPARa and 
facilitates efflux of cholesterol from the periphery, including macrophages, through 
the increased expression of ABC transporters (Kalaany et al, 2006; Pascussi et al, 
2008). PPARa induction leads to the repression of ApoC-III (Duval et al, 2007; 
Feldman et al, 2008; Yamada et al, 2007). As LXRa plays a key role in numerous 
metabolic pathways it makes it an ideal candidate gene for the investigation of 
susceptibility to the metabolic complications associated with HADL.
5.1.2 LXRa Single Nucleotide Polymorphisms (SNPs) Associated with Metabolic 
Complications
Candidate SNPs were identified by a review of published LXRa SNP associations 
with dyslipidaemia in the general population in PubMed. The results were further 
refined to include only those with a minor allele frequency (MAF) >0.1 in Caucasian 
populations.
SNPs in LXRa have been implicated in a number of metabolic disorders including 
metabolic syndrome, dyslipidaemia and Type II diabetes mellitus (Dahlman et al, 
2009; Dahlman et al, 2006; Legry et al, 2008; Steffensen et al, 2004). A specific 
association has been made with the heterozygous genotype of the rs2279238C/T SNP 
in LXRa with increased body mass index (BMI) and a hypothesised association in 
the homozygous T-allele population (rare TT genotype in cohort) with obesity 
(Dahlman et al, 2006). A positive association has been made with the T allele and 
increased risk of a fatal cardiovascular event in a non-black population (Price et al.
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2011). The rs2279238C/T SNP in LXRa was considered to be a suitable candidate 
for investigation in a HIV+ cohort with associated HADL complications.
5.2 Aim
The aim of this chapter was to investigate the impact of a specific SNP in the LXRa 
gene which had previously been associated with metabolic complications 
(rs2279238CT, also known as C297T) in non-HIV+ individuals, in a HIV+ cohort 
which was treated with a HAART regimen which comprised Pis and NRTIs 
previously associated with HADL complications. The investigation focused on 
whether the SNP influenced the development of HADL in the HIV+ cohort.
5.3 Materials and Methods
5.3.1 Materials
Qiagen Miniprep Blood Kit, Qiagen Protease and Qiagen buffer AL, and Qiagen spin 
column were purchased from Qiagen Limited, (Crawley, West Sussex, UK). Pico 
Green dsDNA Quantitation Reagent was purchased from Invitrogen Limited 
(Paisley, UK). Taqman universal PCR master mix and inventoried Taqman allelic 
discrimination genotyping assay for LXRa rs2279238C/T were purchased from 
Applied Biosystems, (Warrington, UK). The 7900HT Fast Real Time PCR System 
(Applied Biosystems, Foster City, California, USA). Molecular grade Ethanol, 
Molecular Grade Isopropanol, RNAse free water, DNAse free water, and 2- 
mercaptoethanol were purchased from Sigma Aldrich Co. Limited (Irvine, Ayrshire, 
UK).
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5.3.2 Patients
A United Kingdom (UK) cohort of HIV+ patients in this study were recruited from 
two centres in the UK (North Manchester General Hospital and the MRC Clinical 
Trials Unit). All subjects provided consent for blood donation/DNA samples and 
subsequent genetic analysis. The studies were approved by the local ethics 
committees. Patients were recruited as they consecutively attended the clinics during 
the period between 1998 and 2004. The diagnosis of HAUL was based on the 
clinician's confirmation of patient self-report or on the clinician's observation alone 
after start of antiretroviral therapy, which had a PI backbone. HAUL was defined as 
either lipoatrophy (fat wasting of arms, face, legs, or buttocks) or fat accumulation in 
the abdomen, or over the dorsocervical region or breasts, and presence of associated 
metabolic abnormalities. UNA samples were obtained from 172 HAART-treated 
HIV+ patients: 131 with HAUL (HADL+) and 41 without HAUL (HAUL-). The 
inclusion criteria for the study were: age >18 years; Caucasian ethnicity and PI intake 
(including RTV) for at least 12 months before recruitment. HIV+ patients who met 
the above criteria but did not develop any features of HAUL after 12 months of 
protease inhibitor treatment were recruited as controls. All the patients recruited were 
evaluated by the clinician at least three times over the course of a year. The 
following data were collected: age, sex, HAUL status, concomitant ARVs, and 
baseline lipid parameters.
UNA samples were also obtained from 170 Caucasian HIV- healthy individuals with 
no known infectious or immune diseases to establish the population frequency of the
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allelic variants investigated. Demographic data for the healthy controls was not 
retained. Study cohort demographics are as shown in Table 5.1 below.
Table 5.1: UK Patient Cohort Demographics for HADL LXRot Polymorphism Study
Patient Status Patient
Numbers
Age (Years) 
Median (Range)
Gender %
HADL+ 131 40 (29-68) 80 (M), 20 (F)
HADL- 41 41 (24-65) 85.7 (M), 14.3 (F)
Healthy Controls 170 Not known Not Known
The Pis administered included IDV, RTV, SQV, nelfinavir, amprenavir and 
lopinavir. All patients included in this study had also received NRTIs which included 
stavudine, zidovudine and lamivudine.
5.3.3 Extraction of Genomic DNA from Whole Blood
Total genomic DNA was extracted from whole blood using the Qiagen Miniprep 
Blood Kit. Whole blood (200pi) was mixed with Qiagen Protease (20pi) and buffer 
AL (200pi) and pulse vortexed (15s). Samples were incubated (10 min, 56°C) and 
pulse vortexed (15s) before the addition of ethanol (200pl) and transferred to a 
Qiagen spin column. The spin column was centrifuged (6000 x g, 1 min, 4°C) and 
the flow-through discarded. Buffer AW1 (500pi) was added and the column 
centrifuged (6000 x g, 1 min, 4°C) discarding the flow-through. A further wash with 
buffer AW1 was carried out (500pl, 17000 x g, 1 min, 4°C). Buffer AE (200pl) was 
then added and the spin column was incubated (5 min, 22°C) before centrifugation 
(17000 x g, 1 min, 4°C) and collection of flow-through in clean collection tubes. 
Samples were diluted (1:100), analysed and quantified using the PicoGreen® dsDNA
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Quantitation Reagent, validated by standard curve and were normalised to a 
concentration of 20ng/jal by the addition of DNAse free water.
5.3.4 LXRa Genotyping by Taqman Allelic Discrimination Assay
DNA isolated from whole blood was genotyped for the rs2279238CT (SNP within 
LXRa by Taqman allelic discrimination assay. The assay involves qPCR of both C 
and T alleles by the same primers in the presence of two probes, one specific for each 
allele, and labelled with different reporter dyes (FAM and VIC) between which the 
detector can distinguish. Following amplification, the 7900HT Fast Real Time PCR 
System (Applied Biosystems, Foster City, California, USA) reports on which 
wavelength fluorescence is detected. If amplification is detected (i.e. the cycle 
threshold is exceeded) in only one wavelength, the sample is considered homozygous 
for whichever allele the probe fluorescing at that wavelength is specific. Samples in 
which amplification is detected in both wavelengths are considered heterozygous. 
The reaction mixture consisted of Taqman universal PCR master mix (2.5pi), LXRa 
rs2279238CT primer and probe mix (0.25pl), nuclease-free water (0.25pl) and DNA 
nonnalised stock (2 pi) per well of a 384 well optical reaction plate. Thermal cycling 
conditions consisted of 1 cycle at 95°C for 10 minutes, then 40 cycles of 92°C for 15 
seconds and a combined annealing/extending temperature of 60°C for 1 minute.
5.4. Statistical Analysis
All data are given as frequency number (percentage), unless otherwise stated. 
Genotypes were tested for Hardy-Weinberg equilibrium by %2 (Chi-square) test of 
observed versus predicted (from allele frequency) genotype frequencies. Statistical 
significance was assessed using the x;2 test and Fishers exact tests for subset analysis.
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5.5.
5.5.1
Spearman’s rank correlations were used to assess the correlation of age and gender 
with HADL status, baseline total cholesterol, baseline glucose and baseline 
triglyceride levels. Univariate and multivariate associations were assessed with SPSS 
vl7 (SPSS Inc., Chicago, IL, USA) using backward logistic regression. A statistical 
trend was defined as a P value <0.1. Statistical significance was set at P<0.05.
Results
Quantification of Genomic DNA
Total genomic DNA samples were diluted (1:100), analysed and quantified using the 
PicoGreenK dsDNA Quantitation Reagent, validated by standard curve prepared 
from known DNA concentrations at 1.5625ng/|xl, 3.125ng/pl, 6.25ng/pl, 12.5ng/pl, 
25ng/pl and SOng/pl as shown in Figure 5.1 below.
Standard Curve of Genomic DNA
y = 0.1994x 
R2 = 0.9896-
it 6
[DNA] ng/ul
Figure 5.1: Standard Curve of known concentration genomic DNA used for quantification of 
sample genomic DNA.
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5.5.2 LXRa Genotyping by Taqman Allelic Discrimination Assay
Patient demographics and characteristics were outlined in Section 5.3.2 and Table 
5.1. The distribution of the genotypes for the LXRa rs2279238C/T SNP included 239 
individuals with the CC genotype (95 HADL+, 35 HADL- and 109 healthy 
volunteers), 94 heterozygotes with the CT genotype (32 HADL+, 6 HADL- and 56 
healthy volunteers) and 9 homozygous TT individuals (4 HADL+, no HADL- and 5 
healthy volunteers). Allele frequencies for the LXRa rs2279238C/T SNP were 
confinned to be in Hardy-Weinberg equilibrium and are summarised in Table 5.2 
below.
Table 5.2: Summary allelic frequencies and Hardy-Weinberg analysis for rs2279238CT SNP 
in LXRa.
Hardy-Weinberg equilibrium for Manchester/MRC Lipodystrophy study
The 5% significance level for 2 degrees of freedom for x2 value is 3.S4 or P value < 0.05
(n=131/41/170)
SNP
Genotype
frequencies
{(1=131/41/170)
Genotype 
frequencies (%}
Allele
frequencies
(n=131/41/170)
Allele
frequencies %
XZtest P value
P q
LXRa C297T HADL+ CC CT TT CC CT TT C T
95 32 4 72.5 24.4 3.1 222 40 84.7 15.3 0.1870 0.9107
LXRa C297T HADL- CC CT TT CC CT TT C T
35 6 0 85.4 14.6 0.0 76 6 92.7 7.3 0.2374 0.8881
LXRa C297T Healthy
Volunteers CC CT TT CC CT TT C T
109 56 5 64.1 32.9 2.9 274 66 80.6 19.4 0.2547 0.8804
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Figure 5.2 below shows the cycle threshold analysis of the allelic discrimination 
assay. Figures 5.3, 5.4 and 5.5 are representative plots of the homozygous wild type 
CC, heterozygote CT and homozygous mutant TT respectively.
I Z] G— f ZD » 1^=* Ql I
m MTC
Figure 5.2: LXRa SNR rs2279238C/T: Cycle Threshold analysis of allelic discrimination 
assay by qPCR
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Figure 5.3: LXRa SNR rs2279238C/T: Representative Plot of Homozygous Wild Type-CC by 
allelic discrimination assay by qPCR, n=1
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Figure 5.4: LXRa SNP rs2279238C/T: Representative Plot of Heterozygous-CT by allelic 
discrimination assay by qPCR, n=1
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Figure 5.5: LXRa SNR rs2279238CAT: Representative Plot of Homozygous Mutant-TT by 
allelic discrimination assay by qPCR, n=1
There were no significant associations with any of the genotypes with baseline lipid 
parameters (Table 5.3 below). A trend was observed with HADL+ status and 
baseline triglyceride levels >200mg/dl (P=0.069), and with baseline glucose levels 
>100mg/dl (P=0.087). A significant association was observed with high baseline 
cholesterol levels >240mg/dl and HADL+ status (P=0.001) and age (P=0.009). 
Summary univariate and multivariate outcomes are detailed below. Table 5.3. 
Spearman’s rank correlations did not confirm a correlation of age and/or gender with 
HADL status, baseline total cholesterol, baseline glucose and baseline triglyceride 
levels. A moderate correlation between HADL status and baseline total cholesterol 
levels (r=0.319) was confirmed by Spearman’s rank correlation. Multivariate logistic 
regression did not confirm significant associations with any of the genotypes in the 
either the HADL+ or HADL- cohorts. Subset analysis of HADL+ and HADL-
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cohorts underpinned this finding, however, a trend was observed when the alleles 
were compared in the same groups (P=0.09). A significant association was observed 
when HADL- and healthy volunteer cohorts were analysed (P=0.0012) whilst the 
power of this association increased when the alleles in the same cohorts were 
analysed (P=0.008). Frequency distribution analysis confirmed that there were 
differences between the phenotype outcomes for the three genotypes in that the TT 
genotype was not observed in the HADL- cohort. Individuals with at least one copy 
of the rare T allele were more prevalent in the HADL+ and healthy volunteer 
cohorts, see Figure 5.6 below.
Table 5.3: Summary univariate and multivariate regression analysis of rs2279238CT SNP in 
LXRa together with Spearman’s Rank correlation analysis with HADL status. Significance = 
P=<0.05, Trend = P=<0.1.
Baseline
Cholesterol
>240mg/dl
Baseline
Triglycerides
>200mg/dl
Baseline
Glucose
>100mg/dl
Age Gender HADL+
Univariate P
Value 0.05 0.069 0.087 0.633 0.312 0.648
Multivariate
P Value 0.033 0.082 0.067 0.009 0.238 0.001
95%
Confidence
Interval
0.208-0.802 0.856-1.595 0.000-0.368
0.005-
0.037
-0.537-
0.235
0.193-
0.786
Spearman’s 
Rho (r=) 0.319 0.091 0.073 -0.010 0.059
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Frequency of LXRa rs2279238C/T SNR (C297T) in UK Cohort
■ CC CT ■TT
HALO+ HALO- Healthy Volunteers
Figure 5.6: LXRa SNR rs2279238C/T: Frequency distribution (%) of genotypes for the 
C297T SNR in HIV+ Patient Cohort and Healthy Volunteer populations, P = 0.645. HADL+ = 
HIV+ with HADL symptoms, HADL- = HIV+ without HADL symptoms.
Discussion
This chapter sought to validate the importance of a known polymorphism in the 
LXRa gene which had previously been associated with lipid abnormalities and 
cardiovascular risk in non-HIV+ populations (Dahlman et ai, 2009; Legry et ai, 
2008; Price et a/., 2011) in a HIV+ cohort with confirmed HADL complications. The 
investigation determined that there were no significant associations with any of the 
CC, CT and TT genotypes of the rs2279238C/T SNP in either the HADL+ or 
HADL- cohorts, although it should be noted that the rare TT genotype was 
completely absent in the HADL- cohort. Subset analysis of the allele frequency in 
the HADL+ and HADL- cohorts revealed a trend associated with the T allele and 
HADL symptoms (P=0.09). When the HADL- cohort was compared to the healthy
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volunteer cohort a significant association was observed which suggested a protective 
role for the CC genotype in this cohort (P=0.0012) whilst the power of this 
association increased when the alleles in the same cohorts were analysed (P=0.008) 
with an odds ratio of 3. This suggested that the polymorphism was 3 times more 
likely in healthy volunteers than in the HADL- cohort which supported the 
hypothesis that absence of the polymorphism may be protective against HADL 
symptoms. It should also be noted that the mutant TT genotype was rare in the 
patient cohort. Baseline lipid parameters and patient demographics were not obtained 
for the healthy volunteers and some HADL patients had incomplete lipid profiles. 
The parameters used for analysis of the lipid levels in the HADL cohort were in line 
with the recommendations of the National Institute of Health (NIH), USA (Public- 
Health, 2001). Further investigations in a larger population would need to be 
undertaken to establish whether the association with the TT genotype previously 
observed in HIV absent populations (Dahlman et aL, 2009; Legry et al, 2008; Price 
et a/., 2011) influences HADL outcomes in non-Caucasian populations or is gender 
specific in a HIV+ cohort, as this patient group was wholly Caucasian and 
predominantly male.
Weak associations between baseline lipid parameters; total cholesterol >240mg/dl 
(P=0.05); triglycerides >200mg/dl (P=0.069); and blood glucose >100mg/dl 
(P=0 087) were observed in the HADL+ cohort, although these associations were not 
linked to a specific genotype. Power for these associations increased in the 
multivariate analysis when increasing age of the patients was correlated with HADL 
status and the baseline parameters, however, these did not correlate with a specific
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genotype. Total cholesterol >240mg/dl was established in 39/95 HADL+ 
homozygous wild type (CC) patients, 15/32 heterozygotes (CT) and 1/4 homozygous 
rare allele (TT) patients. Triglycerides >200mg/dl were determined in 42/95 
(although TG data was missing for 25/95 patients in this category) HADL+ 
homozygous wild type (CC) patients, 13/32 (although TG data was missing for 10/32 
patients in this category) heterozygotes (CT) and 1/4 homozygous rare allele (TT) 
patients (TG data was missing for the other 3 patients in this category). Blood 
glucose >100mg/dl was detected in 20/95 (although glucose data was missing for 
7/95 patients in this category) HADL+ homozygous wild type (CC) patients, 8/32 
heterozygotes (CT) and 1/4 homozygous rare allele (TT) patients (glucose data was 
missing for the other 3 patients in this category). In order to validate these 
associations further investigations in a larger population would need to be undertaken 
to establish whether these parameters correlate with a specific genotype.
It is hypothesised that the LXRa SNP rs2279238C/T influences the risk of HADL 
development in Caucasian HIV+ populations, it may also be linked to increased risk 
of a fatal cardiovascular event where HADL complications are present. Survival 
outcome and follow-up data for this cohort were not recorded so the cardiovascular 
risk is unconfirmed. HADL is a multifactorial disease and in this chapter a single 
polymorphism in a single gene has been investigated. It is difficult to conclude that 
the presence of a single polymorphism in LXRa could predict future cardiovascular 
events in a HIV+ or HADL+ population, although it is possible to make associations 
with other SNPs in linkage disequilibrium with rs2279238C/T by use of the HapMap 
to establish the presence of multiple SNPs which contribute to the phenotype.
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Research into the role of host genetics in the development of lipid abnormalities in 
response to ARVs continues with polymorphisms in ApoA-5, ApoC-III, ApoE and 
ABCA1 widely implicated (Owen etaL, 2008; Tarr el aL, 2007; Telenti et aL, 2008).
HIV is a chronic but manageable disease, as the HIV+ population ages the risk of 
developing metabolic disorders including diabetes mellitus and cardiovascular 
disease increases. In order to offset this risk, health care professionals need to 
consider metabolic complications, especially cardiovascular risk assessment, as a 
routine component of treatment of HIV+ individuals (Moyle, 2007). Knowledge of 
specific polymorphisms which increase this risk will provide an insight into future 
treatment regimens so that those individuals with the greatest risk of metabolic 
complications receive treatment which incorporates lipid sparing ARVs. This 
knowledge will also influence the future development of drugs to treat HIV as more 
is known about the complex mechanisms which underpin HADL and individual 
susceptibility to its development.
In summary, this chapter described the association of a known polymorphism in the 
metabolic gene LXRa which had previously been linked with lipid abnormalities in 
HIV- populations and the role that this polymorphism has had in influencing the 
development of HADL in a Caucasian HIV+ cohort together with the potential 
influence that these findings may have as future predictors of HADL risk.
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CHAPTER 6
THE INFLUENCE OF SINGLE NUCLEOTIDE 
POLYMORPHISMS IN ENDOGENOUS 
CHOLESTEROL METABOLISM GENES IN AN 
ITALIAN HIV COHORT
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6.1 Introduction
The risk of developing HTV7HAART associated dyslipidaemic lipodystrophy 
(HADL) has emerged as a major long term concern for HIV-!- individuals treated 
with HAART. The onset of HADL greatly increases the risk of developing 
cardiovascular disease and associated metabolic complications (Kim et al, 2006b; 
Mallon, 2007). Protease inhibitor (Pis) containing regimens in particular have been 
associated with an increased cardiovascular risk which is in part mediated by 
dyslipidaemia (Friis-Moller et al, 2003; Friis-Moller et al, 2008), The three major 
classes of antiretrovirals: Pis, nucleoside/nucleotide reverse transcriptase inhibitors 
(NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) have all been 
implicated in HADL, although Pis are most widely implicated with symptoms 
occurring in 60-80% of HIV+ individuals on PI based regimens (Behrens et al, 
2000; Carper et al, 2008; Carr, 2000; Carr et al, 1998; Falutz, 2007; Mallon, 2006). 
Ritonavir (RTV) is no longer used as a PI in HAART but is used at low dose to boost 
the activity of other Pis through its inhibition of the cytochrome P450 (CYP) 
enzyme, CYP3A4. RTV has no intrinsic antiviral activity at low dose but it has been 
widely implicated in hypertriglyceridaemia (Kim et al, 2006b; Mallon, 2007; Purnell 
et al, 2000).
HADL may include increased low-density lipoprotein cholesterol (LDL-C) levels, 
decreased high-density lipoprotein cholesterol (HDL-C) levels, and 
hypertriglyceridaemia (Fontas et al, 2004; Periard et al, 1999; Young et al, 2005). 
The severity and category of dyslipidaemia may vary with the HAART regimen 
used. For example, hypertriglyceridaemia is frequently associated with RTV
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containing regimens (Fontas et al9 2004; Periard et aL, 1999), whereas increased 
LDL-C levels are associated with multiple classes of antiretrovirals (ARVs) 
including Pis and NNRTIs, especially efavirenz (Fontas et aL, 2004; Periard et aL, 
1999; van Leth et aL, 2004). Hypercholesterolaemia, hypertriglyceridaemia and 
elevated apolipoprotein B (ApoB) levels are more widely associated with the use of 
PI based regimens (Lekakis et aL, 2008; Liang et aL, 2001; Purnell et aL, 2000; 
Tsiodras et aL, 2000). RTY has also been associated with enhanced fonnation of 
very low density lipoproteins (VLDL), whilst saquinavir is associated with a 
decrease in lipoprotein lipase (LPL) activity and increased mobilisation of lipid 
stores (Purnell et aL, 2000; Ranganathan et aL, 2002; Reeds et aL, 2003).
HADL does not, however, develop in all HIV+ patients despite similar HAART 
exposure and comparable immunological and demographic characteristics. This may 
implicate host genetic factors playing a significant role in metabolic complications 
including HADL.
6.1.1 Single Nucleotide Polymorphisms (SNPs) Associated with Metabolic 
Complications
Candidate SNPs were identified by a review of published SNP associations with 
dyslipidaemia in the general population in PubMed, excluding those which had 
previously been extensively associated in the HIV+ population. The results were 
further refined to include only those with a minor allele frequency (MAF) >0.1 in 
Caucasian populations.
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Two SNPs in the low density lipoprotein receptor (LDLR) were identified which had 
previously been associated with increased LDL-C and an increased risk of 
cardiovascular events, rsl529729C/T and rs2228671C/T (Aulchenko et aL, 2009; 
Kathiresan et aL, 2008; Linsel-Nitschke et aL, 2008). The C allele in both SNPs was 
associated with increased LDL-C (Kathiresan et aL, 2008; Linsel-Nitschke et aL, 
2008), whilst the risk of cardiovascular events further increased when the 
rsl529729C/T SNP was present in association with other SNPs including the 
rs693A/G and rs7575840G/T SNPs found in the apolipoprotein-B (ApoB) gene, 
which were also associated with increased LDL-C levels (Kathiresan et aL, 2008). 
The C allele for the SNP rs2278986C/T in the scavenger receptor class B1 
(SCARB1, also known as SRB1)) gene has been implicated in reduced SRB1 protein 
levels which are inversely associated with HDL-C levels, with the prevalence for 
higher HDL-C levels being greater in females with hyperalphalipoproteinaemia 
(West e^/., 2009).
The rs2230806G/A SNP in the ATP binding cassette protein A1 (ABCA1, formerly 
known as the cholesterol efflux regulatory protein, CHRP) has been associated with 
elevated LDL-C levels in men with the AA genotype (Abelian et aL). Females with 
the AA genotype for the rs 1893590A/C SNP in the ATP binding cassette protein G1 
(ABCG1) have been shown to have decreased HDL-C levels (Abelian et aL). The T 
allele of the rs6544713C/T SNP in the ATP binding cassette protein G8 (ABCG8) 
has been associated with elevated LDL-C levels and an increased risk of carotid 
artery disease (Ronald et aL, 2009).
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Total cholesterol is defined as low if it is <200mg/dl in whole blood. At 200- 
239mg/dl the patient is described as borderline hypercholesterolaemia and values 
>240mg/dl are determined to be high total cholesterol (Public-Health, 2001), The 
parameters for HDL-C differ in males and females within the following ranges: Low 
HDL-C in men is <40mg/dl whereas <50mg/dl is considered low in women. Average 
HDL-C levels are in the range 40-50mg/dl for males and 50-60mg/dl in females, 
with high HDL-C levels >50mg/dl in men and >60mg/dl in women, the latter 
category is regarded as beneficial (Public-Health, 2001).
Optimal LDL-C levels are <100mg/dl for both males and females. Levels in the 
range 100-129mg/dl are considered near optimal whilst those in the range 130- 
159mg/dl are considered to be borderline high. High LDL-C is in the range 160- 
189mg/dl whereas >190mg/dl is considered to be very high LDL-C (Grundy et al, 
2004; Public-Health, 2001).
Normal triglyceride (TG) levels are <150mg/dl, with borderline high levels in the 
range 150-199mg/dl. High TG levels are in the range 200-499mg/dl with very high 
TG levels >500mg/dl (Public-Health, 2001).
Blood glucose levels are considered normal when <100mg/dl, whereas 100-126mg/dl 
is considered to represent impaired fasting or pre-diabetes. Individuals with diabetes 
would have blood glucose levels >126mg/dl.
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6.2 Aim
The aim of this chapter was to investigate the impact of specific polymorphisms in 
genes which had previously been associated with metabolic complications (ABCA1, 
LDLR, SCARE 1, ABCG1, ABCG8 and ApoB) in non-HIV-t- individuals, in a HIY+ 
cohort with known HADL symptoms who had been switched from a RTV-ATV 
boosted regimen to an un-boosted AT V regimen.
6.3 Materials and Methods
6.3.1 Materials
Qiagen Miniprep Blood Kit, Qiagen Protease, Qiagen buffer AL, and Qiagen spin 
columns were purchased from Qiagen Limited, (Crawley, West Sussex, UK). 
Taqman universal master mix, inventoried Taqman allelic discrimination genotyping 
assays for ABCA1 rs22308G6G/A, LDLR rsl529729C/T and rs2228671C/T, 
SCARE 1 rs2278986C/T, ABCG1 rsl893590A/C, ABCG8 rs6544713C/T, and ApoB 
rs693A/G and rs7575840G/T were purchased from Applied Biosystems, 
(Warrington, UK). Pico Green dsDNA Quantitation Reagent was purchased from 
Invitrogen Limited (Paisley, UK). Molecular grade Ethanol and DNAse free water 
were purchased from Sigma Aldrich Co. Limited (Irvine, Ayrshire, UK). The DNA 
Engine Opticon 2 and Chromo 4 systems were from MJ Research Inc. (USA).
6.3.2 Patients
An Italian cohort of Caucasian HIV+ patients from the Department of Infectious 
Diseases, University of Turin, Italy (n = 32, 17 male and 15 female) participated in 
this study. Inclusion criteria for the cohort was as follows: receipt of un-boosted 
atazanavir (400 mg once per day), age >18 years, and no receipt of drugs known to
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alter plasma concentration of atazanavir (e.g. proton pump inhibitors or non­
nucleoside reverse-transcriptase inhibitors). The following data were collected: age, 
sex, body weight, total cholesterol (mg/dl), HDL-cholesterol (mg/dl), blood glucose 
(mg/dl), LDL-cholesterol (mg/dl), triglycerides (mg/dl), (Table 6.1, below) 
concomitant antiretroviral drugs, and other medications. Parameters were measured 
at baseline (week 0, last date for RTV boosted ATV), with follow up values taken at 
weeks 4, 12, 24, 36, 48, 60, 72, 84 and 96. All subjects provided consent for blood 
donation and the study was approved by the local ethics committee.
Table 6.1: Italian Patient Cohort Demographics for Cholesterol Transport Genes SNP Study
Patient Numbers 32
Age (Years) Median (Range) 45(34-64)
Height (cm) Median (Range) 168(150-185)
Weight (kg) Median (Range) 60 (41-90)
Baseline Total Cholesterol 
(mg/dl) Median (Range)
137(101-323)
Baseline HDL Cholesterol 
(mg/dl) Median (Range)
30 (24-62)
Baseline Blood Glucose (mg/dl) 
Median (Range)
95 (67-128)
Baseline LDL Cholesterol 
(mg/dl) Median (Range)
63 (51-216)
Baseline Triglycerides (mg/dl) 
Median (Range)
217(74-629)
Gender % 53 (M), 47 (F)
6.3.3 Extraction of Genomic DNA from Whole Blood
Total genomic DNA was extracted from whole blood using the Qiagen Miniprep 
Blood Kit. Whole blood (200pl) was mixed with Qiagen Protease (20pl) and buffer 
AL (200pl) and pulse vortexed (15s). Samples were incubated (10 min, 56°C) and 
pulse vortexed (15s) before the addition of ethanol (200pl) and transferred to a
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6.3.4
Qiagen spin column. The spin column was centrifuged (6000 x g5 1 min, 4°C) and 
the flow-through discarded. Buffer AW1 (500j.il) was added and the column 
centrifuged (6000 x g, 1 min, 4°C) discarding the flow-through. A further wash with 
buffer AW1 was carried out (500pl, 17000 x g, 1 min, 4°C). Buffer AE (200pl) was 
then added and the spin column was incubated (5 min, 22°C) before centrifugation 
(17000 x g, 1 min, 4°C) and collection of flow-through in clean collection tubes. 
Samples were diluted (1:100), analysed and quantified using the PicoGreen® dsDNA 
Quantitation Reagent, validated by standard curve and were normalised to a 
concentration of 20ng/pl by the addition of DNAse free water.
Genotyping by Taqman Allelic Discrimination Assay
The following genes and associated SNPs were genotyped by Taqman Allelic 
Discrimination Assay: ABCA1 (rs2230806G/A SNP), LDLR (rsl529729C/T and 
rs2228671C/T SNPs), SCARB1 (rs2278986C/T SNP), ABCG1 (rsl893590A/C 
SNP), ACG8 (rs6544713C/T SNP), and ApoB (rs693A/G and rs7575840G/T SNPs) 
in DNA isolated from whole blood as described below.
The assay involves qPCR of both G (C) and A (T) alleles by the same primers in the 
presence of two probes, one specific for each allele, and labelled with different 
reporter dyes (FAM and VIC) between which the detector can distinguish. Following 
amplification, the Real Time PCR machine (Opticon 2/Chromo4) reports on which 
wavelength fluorescence is detected. If amplification is detected (i.e. the cycle 
threshold is exceeded) in only one wavelength, the sample is considered homozygous 
for whichever allele the probe fluorescing at that wavelength is specific. Samples in
Chapter 6
214
which amplification is detected in both wavelengths are considered heterozygous. 
The reaction mixture consisted of Taqman universal master mix (12.5 pi), specific 
Taqman Allelic Discrimination Assay primer and probe mix (1.25 pi), water (9.25 
pi) and DNA normalised stock (2 pi) per well of a 96 well optical reaction plate. 
Thermal cycling conditions consisted of 46 cycles with a combined 
annealing/extending temperature of 60°C.
6.4. Statistical Analysis
All data are given as frequency number (percentage), unless otherwise stated. 
Genotypes were tested for Hardy-Weinberg equilibrium by %2 test of observed versus 
predicted (from allele frequency) genotype frequencies. Statistical significance was 
assessed using the x2 test. Univariate and multivariate associations were assessed 
with SPSS vl7 (SPSS Inc., Chicago, IL, USA) using backward logistic regression. A 
statistical trend was defined as a P value <0.1. Statistical significance was set at 
P<0,05.
6.5. Results
6.5.1 Quantification of Genomic DNA
Total genomic DNA samples were diluted (1 TOO), analysed and quantified using the 
PicoGreen® dsDNA Quantitation Reagent, validated by standard curve prepared 
from known DNA concentrations at 1.5625ng/pl, 3.125ng/pl, 6.25ng/pl, 12.5ng/pl, 
25ng/pl and 50ng/pl as shown in Figure 6.1 below.
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6.5.2
Standard Curve of Genomic DNA
y = 0.1994x 
R2 = 0.9896'
[ONA] ng/|il
Figure 6.1: Standard Curve of known concentration genomic DNA used for quantification of 
sample genomic DNA.
Summary Allele Frequencies in HIV+ Cohort
Allele frequencies for ABCA1 rs2230806G/A, LDLR rsl529729C/T and 
rs2228671C/T, SCARB1 rs2278986C/T, ABCG1 rsl893590A/C, ACG8 
rs6544713C/T, ApoB rs693A/G and rs7575840G/T were in Hardy-Weinberg 
equilibrium (Table 6.2).
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Table 6.2: Summary allelic frequencies and Hardy-Weinberg analysis for SNPs in ABCA1, 
LDLR, SCARB1, ABCG1, ABCG8 and ApoB. The 5% significance level for 2 degrees of 
freedom for x2 value is 3.84 or P value < 0.05
Genotype Genotype Expected genotype Allele 
frequencies frequencies (%) frequencies frequencies ^
(0=32) (n=32) P q
ABCAlG105iA*rs2230806GA GG GA AA GG GA AA GG GA AA
11 17 4 34.4 53.1 12.5 11.88 15.23 4.88 0,60940.3906 0.218508 0.8965
LDLR {SiyiARCA4)rsl529729 C/I CC CT TT CC CT TT CC CT IT
5 13 14 15.6 40,6 43.8 4.13 14,73 13.13 0,3594 0.6406 0,218518 0.8965
SCARBl-rs2278986 C/T CC CT IT CC CT TT CC CT IT
2 22 8 6,3 68.8 25.0 5.28 15,44 11.28 0,40630.5938 3.187427 0.2032
LDLR-rs2228671 C/T CC CT TT CC CT TT CC CT TT
30 2 0 93,8 6.3 0.0 30.03 1,94 0,03 0.96880.0313 0.032258 0.984
ABCGl-rslMO A/C AA AC CC AA AC CC AA AC CC
18 13 1 56,3 40.6 3.1 18.76 11,48 1.76 0.7656 0.2344 0.317681 0.8531
ABCG8-rs6544713 C/T CC CT Tf CC CT TT CC a TT
13 14 5 40,6 43,8 15.6 12,50 15,00 4,50 0.625 0.375 0.070602 0.9653
ApoB-rs693A/G AA AG GG AA AG GG AA AG GG
4 15 13 12,5 46,9 40.6 4.13 14,73 13.13 0.3594 0.6406 0.005217 0.9974
ApoB-rs7575840 G/T GG GT TT GG GT TT GG GT TT
22 10 0 68.8 31,3 0.0 22.78 8.44 0.78 0.84380.1563 0.927295 0.629
6.5.3 ABCA1 Genotyping and Association with Metabolic Parameters
The distribution of the genotypes for the rs2230806G/A SNP within ABCA1 
included 4 individuals with the AA genotype (1 male and 3 female), 17 
heterozygotes with the GA genotype (8 male and 9 female) and 11 homozygous GG 
individuals (8 male and 3 female). Univariate analysis of the patient data did not 
confirm any significant associations between the patient genotype and the baseline or 
week 24 follow-up lipid parameters, Table 6.3.
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Table 6.3: Univariate analysis of ABCA1 rs2230806G/A SNP in Italian Patient Cohort on 
Metabolic Parameters (n=32)
GG GA AA P
Value
Patient Numbers 11 17 4
Baseline Total Cholesterol (mg/dl) Median 167 245 207 0.472
Baseline HDL Cholesterol (mg/dl) Median 35 46 44 0.835
Baseline Blood Glucose (mg/dl) Median 82 87 97 0.488
Baseline LDJL Cholesterol (mg/di) Median 96 136 125 0.581
Baseline Triglycerides (mg/dl) Median 162 178 144 0.161
W24 Total Cholesterol (mg/dl) Median 172 210 195 0.961
W24 HDL Cholesterol (mg/dl) Median 39 43 45 0.788
W24 Blood Glucose (mg/dl) Median 90 87 95 0.854
W24 LDL Cholesterol (mg/dl) Median 101 131 100 0.821
W24 Triglycerides (mg/dl) Median 120 151 166 0.514
Gender % (MZF) 73/27 47/53 25/75
Figure 6.2 below shows the cycle threshold analysis of the allelic discrimination 
assay. There were no significant correlations with baseline lipid parameters for any 
of the genotypes, although median total cholesterol and LDL-C were higher at both 
the baseline and week 24 where at least one copy of the A allele was present, Figure 
6.3 (A and D) below. Median TG values were higher at both the baseline and week 
24 where at least one copy of the G allele was present. Figure 6.3 (E) below. A trend 
was associated with higher LDL-C levels (P=0.0817) in females with the A allele, 
within ABCA1 (rs2230806G/A), see Figure 6.4 below.
Chapter 6
Figure 6.2: - ABCA1 SNR rs2230806G/A - Cycle threshold analysis of allelic discrimination 
assay by qPCR.
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Figure 6.3: - ABCA1 SNR rs2230806G/A - Analysis of genotype influence on lipid 
parameters: A= Comparison of Baseline Total Cholesterol levels against Week 24 Total 
cholesterol levels (mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C 
levels (mg/dl); C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 
Fasted Blood Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against 
Week 24 LDL-C levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG 
levels (mg/dl) Median values denoted by black line.
Baseline LDL-rs2230806G/A - Male Baselne LDL-rs2230806G/A ■ Female
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Figure 6.4: - ABCA1 SNR rs2230806G/A - Analysis of genotype influence on LDL-C 
parameters by Gender- Comparison of Baseline LDL-C levels against Week 24 LDL-C levels 
(mg/dl) Median values denoted by black line, red line denotes upper thresholds of lipid 
parameters whilst blue dotted line denotes upper limit of normal range, where shown.
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6.5.4 LDLR Genotyping and Association with Metabolic Parameters
The distribution of the genotypes for the rs1529729C/T SNP within LDLR included 
5 individuals with the CC genotype (3 male and 2 female), 13 heterozygotes with the 
CT genotype (5 male and 8 female) and 14 homozygous TT individuals (9 male and 
5 female). Univariate analysis of the patient data did not confirm any significant 
associations between the patient genotype and the baseline lipid parameters, 
however, at week 24 a significant association between the TT genotype and 
triglyceride levels was observed (P=0.011), Table 6.4.
Table 6.4: Univariate analysis of LDLR rs1529729C/T SNP in Italian Patient Cohort on 
Metabolic Parameters (n=32)
CC CT TT P
Value
Patient Numbers 5 13 14
Baseline Total Cholesterol (mg/dl) Median 220 246 171 0.415
Baseline HDL Cholesterol (mg/dl) Median 42 43 39 0.556
Baseline Blood Glucose (mg/dl) Median 88 95 85 0.607
Baseline LDL Cholesterol (mg/dl) Median 139 118 103 0.993
Baseline Triglycerides (mg/dl) Median 166 195 150 0.22
W24 Total Cholesterol (mg/dl) Median 241 195 192 0.6
W24 HDL Cholesterol (mg/dl) Median 46 42 39 0.394
W24 Blood Glucose (mg/dl) Median 96 89 89 0.615
W24 LDL Cholesterol (mg/dl) Median 142 124 102 0.941
W24 Triglycerides (mg/dl) Median 261 216 116 0.011
Gender % (M/F) 60/40 39/61 64/36
Figure 6.5 below shows the cycle threshold analysis of the allelic discrimination 
assay. Figure 6.6, below, shows the distribution of baseline lipid parameters 
contrasted with the corresponding week 24 parameters by genotype with median 
parameter values highlighted within each scatter plot.
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Figure 6.5: LDLR rs1529729C/T - Cycle threshold analysis of allelic discrimination assay by 
qPCR.
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Figure 6.6: - LDLR SNR rs1529729C/T - Analysis of genotype influence on lipid parameters: 
A= Comparison of Baseline Total Cholesterol levels against Week 24 Total cholesterol levels 
(mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C levels (mg/dl); 
C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 Fasted Blood 
Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against Week 24 LDL-C 
levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG levels (mg/dl) 
Median values denoted by black line.
The distribution of the genotypes for the rs2228671C/T SNP within LDLR included 
30 individuals with the CC genotype (16 males and 14 females) and 2 heterozygotes
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with the CT genotype (1 male and 1 female). Figure 6.7 below shows the cycle 
threshold analysis of the allelic discrimination assay. Univariate analysis of the 
patient data did not confirm any significant associations between the patient 
genotype and the baseline lipid parameters, however, a trend was observed between 
the wild type homozygous CC genotype and baseline triglyceride levels (P=0.059), 
Table 6.5. This should be interpreted with caution as the homozygous rare genotype 
TT was not represented in the patient cohort. There were no significant associations 
in the univariate analysis of the CC and CT genotypes and week 24 lipid levels, 
Table 6.5.
Table 6.5: Univariate analysis of LDLR rs2228671C/T SNP in Italian Patient Cohort on 
Metabolic Parameters (n=32)___________________________ ________^^_______
CC CT TT P
Value
Patient Numbers 30 2 0
Baseline Total Cholesterol (mg/dl) Median 208 239 NA 0.187
Baseline HDL Cholesterol (mg/dl) Median 39 48 NA 0.139
Baseline Blood Glucose (mg/dl) Median 89 90 NA 0.379
Baseline LDC Cholesterol (mg/dl) Median 106 166 NA 0.193
Baseline Triglycerides (mg/dl) Median 166 124 NA 0.059
W24 Total Cholesterol (mg/dl) Median 197 175 NA 0.813
W24 HDL Cholesterol (mg/dl) Median 43 40 NA 0.928
W24 Blood Glucose (mg/dl) Median 89 87 NA 0.993
W24 LDL Cholesterol (mg/dl) Median 119 118 NA 0.971
W24 Triglycerides (mg/dl) Median 141 86 NA 0.484
Gender % (M/F) 53/47 50/50 0/0
Figure 6.8, below, shows the distribution of baseline lipid parameters for 
rs2228671C/T contrasted with the corresponding week 24 parameters by genotype 
with median parameter values highlighted within each scatter plot.
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Figure 6.7: LDLR rs2228671C/T - Cycle threshold analysis of allelic discrimination assay by 
qPCR.
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Figure 6.8: - LDLR SNR rs2228671C/T - Analysis of genotype influence on lipid parameters: 
A= Comparison of Baseline Total Cholesterol levels against Week 24 Total cholesterol levels 
(mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C levels (mg/dl); 
C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 Fasted Blood 
Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against Week 24 LDL-C 
levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG levels (mg/dl) 
Median values denoted by black line.
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6.5.5 SCARB1 Genotyping and Association with Metabolic Parameters
The distribution of the genotypes for the rs2278986C/T SNP within SCARE 1 
included 2 individuals with the CC genotype (2 females) and 22 heterozygotes with 
the CT genotype (13 males and 9 females) and 8 homozygous TT individuals (4 
males and 4 females). Figure 6.9 below shows the cycle threshold analysis of the 
allelic discrimination assay, endpoint analysis is also shown in Figure 6,10 for 
validation purposes. Univariate analysis confinned that there were no significant 
correlations with baseline lipid parameters and week 24 lipid for any of the 
genotypes, although a trend was associated with the homozygous wild type CC 
genotype and week 24 HDL cholesterol levels (P=0.098), Table 6.6. This should be 
interpreted with caution as there were only 2 females in this genotype group of the 
patient cohort and the findings would need to be validated in a larger cohort to prove 
this association.
Table 6.6: Univariate analysis of SC ARB 1 rs2278986C/T SNP in Italian Patient Cohort on 
Metabolic Parameters (n=32)
CC CT TT P
Value
Patient Numbers 2 22 8
Baseline Total Cholesterol (mg/di) Median 197 208 216 0.155
Baseline HDL Cholesterol (mg/dl) Median 45 39 40 0.529
Baseline Blood Glucose (mg/dl) Median 87 87 104 0.695
Baseline LDL Cholesterol (mg/dl) Median 124 107 130 0.867
Baseline Triglycerides (mg/dl) Median 140 175 158 0.183
W24 Total Cholesterol (mg/dl) Median 197 197 157 0.597
W24 HDL Cholesterol (mg/dl) Median 60 39 35 0.098
W24 Blood Glucose (mg/dl) Median 90 88 89 0.772
W24 LDL Cholesterol (mg/dl) Median 110 121 86 0.53
W24 Triglycerides (mg/dl) Median 137 129 195 0.336
Gender % (M/F) 0/100 59/41 50/50
Chapter 6
228
Figure 6.9: SCARB1 rs2278986C/T - Cycle threshold analysis of allelic discrimination assay 
by qPCR.
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Figure 6.10: SCARB1 rs2278986C/T - Endpoint analysis of allelic discrimination assay by 
qPCR.
Figure 6.11, below, shows the distribution of baseline lipid parameters for 
rs2278986C/T contrasted with the corresponding week 24 parameters by genotype 
with median parameter values highlighted within each scatter plot.
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Figure 6.11: - SCARB1 SNR rs2278986C/T - Analysis of genotype influence on lipid 
parameters: A= Comparison of Baseline Total Cholesterol levels against Week 24 Total 
cholesterol levels (mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C 
levels (mg/dl); C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 
Fasted Blood Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against 
Week 24 LDL-C levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG 
levels (mg/dl) Median values denoted by black line.
6.5.6 ABCG1 Genotyping and Association with Metabolic Parameters
The distribution of the genotypes for the rsl893590A/C SNP within ABCG1 
included 18 individuals with the AA genotype (9 male and 9 female), 13 
heterozygotes with the AC genotype (7 male and 6 female) and 1 homozygous CC 
individual (1 male). Figure 6.12 below shows the cycle threshold analysis of the 
allelic discrimination assay. There were no significant associations in the univariate 
analysis of the genotypes with baseline and week 24 lipid parameters, Table 6.7, 
however, a trend was observed with the homozygous CC genotype and baseline 
triglyceride levels (P:=0.096). This association should be interpreted with caution as 
there was only one patient in the cohort with the CC genotype. Further validation in 
a larger cohort would be necessary to establish the significance of this association. 
Figure 6.13, below, shows the distribution of baseline lipid parameters for 
rs 1893590A/C compared to the corresponding week 24 parameters by genotype with 
median parameter values highlighted within each scatter plot.
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Table 6.7: Univariate analysis of ABCG1 rs1893590A/C SNR in Italian Patient Cohort on 
Metabolic Parameters (n=32)
AA AC CC P
Value
Patient Numbers 18 13 1
Baseline Total Cholesterol (mg/dl) Median 167 245 207 0.377
Baseline HDL Cholesterol (mg/dl) Median 35 46 44 0.412
Baseline Blood Glucose (mg/dl) Median 82 87 97 0.622
Baseline LDL Cholesterol (mg/dl) Median 96 136 125 0.584
Baseline Triglycerides (mg/dl) Median 162 178 144 0.096
W24 Total Cholesterol (mg/dl) Median 172 210 195 0.7
W24 HDL Cholesterol (mg/dl) Median 39 43 45 0.87
W24 Blood Glucose (mg/dl) Median 90 87 95 0.702
W24 LDL Cholesterol (mg/dl) Median 101 131 100 0.531
W24 Triglycerides (mg/dl) Median 120 151 166 0.453
Gender % (M/F) 50/50 54/46 100/0
Figure 6.12: ABCG1 rs1893590A/C - Cycle threshold analysis of allelic discrimination assay 
by qPCR
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Figure 6.13: - ABCG1 SNR rs1893590A/C - Analysis of genotype influence on lipid 
parameters: A= Comparison of Baseline Total Cholesterol levels against Week 24 Total 
cholesterol levels (mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C 
levels (mg/dl); C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 
Fasted Blood Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against 
Week 24 LDL-C levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG 
levels (mg/dl) Median values denoted by black line.
6.5.7 ABCG8 Genotyping and Association with Metabolic Parameters
The distribution of the genotypes for the rs6544713C/T SNP within ABCG8 
included 13 individuals with the CC genotype (6 male and 7 female), 14 
heterozygotes with the CT genotype (6 male and 8 female) and 5 homozygous TT 
individuals (5 male). Figure 6.14 below shows the cycle threshold analysis of the 
allelic discrimination assay. There were no significant associations in the univariate 
analysis with baseline lipid parameters and week 24 lipid levels for any of the 
genotypes. Trends were observed, however, between the T allele and increased 
baseline HDL (P=0.095) and lower baseline triglycerides with the homozygous rare 
TT genotype, (P=0.056). At week 24 a trend was observed increased blood glucose 
levels and the rare homozygous TT genotype, (P=0.095), Table 6.8.
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Table 6.8: Univariate analysis of ABCG8 rs6544713C/T SNR in Italian Patient Cohort on 
Metabolic Parameters (n=32)____________________ _______ ________ _______ ________
CC CT TT P
Value
Patient Numbers 13 14 5
Baseline Total Cholesterol (mg/dl) Median 167 245 207 0.538
Baseline HDL Cholesterol (mg/dl) Median 35 46 44 0.095
Baseline Blood Glucose (mg/dl) Median 82 87 97 0.508
Baseline LDL Cholesterol (mg/dl) Median 96 136 125 0.472
Baseline Triglycerides (mg/dl) Median 162 178 144 0.056
W24 Total Cholesterol (mg/dl) Median 172 210 195 0.892
W24 HDL Cholesterol (mg/dl) Median 39 43 45 0.441
W24 Blood Glucose (mg/dl) Median 90 87 95 0.095
W24 LDL Cholesterol (mg/dl) Median 101 131 100 0.751
W24 Triglycerides (mg/dl) Median 120 151 166 0.246
Gender % (M/F) 46/54 43/57 100/0
Figure 6.15, below, shows the distribution of baseline lipid parameters for 
rs6544713C/T contrasted with the corresponding week 24 parameters by genotype 
with median parameter values highlighted within each scatter plot.
Figure 6.14: ABCG8 rs6544713C/T - Cycle threshold analysis of allelic discrimination assay 
by qPCR.
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Figure 6.15: - ABCG8 SNR rs6544713C/T - Analysis of genotype influence on lipid 
parameters: A= Comparison of Baseline Total Cholesterol levels against Week 24 Total 
cholesterol levels (mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C 
levels (mg/dl); C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 
Fasted Blood Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against 
Week 24 LDL-C levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG 
levels (mg/dl) Median values denoted by black line.
6.5.8 ApoB Genotyping and Association with Metabolic Parameters
The distribution of the genotypes for the rs693A/G SNP within ApoB included 4 
individuals with the AA genotype (1 male and 3 female), 15 heterozygotes with the 
AG genotype (9 male and 6 female) and 13 homozygous GG individuals (7 male and 
6 female). Figure 6.16 below shows the cycle threshold analysis of the rs693A/G 
allelic discrimination assay. There were no significant correlations with baseline lipid 
parameters and week 24 lipid levels in the univariate analysis for any of the 
genotypes, although a trend was observed between baseline triglyceride levels and 
the homozygous GG genotype (P=0.07), Table 6.9.
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Table 6.9: Univariate analysis of ApoB rs693A/G SNR in Italian Patient Cohort on Metabolic 
Parameters (n=32)_____________
AA AG GG P Value
Patient Numbers 4 15 13
Baseline Total Cholesterol (mg/di) Median 167 245 207 0.995
Baseline HDL Cholesterol (mg/dl) Median 35 46 44 0.493
Baseline Blood Glucose (mg/dl) Median 82 87 97 0.92
Baseline LDL Cholesterol (mg/dl) Median 96 136 125 0.389
Baseline Triglycerides (mg/dl) Median 162 178 144 0.07
W24 Total Cholesterol (mg/dl) Median 172 210 195 0.476
W24 HDL Cholesterol (mg/dl) Median 39 43 45 0.777
W24 Blood Glucose (mg/dl) Median 90 87 95 0.823
W24 LDL Cholesterol (mg/dl) Median 101 131 100 0.602
W24 Triglycerides (mg/dl) Median 120 151 166 0.215
Gender % (M/F) 25/75 60/40 54/46
Figure 6.16: ApoB rs693A/G - Cycle threshold analysis of allelic discrimination assay by 
qPCR.
Figure 6.17, below, shows the distribution of baseline lipid parameters for rs693A/G 
compared to the corresponding week 24 parameters by genotype with median 
parameter values highlighted within each scatter plot.
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Figure 6.17: - LDLR SNR rs1529729C/T -Analysis of genotype influence on lipid parameters: 
A= Comparison of Baseline Total Cholesterol levels against Week 24 Total cholesterol levels 
(mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C levels (mg/dl);
C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 Fasted Blood 
Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against Week 24 LDL-C 
levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG levels (mg/dl) 
Median values denoted by black line.
The distribution of the genotypes for the rs7575840G/T SNP within ApoB included 
22 individuals with the GG genotype (14 male and 8 female) and 10 heterozygotes 
with the GT genotype (3 male and 7 females). Figure 6.18 below shows the cycle 
threshold analysis of the rs7575840G/T allelic discrimination assay. Univariate 
analysis showed a trend between the T allele and HDL cholesterol levels at both 
baseline and week 24 (P=0.074 and P=0.083 respectively), caution is needed in the 
interpretation of this association in the absence of homozygous TT patients and the 
low numbers of patients in the cohort. There was a significant association with lower 
baseline and week 24 triglyceride parameters for homozygous wild type GG 
genotype (P= 0.041 and P=0.003, respectively). Table 6.10.
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Table 6.10: Univariate analysis of ApoB rs7575840G/T SNP in Italian Patient Cohort on 
Metabolic Parameters (n=32)
GG Cji* TT P
Value
Patient Numbers 22 10 0
Baseline Total Cholesterol (mg/dl) Median 167 245 NA 0.625
Baseline HDL Cholesterol (mg/dl) Median 35 46 NA 0.074
Baseline Blood Glucose (mg/dl) Median 82 87 NA 0.512
Baseline LDL Cholesterol (mg/dl) Median 96 136 NA 0.311
Baseline Triglycerides (mg/dl) Median 142 178 NA 0.041
W24 Total Cholesterol (mg/dl) Median 172 210 NA 0.42
W24 HDL Cholesterol (mg/dl) Median 39 43 NA 0.083
W24 Blood Glucose (mg/dl) Median 90 87 NA 0.354
W24 LDL Cholesterol (mg/dl) Median 101 131 NA 0.438
W24 Triglycerides (mg/dl) Median 120 151 NA 0.003
Gender % (M/F) 64/36 30/70 0/0
Figure 6.19, below, shows the distribution of baseline lipid parameters for 
rs7575840G/T compared to the corresponding week 24 parameters by genotype with 
median parameter values highlighted within each scatter plot.
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Figure 6.18: ApoB rs7575840G/T - Cycle threshold analysis of allelic discrimination assay by 
qPCR.
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Figure 6.19: - LDLR SNR rs1529729Crr - Analysis of genotype influence on lipid parameters: 
A= Comparison of Baseline Total Cholesterol levels against Week 24 Total cholesterol levels 
(mg/dl); B= Comparison of Baseline HDL-C levels against Week 24 HDL-C levels (mg/dl); 
C= Comparison of Baseline Fasted Blood Glucose levels against Week 24 Fasted Blood 
Glucose levels (mg/dl); D= Comparison of Baseline LDL-C levels against Week 24 LDL-C 
levels (mg/dl); E= Comparison of Baseline TG levels against Week 24 TG levels (mg/dl) 
Median values denoted by black line.
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6.5.9 Multivariate Analysis of SNPs and Associations with Metabolic Parameters
Table 6.11 below summarises the associations of the SNPs in the metabolic genes: 
ABCA1, LDLR, SCARB1, ABCG1, ABCG8 and ApoB with the key lipid 
parameters: total cholesterol, HDL-cholesterol, fasted blood glucose levels, LDL- 
cholesterol and triglycerides. P values are shown for univariate and multivariate 
associations.
Multivariate logistic regression confirmed significant associations with the A allele 
in ABCA1 rs2230806G/A SNP at week 24 for elevated total cholesterol (P=0.04) 
and increased LDL-C (P=0.03) Figure 6.3 (A and D) above, correlated with age 
(P=0.0004), height (P=0.02) and five other SNPs (see sections 6.5.4 - 6.5.8) in LDLR 
(rsl529729C/T, C allele, P=0.0002), SCARB1 (rs2278986C/T, T allele, P0.0006), 
ABCG1 (rsl893590A/C, A allele, P-0.0072), ABCG8 (rs6544713C/T, T allele, 
P-0.0001) and ApoB (rs693A/G, G allele, P-0.003), Table 6.9.
Multivariate backward logistic regression analysis of the LDLR rsl529729C/T SNP 
confirmed a highly significant association of the TT genotype with lower baseline 
TG levels, (P-0.0008), an association which was maintained at week 24 TG levels 
(P=<0,00001), see Figure 6.7 (E). The T allele was also highly significantly 
associated with lower total cholesterol (P-0.0002) and lower LDL-C (P-0.0001) at 
week 24, see Figure 6.7 (A and D), correlated with height (P-0.02) and two other 
SNPs, a second in LDLR (rs2228671C/T, C allele, P-0.05), although this association 
should be interpreted with caution as only 2 patients were heterozygous for the T 
allele and there were no homozygous TT patients in the cohort (see Figure 6.8, (A
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and D)); and the other in ABCG1 (rsl893590A/C, C allele, P=0.0014), see section 
6.5.6, although the number of carriers of the C allele is low (7) so caution should be 
exercised when interpreting this association. Multivariate logistic regression analysis 
of the LDLR rs2228671C/T SNP showed a significant association of the T allele 
with lower baseline TG levels, (P=0.032), and at week 24 in TG levels (PO.OOOl), 
see Figure 6.8 (E), Table 6.11. Although, as previously discussed, interpretation of 
this association should be with caution as only 2 patients carried the T allele for this 
SNP in the patient cohort.
Multivariate analysis of the SCARE 1 rs2278986C/T SNP also confirmed highly 
significant associations with the T allele at week 24 for elevated total cholesterol 
(P=0.0006), decreased HDL-C (P=<0.00001) and elevated LDL-C (P-0.0005) Figure 
6.11 (A, B and D), correlated with age (P-0.0004), height (P-0.02) and five other 
SNPs one in ABCA1 (rs2230806G/A, A allele), ABCG8 (rs6544713C/T, T allele) 
and ApoB (rs693A/G, G allele) and LDLR (rsl529729C/T, C allele), as previously 
discussed; and ABCG1 (rs 1893590A/C, C allele, P-0.0072, see 6.5.6).
Multivariate backward logistic regression analysis of the ApoB rs693A/G SNP 
confinned significant associations with the G allele at week 24 for elevated total 
cholesterol (P-0.0003), increased HDL-C (P-0.0029) increased LDL-C (P-0.0002), 
and increased TG levels (P-0.0012), Figure 6.17 (A, B, D and E), correlated with 
age (P-0.0004), height (P-0.0242) and five other SNPs, (previously discussed in 
relation to total cholesterol and LDL-cholesterol), one in ABCA1 (rs2230806G/A, A 
allele, P-0.04), one in LDLR (rs!529729C/T, C allele, P-0.0002), SCARB1
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(rs2278986C/T, T allele, P=0.0006), ABCG1 (rs 1893590A/C, C allele, P=0.0072), 
and ABCG8 (rs6544713C/T, T allele, P=0.0001). Multivariate logistic regression 
analysis of ApoB rs7575840G/T SNP confirmed significant associations with the T 
allele at week 24 for total elevated TG levels (P0.0003) Figure 6.19 (E), correlated 
with age (P=0.0017), and five other SNPs, two in LDLR (rsl529729C/T, C allele, 
P=<0.00001, and rs2228671C/T, C allele, PHX0001, see 6.5.4), ABCG1 
(rsl893590A/C, C allele, P-0.0082, see 6.5.6), and ABCG8 (rs6544713C/T, T allele, 
P—0.004, see 6.5.7) and ApoB (rs693A/G, G allele, P—0.0012, see above).
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6.6 Discussion
This chapter sought to validate the importance of eight known polymorphisms in six 
metabolic genes which had previously been associated with lipid abnormalities and 
cardiovascular risk in a HIV+ cohort who had been switched to a lipid sparing 
regimen of un-boosted ATV due to prior display of HADL characteristics. Although 
repeat measures were taken during clinic visits for a period up to 96 weeks, patient 
attendance for clinic visits was poor and the findings should also be interpreted in the 
context of this and the small numbers involved.
The rs2230806G/A SNP in ABCA1 had previously been shown to be associated with 
elevated LDL-C levels in HIV- men who were homozygous AA (Abelian el al). 
This study only had four participants with that genotype, three of which were female. 
It was interesting therefore to find that elevated LDL-C in the HIV+ cohort was more 
prevalent in females with at least one copy of the A allele, than we had expected, 
with values in the range 102mg/dl - 216mg/dl with 9/12 in the range borderline high 
to very high as defined in section 6.1.2 above. An association with elevated LDL-C 
in men with at least one copy of the A allele was more established in individuals who 
cany at least one copy of the A allele in the ABCA1 SNP rs2230806G/A and are 
also homozygous GG genotype for the rs7575840GT SNP in ApoB 8/9 patients with 
LDL-C in the range 70mg/dl - 176mg/dl. Eight of the same female population were 
also homozygous GG genotype for the rs7575840GT SNP in ApoB and all had 
elevated LDL-C in the range borderline high to very high (134mg/dl - 193mg/dl). 
We hypothesise therefore that the combination of the GG genotype for ApoB 
rs7575840GT and a single copy of the A allele from the ABCA1 rs2230806G/A SNP
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is sufficient to result in elevated LDL-C in Caucasian HIV-)- patients. This confirms 
the association with increased risk previously reported in individuals with a 
combination of these two SNPs (Kathiresan et aL, 2008). Further investigations in a 
larger population would need to be undertaken to confirm the hypothesis that this 
association is gender independent in a HIV+ cohort. Such confinnation may provide 
a future predictor of HADL risk in HIV+ individuals and provide insights into lipid­
sparing alternative therapies.
We were also able to confinn associations seen in HIV negative populations with 
other SNP combinations and other lipid parameters. It has previously been reported 
that the two SNPs in LDLR, (rs2228671C/T and rsl529729C/T) were associated 
with elevated LDL-C levels and an increased risk of developing coronary arteiy 
disease (Kathiresan et ah, 2008; Linsel-Nitschke et aL, 2008). The former has also 
been associated with hypercholesterolaemia (Aulchenko et aL, 2009). We observed 
an association between the C allele in the LDLR rsl529729C/T SNP and elevated 
total cholesterol, increased LDL-C and higher TG levels. When this SNP was 
combined with the GG genotype for ApoB rs7575840GT, 11/12 patients had 
elevated total cholesterol in the range 206mg/dl - 511mg/dl (borderline - high as 
defined in Section 6.1.2 above), 9/12 patients in the same group also had high LDL- 
C in the range 130mg/dl - 176mg/dl. Baseline TG levels were in the range 166mg/dl 
- 1685mg/dl borderline high to very high (per Section 6.1.2 above) in the same 
patient group. In the same group 11/12 patients were also homozygous CC for the 
LDLR SNP rs2228671C/T with the twelfth patient heterozygous CT at the same 
SNP. This confirms, therefore, the increased risk associated with a combination of 
these three SNPs (Kathiresan et aL, 2008). Again further investigations in a larger
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population would be required to confirm the hypothesis that these associations are 
prevalent in a larger HIV+ cohort. Such confirmation may prove a useful tool for 
clinicians requiring a predictor of HADL risk in HIV+ individuals.
Our investigations were unable to confinn the inverse association with HDL-C levels 
previously reported as a consequence of reduced SRB1 protein levels linked with the 
C allele in the SCARB1 rs2278986C/T SNP (West et aL, 2009). The cohort 
contained 2 homozygous CC genotypes (both female), and 22 heterozygotes 
carrying one C allele but HDL-C levels were in the range 24mg/dl to 55mg/dl for the 
17 men in the cohort with only 1/17 exhibiting high HDL-C levels (>50mg/dl), and 
in the range 25mg/dl - 64mg/dl for the 11 women with at least one copy of the C 
allele with only 2/11 exhibiting high HDL-C levels (>60mg/dl). We were unable to 
confirm an association with this SNP in the homozygous TT patients which may 
have indicated an opposite effect in HIV+ populations. We were able to confirm an 
association with decreased HDL-C in patients with the T allele when it was also 
associated with a combination of other SNPs and demographic factors including age, 
height and the following SNPs: ABCA1 rs2230806G/A, A allele; LDLR 
rsl529729C/T, C allele; ABCG1 rsl893590A/C, C allele; ABCG8 rs6544713C/T, T 
allele; and ApoB rs693A/G, G allele. The same combination was also confirmed as 
associated with elevated total cholesterol and increased LDL-C after 24 weeks on a 
lipid-sparing regimen of un-boosted ATV in 24/32 patients in the HIV+ cohort. 
Whilst previous studies have reported an increased risk of combined SNPs in non- 
HIV related metabolic disorders, it is necessary to remain cautious when predicting 
the same outcome in larger HIV+ cohorts without further validation of these 
findings. If further validation confirms these findings in larger populations and
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different ethnicities, these SNPs could form the basis of a matrix for predicting 
HADL outcomes.
We were also unable to confirm the association between the AA genotype of the 
rsl893590A/C SNP within ABCG1 with lower HDL-C levels in women as 
previously reported in non-HIV patients (Abelian et aL). We only observed 9 
females in the cohort with the AA genotype and their HDL-C levels were in the 
range 39mg/dl - 62mg/dl compared to a range of 25mg/dl - 64mg/dl in all females 
and the combined genders group. The lack of association may be attributed to the 
small numbers, but the trend in the group was towards higher levels of HDL-C in the 
homozygous A A females than for the heterozygous females and for all genotypes in 
the male group. An association was shown between reduced baseline TG values and 
the C allele although again the numbers were low (7) and validation in a larger 
cohort is required. Elevated total cholesterol and increased LDL-C levels were 
associated with the C allele at week 24 when the SNP was grouped with a number of 
demographic factors and other SNPs including: age; height; and a combination of 
five SNPs: ABCA1 (rs2230806G/A, A allele); LDLR (rsl529729C/T, C allele); 
SCARE 1 (rs2278986C/T, T allele); ABCG8 (rs6544713C/T, T allele); and ApoB 
(rs693A/G, G allele).
The rs693A/G SNP within ApoB has previously been associated with increased 
LDL-C levels and increased risk of cardiovascular events, especially when combined 
with SNPs at rsl529729C/T, (C allele) in LDLR and rs7575840G/T (T allele) 
(Kathiresan et aL, 2008). We were able to confirm this finding in the HIV+ cohort 
associated with the G allele in rs693SA/G. At week 24 we detennined an association
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of the G allele with elevated total cholesterol, increased HDL-C levels and LDL-C 
levels and elevated TG levels. These correlations were statistically significant when 
the SNP was correlated with demographic factors age and height together with five 
other SNPs: ABCA1 (rs2230806G/A, A allele); LDLR (rsl529729C/T, C allele); 
SCARE 1 (rs2278986C/T, T allele); ABCG1 (rs1893590A/C, C allele); and ABCG8 
(rs6544713C/T,T allele).
In summary, this chapter describes the association of known polymorphisms in 
metabolic genes which have previously been linked with lipid abnormalities in non- 
HIV populations. The role that these polymorphisms have in influencing 
characteristics of HADL in five key lipid parameters: total cholesterol, HDL-C, 
Blood glucose (fasted), LDL-C and TGs in a Caucasian HIV+ cohort and the 
potential influence that these findings may have as future predictors of HADL risk 
now requires further validation in larger cohorts.
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7.1 General Discussion
Despite the advances in ARVs to treat HIV over the last 20 years, there is still no 
cure or vaccine. HIV+ individuals have a lifelong treatment burden to suppress their 
viral loads to below detectable levels. Long tenn treatment with HAART has greatly 
improved patient mortality and morbidity outcomes (Falutz, 2007), but long-term 
HAART is widely associated with cardiovascular and metabolic complications 
including HADL (Behrens et al., 2000; Bonfanti et aL, 2000; Carr, 2000; Mallon, 
2007; Mallon et aL, 2003). Pis, NRTIs and NNRTIs, have all been implicated in 
HADL, although Pis are the most widely associated (Behrens et al, 2000; Carr, 
2000; Carr et al, 1998; Falutz, 2007; Mallon, 2006). Insulin resistance is common 
with Pis and NRTIs (Falutz, 2007; Lagathu et al, 2005) and they have previously 
been shown to impact several key lipid metabolism molecular pathways including 
intra-nuclear transcription factors and the nuclear proteasome (Lagathu et al, 2005; 
Mallon, 2007).
The primary focus of this PhD thesis was to detennine the direct effects of the Pis 
RTV and ATV on the metabolic NRs involved in lipid metabolism, by in vitro 
methods, with a specific focus on the roles of FXR, LXRa and PPARa in the 
metabolic complications associated with the use of these drugs. The secondary focus 
of this thesis was to establish the importance of known polymorphisms in the LXRa 
gene and eight known polymorphisms in six metabolic genes (ABCA1, LDLR, 
SCARB1, ABCG1, ABCG8 and ApoB) which had previously been associated with 
lipid abnormalities and cardiovascular risk in non-HIV+ populations (Abelian et at, 
Aulchenko et al, 2009; Dahlman et al, 2009; Kathiresan et al, 2008; Legry et al.
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2008; Linsel-Nitschke et al, 2008; Price et ah, 2011; West et al, 2009) in HIV+ 
cohorts with confinned HADL complications. The patients in the Italian HIV+ 
cohort were switched to a lipid-sparing regimen of un-boosted ATV at baseline, due 
to prior display of HADL characteristics. This cohort was probed to validate the 
importance of the eight polymorphisms in ABCA1, LDLR, SCARE 1, ABCG1, 
ABCG8 andApoB.
High levels of toxicity associated with RTV mean that it is no longer used at 
therapeutic doses. This has been counterbalanced by the availability of other Pis 
with more attractive lipid profiles (Foisy et al, 2008) including ATV (Barreiro el al, 
2005). RTV, as a pharmacoenhancer, was reported as a notorious mediator of drug- 
drug interactions and toxological effects due to non-clearance of these drugs 
(Barreiro et al, 2005; Foisy et al, 2008). Patients taking a RTV boosted regimen 
incurred significant increases in total cholesterol and triglyceride levels following 48 
week trials, whereas the same parameters in the ATV cohort were unchanged 
(Barreiro et al, 2005). In Chapter 2, initial studies determined that the cellular 
accumulation of ATV was 2 fold greater than that of RTV in the Huh? cell line. This 
was an important discovery because it determined that the metabolic disruption and 
the deleterious side effects associated with RTV, compared to the more favourable 
lipid profile of ATV, were not due to higher intracellular accumulation of the fonner.
Gene expression studies, in Chapter 2, detennined that LXRct was significantly up- 
regulated, in the presence of RTV, and it was a master regulator of key downstream 
target gene expression, including SREBP-lc, which was previously implicated in PI 
induced lipodystrophy (Telenti et al, 2002). The role of LXRa in the regulation of
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target gene expression was under-pinned by co-incubation of RTV with the LXRa 
antagonist 22(S)-hydroxycholesterol. In Chapter 3, the effects of RTV on LXRa 
target gene expression, observed in Chapter 2, were validated by the use of siRNA to 
knockdown LXRa gene expression. LXRa knockdown was also confirmed at the 
protein level in Chapter 3.
In Chapter 2, FXR gene expression was also significantly up-regulated in the 
presence of RTV. The effects on downstream target genes of FXR were consistent 
with its up-regulation, with significant up-regulation of ApoC-II and significant 
down-regulation of HNF4a gene expression observed. Co-incubation with the LXRa 
antagonist 22(S)-hydroxycholesterol did not inhibit the up-regulation of FXR or the 
down-regulation of HNF4a by RTV. The up-regulation of ApoC-II by RTV was, 
however, completely abolished in the presence of the LXRa antagonist which 
indicated more than one mechanism was involved in its up-regulation. The observed 
significant down-regulation of ApoC-II, a mediator of TG metabolism, by ATV may 
be attributed to regulation of this gene by PPARa. This may present a future 
opportunity for further investigation, but was not further probed in these studies as 
the focus was on the deleterious metabolic side effects associated with RTV. In 
Chapter 3, incubation of RTV in the biological knockdown of LXRa by siRNA 
samples did not prevent the up-regulation of FXR or the down-regulation of HNF4a. 
The up-regulation of ApoC-II by RTV was, however, completely abolished in the 
siRNA knockdown of LXRa samples which supported the hypothesis that more than 
one mechanism was involved in its up-regulation in response to RTV.
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Initial gene expression studies in Chapter 2 also demonstrated that incubation with 
ATV resulted in significant down-regulation of FXR, whilst HNF4a gene expression 
was significantly up-regulated by ATV suggesting that down-regulation of FXR may 
have a role in this response. This was the opposite effect to that observed for RTV at 
these genes. This was an important discovery because it demonstrated that the gene 
expression response to RTV and ATV of two key metabolic nuclear receptors, FXR 
and HNF4ot, had contrasting profiles, which may provide an insight into the 
contrasting lipid profiles of the two Pis.
FXR has been reported as a down-regulator of SREBP-lc gene expression (via SHP- 
1), a mechanism reported to have positive effects on glucose metabolism (Fiorucci et 
al., 2007). As FXR was up-regulated by RTV, a down-regulation of SREBP-lc gene 
expression was anticipated, if FXR was the master regulator of its gene expression. 
The investigations in Chapter 2 resulted in the opposite effect, however, with RTV 
significantly up-regulating SREBP-lc. This indicated that another mechanism was 
involved with SREBP-lc up-regulation. We hypothesised that this mechanism was 
the observed significant up-regulation of LXRa by RTV. When the hypothesis was 
tested by the inhibition of LXRa by the antagonist 22(S)-hydroxycholesterol 
(Chapter 2) and biological knockdown by siRNA (Chapter 3) the effects of RTV on 
both LXRa and SREBP-lc were abolished supporting the hypothesis. This is 
important because the up-regulation of SREBP-lc was previously reported to be 
involved in PI induced lipodystrophy (Bastard et al.9 2002; Telenti et al., 2002) and 
its up-regulation leads to increased production of triglycerides and lipogenesis. 
Elevated triglyceride levels are key clinical concern in HADL and other metabolic
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disorders. Furthermore SREBP-lc gene expression was significantly down-regulated 
at all concentrations of ATV suggesting a potential explanation for the contrasting 
lipid profiles of ATV and RTV.
Interestingly, in Chapter 3, biological knockdown of LXRa by siRNA resulted in 
down-regulation of LXRa gene expression in the presence of all RTV. This is 
important because it could provide a potential future therapeutic mechanism for 
inhibition of LXRa in vivo, either by chemical antagonism of therapeutic use of 
siRNA. This would be a viable option if the issues which were previously associated 
with increased production of liver TGs and increased lipogenesis by LXRa agonists 
(Bradley et al, 2005; Calkin et al) can be avoided. As interest develops in the use of 
siRNA for gene therapy for complex metabolic disorders these biological mediators 
of inhibition will provide opportunities to specifically regulate key therapeutic 
targets without the “off-target” side effects widely associated with drugs in this class 
(Lee et al, 2003; Rader, 2007).
LXRa was reported to inhibit PPARa signalling (Miyata et al, 1996). It was 
hypothesised that LXRa was regulating PPARa in the RTV gene expression studies 
(Chapter 2). PPARa gene expression was significantly down-regulated by RTV, 
however, inhibition of LXRa by 22(S)-hydroxycholesterol and by biological 
knockdown by LXRa siRNA abolished these effects on PPARa. This was important 
because it supported the hypothesis that LXRa is a key player in the regulation of 
PPARa. The down-regulation of PPARa by ATV observed at lOpM (maximal 
decrease of 1.1 fold compared to vehicle) was to a lesser magnitude than observed in 
the RTV experiments. It was proposed that this reflected the magnitude of difference
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between the observed ATV-mediated increase in LXRa expression and the observed 
RTV-mediated increase in LXRa expression.
It was reported that PPARa induction leads to the repression of ApoC-III (Duval et 
aL, 2007; Feldman et al., 2008; Yamada et aL, 2007). Down-regulation of PPARa 
was observed in the RTV assays. It was hypothesised that this contributed to the up- 
regulation of ApoC-III, as LXRa up-regulated ApoC-III through its down-regulation 
of PPARa. This hypothesis was confinned when the inhibition of LXRa by 22(S)- 
hydroxycholesterol and biological knockdown by LXRa siRNA abolished the effects 
of RTV on ApoC-III (and PPARa) supporting the role of LXRa as a key player in 
the regulation of both ApoC-III and PPARa. This was important because ApoC-III 
and PPARa are involved with TG metabolism (Cariou et aL, 2007; Francis et al., 
2003) and ApoC-III was implicated in elevated TG levels in HIV+ men (Mallon, 
2007), furthermore ApoC-III fonns a major constituent of very low density 
lipoprotein (VLDL), levels of which have been elevated in HIV+ cohorts and healthy 
volunteer cohorts with short term exposure to RTV (Mallon, 2007).
It was previously reported that ApoC-III was involved with the modulation of Apo A- 
I in transgenic mice (Kan et al., 2004), and that PPARa was also involved with its 
regulation (Berger et al., 2002; Francis et al, 2003; Lee et al, 2003). PPARa has 
been implicated in the up-regulation of ApoA-I (Tobin et al, 2006). ApoA-I was 
significantly up-regulated by RTV, which led us to probe whether LXRa was 
directly or indirectly involved with its observed regulation. It was hypothesised that 
up-regulation of LXRa or a combination of its target genes could be the mechanism 
involved with ApoA-I up-regulation. Use of die LXRa antagonist, 22(S)-
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hydroxy cholesterol and in the biological knockdown of LXRa by siRNA abolished 
the up-regulation of ApoA-I, supporting this hypothesis. Regulation of ApoA-I gene 
expression is important because it encodes apolipoprotein A-I, which is the major 
protein component of HDL and a key component of reverse cholesterol transport. 
LXRa, PPARa, FXR and VDR are all regulators of ApoA-I gene expression. These 
studies have demonstrated that LXRa is a master regulator in the presence of RTV in 
vitro but further studies are required to determine the implications of inhibition of 
LXRa in vivo on its up-regulation of ApoA-I and its metabolic outcome.
LXRa also represses VLDLR (Scotti et al) which was significantly down-regulated 
by RTV. Inhibition of LXRa with 22(S)-hydroxycholesterol abolished the effects of 
RTV on VLDLR which supported the hypothesis that LXRa was regulating VLDLR 
expression. Biological knockdown of LXRa by siRNA underpinned this hypothesis 
as the impact of RTV on VLDLR gene expression was diminished, in Chapter 3. The 
up-regulation of VLDLR by AT V was consistent with the regulation by FXR and by 
PPARa. This may again underpin the conclusion that these different mechanisms are 
involved in the contrasting lipid profiles of ATV and RTV.
Chapter 2 and Chapter 3 of this thesis demonstrated the involvement of LXRa in the 
differing target gene expression profiles associated with the Pis RTV and ATV. 
These chapters also demonstrated that inhibition of LXRa by a chemical antagonist 
and by biological knockdown using siRNA can be used to confirm the target genes 
for which LXRa is a regulator, with specific focus on the responses to RTV and 
ATV. The endogenous role of LXRa is as a master regulator of cholesterol 
homeostasis in the liver and macrophages (Gronemeyer et al, 2004a; Kalaany et al..
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2006; Pascussi et aL, 2008). It facilitates the processing and storage of cholesterol 
and has been implicated in the increased expression of the ATP binding cassette 
proteins ABCA1, ABCG1, ABCG5 and ABCG8, key players in cholesterol transport 
and metabolism (Eloranta et al, 2005; Pascussi et al, 2008; Tirana et ah, 2005). 
These studies have demonstrated that LXRa is a master regulator in the presence of 
RTV in vitro but further studies are required to contrast the effects of RTV on LXRa 
with those of an endogenous ligand such as 24(S)-hydroxycholesterol and the 
synthetic LXR agonists T0901317 and GW3965 (Tocris Biosciences), although as all 
are active at both the LXRa and LXRp isoforms, further analysis will be required to 
ensure the observed findings are due to agonist effects on LXRa. Confirmation could 
be obtained through the use of siRNA knockdown of LXRp. Further analysis should 
also be undertaken in vivo to confirm the in vitro results in a LXRa knockout 
humanised murine model. The use of specific targeting siRNA knockdown of hepatic 
LXRa would have greater potential as a therapeutic measure than chemical 
antagonists, albeit the method of deliveiy would require careful design. Chemical 
antagonists would be more likely to have unwanted systemic effects targeting LXRs 
throughout the body resulting in inhibition of the pathways key to reverse cholesterol 
transport and affecting the formation nascent HDL cholesterol particles.
Chapter 4 of this thesis focused on the key hepatic transporters involved in 
cholesterol homeostasis, bile acid metabolism and in glucose transport, some of 
which also play key metabolic roles in the periphery and the intestine. This chapter 
investigated the relative impact that LXRa regulation has on cholesterol and bile acid
Chapter 7
262
transporters to detennine its potential contribution to the deleterious metabolic 
complications associated with PI based HAART regimens.
ABCA1 is a mediator of cholesterol and phospholipid efflux to lipid poor 
apolipoproteins for the fonnation of nascent HDL-cholesterol (HDL-c) (Borst et al, 
2002). ABCA1 is a direct target of LXRa (Edwards et aL, 2002). It was predicted 
that ABCA1 gene expression would be up-regulated by RTV and was hypothesised 
that this up-regulation could be inhibited by antagonism of LXRa. This hypothesis 
was confirmed in the RTV plus 22-(S)-hydroxycholesterol assays, and validated by 
the biological knockdown of LXRa by siRNA. Interestingly, the down-regulation of 
ABCA1 gene expression in the RTV plus 22-(S)-hydroxycholesterol assays provided 
an insight into other mechanisms regulating the gene and showed LXRa to be a 
primary regulator of ABCA1 gene expression. It was hypothesised that the co­
repressor molecules NCoR and SMRT may be implicated in the down-regulation of 
ABCA1 expression in the presence of the LXRa antagonist, as a regulatory role for 
these co-repressors has already been reported (Kalaany et al., 2006). Further 
investigation would be required to underpin this hypothesis, but this was outside the 
scope of this thesis.
ABCB1 was previously shown to be involved in the transport of both RTV and ATV 
(Perloff et al, 2005; Solon et al., 2002). Down-regulation of ABCB1 gene 
expression by RTV and the increased gene expression in the presence of LXRa 
antagonism and knockdown suggested LXRa may be involved in ABCB1 gene 
regulation. It was postulated that LXRa may compete with other nuclear receptors, 
which may include PXR and HNF4a (Pascussi et al, 2008; Tirona et al, 2005), at
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the ABCB1 binding site. This may partially explain the differential gene expression 
response in the presence of known PXR agonists (RTV and ATV), and LXRa 
agonists (RTV), and die LXRa antagonist (22-(S)-hydroxycholesterol), although 
further investigations which were outside the scope of this study would be required 
to underpin this theory. The results from Chapter 4 suggested that there may be some 
merit in investigating the effects of PXR knockdown on the ABCB1 transporter 
response and to look at the effects of dual receptor knockdown for both PXR and 
LXRa on the gene expression of ABCB1 in the presence of RTV. This interesting 
further investigation, however, was outside the scope of this thesis.
The up-regulation of ABCB2, a key player in bile acid transport, suggested a role for 
regulation by FXR, however, at higher RTV concentrations down-regulation of 
ABCB2 gene expression was observed which implicated a role for regulation by 
LXRa. The effects of the up-regulation at 0.1 gM RTV were blocked by co­
incubation with the LXRa antagonist and by biological knockdown of LXRa. At 
higher RTV concentrations biological knockdown and chemical antagonism of 
LXRa resulted in only small differences in the regulation of ABCB2 supporting the 
hypothesis that although LXRa played a role in the regulation of this transporter it 
was not the master regulator of this gene.
ABCB11, the bile salt efflux pump, was previously shown to be regulated by FXR 
(Edwards et al., 2002; Kalaany ei ah, 2006). Significant up-regulation of ABCB 11 
gene expression was observed at 0.1 pM RTV, which may be consistent with the up- 
regulation of FXR by RTV and its previously reported role in ABCB 11 regulation 
(Edwards et aL, 2002; Kalaany et aL, 2006). Further probing of the role of FXR
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would be required to confirm this association but this was outside the scope of these 
investigations. At higher RTV concentrations, however, down regulation of ABCB11 
gene expression was evident, furthermore the LXRa antagonist, 20 pM 22-(S)- 
hydroxycholesterol, reversed the effects of RTV on ABCB11. This supported the 
hypothesis that LXRa played a key role in the regulation of ABCB11. This 
hypothesis was also validated by the results of the siRNA LXRa knockdown assays 
where the effects of RTV on ABCB11 were diminished.
Down-regulation of ABCC1 gene expression by RTV was observed. Inhibition of 
LXRa by the antagonist 22-(S)-hydroxycholesterol and siRNA knockdown abolished 
or diminished this down-regulation in a concentration dependent manner. ABCC1 
gene expression was also significantly down-regulated in the presence of all 
concentrations of ATV, suggesting a complex array of mechanisms involved in 
ABCC1 regulation. This was important because the outcome of ABCC1 regulation 
by both RTV and ATV was similar so it is unlikely that its regulation contributes to 
the contrasting profiles of these two drugs. There were still questions to be answered 
in respect of the complex mechanisms involved in its regulation and their impact 
cholesterol efflux and homeostasis, which were outside the scope of this thesis.
Up-regulation of ABCC2 gene expression was observed at lower RTV 
concentrations, however, at lOpM RTV significant ABCC2 down-regulation was 
observed. These effects were diminished by the LXRa antagonist, 22-(S)- 
hydroxycholesterol, and in the biological knockdown assays. This was interesting 
because it suggested a role for LXRa as a key regulator of die xenobiotic responses 
of this gene, albeit that LXRa was not the primary regulator of ABCC2. Other NRs
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including PXR and FXR have been reported to be involved in ABCC2 regulation, 
(Ho etat, 2005; Wang et aL, 2008).
ABCG1, a key player in cholesterol transport, was up-regulated by RTV. This was 
diminished in the presence of the LXRa antagonist 22-(S)-hydroxycholesterol, and in 
the biological knockdown assays supporting a role for LXRa in the regulation of 
ABCG1 gene expression. Another key player in cholesterol transport, ABCG4, was 
also up-regulated by RTV, effects which could be diminished in the presence of 22- 
(S)-hydroxycholesterol and by biological knockdown of LXRa. The regulation by 
LXRa of these genes could provide an insight into some of the metabolic 
complications associated with HADL, as genes on the pathways for both bile acid 
transport and cholesterol transport have been up-regulated simultaneously leading to 
disruption of bile acid and cholesterol homeostasis. These in vitro findings would 
need to be probed in vivo to validate this hypothesis.
Significant up-regulation of ABCG5 and ABCG8 gene expression was also observed 
in the RTV assays. The effects of which could be abolished or diminished by 22-(S)- 
hydroxycholesterol or siRNA knockdown of LXRa. Both of these transporters were 
previously cited as under the regulatory control of LXRa (Francis et al, 2003). The 
studies in Chapter 4 confirmed that the gene expression of these metabolic 
transporters differs in response to RTV and ATV and that the actions of RTV can be 
blocked through modulation of LXRa gene expression. The results also provide 
further insight into the complex mechanisms by which LXRa regulates its targets in 
response to a RTV stimulus. SNPs in transporters and genes involved in lipid
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homeostasis play a key role in the varied metabolic side-effect profiles seen in HIV+ 
individuals on HAART (Mallon, 2006; Telenti et al., 2008).
The findings of these gene expression studies in metabolic transporters may provide 
valuable clues for future drug development, as agonists of LXRa could result in the 
disruption of a cascade of metabolic genes and downstream targets. The observed 
down-regulation of LXRa due to biological knockdown by siRNA has already been 
discussed in this chapter together with the potential for a future therapeutic 
mechanism for antagonism of LXRa in vivo.
Up-regulation of GLUT4 gene expression by RTV was observed. In the presence of 
22-(S)-hydroxycholesterol, this up-regulation was diminished at 0.1 pM and lOpM 
RTV, and abolished at 1.0pM. The biological knockdown of LXRa showed a role 
for LXRa in the regulation GLUT4 gene expression. Although caution should be 
exercised when interpreting the GLUT 4 results as the overall basal and experimental 
expression levels of the gene were quite low in the Huh? cells.
Chapter 5 of this thesis discussed the importance of a known SNP in the LXRa gene, 
rs2279238C/T, which was previously associated with lipid abnormalities and 
cardiovascular risk in HIV negative (HIV-) populations (Dahlman et al, 2009; Legry 
et al, 2008; Price et al, 2011) in a HIV+ cohort with confirmed HAUL 
complications. There were no significant differences between the CC, CT and TT 
genotypes of the rs2279238C/T SNP in either the HADL+ or HAUL- cohorts. It 
should be noted that the TT genotype was rare in the patient cohort with no examples 
in the HAUL- patient group. Subset analysis of the allele frequency in the HADL+
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and HADL- cohorts revealed a trend associated with the T allele and HADL
symptoms. A further significant association was observed when the HADL- cohort 
was compared to the healthy volunteer cohort which suggested a potentially 
protective role for the CC genotype in this cohort, the power of this association 
increased when the analysis was perfonned on the allele frequency in the same 
cohorts. This suggested that the absence of the polymorphism in the HADL- cohort 
may confer protection against HADL symptoms. Further investigations in a larger 
population are needed to establish whether the association with the TT genotype 
previously observed in HIV- populations (Dahlman et al., 2009; Legry et aL, 2008; 
Price et al, 2011) influences HADL outcomes in non-Caucasian populations or is 
gender specific in a HIV+ cohort, as the investigated patient group was wholly 
Caucasian and predominantly male.
It was hypothesised that the LXRa SNP rs2279238C/T potentially influenced the risk 
of HADL development in Caucasian HIV+ populations and that it may be linked to 
increased risk of a fatal cardiovascular event where HADL complications were 
present. As no survival outcome or follow-up data for this cohort were available the 
hypothesised cardiovascular risk was unconfirmed. In order to confinn these 
hypotheses, that the observed SNP is associated with HADL outcomes and increased 
cardiovascular risk, the investigations would need to be repeated in a larger HIV+ 
cohort. HADL is a multifactorial disease and in this chapter a single polymorphism 
in a single gene was investigated. It was difficult to conclude that the presence of a 
single SNP in LXRa could predict future cardiovascular events in a HIV+ or 
HADL+ population.
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Weak associations between baseline lipid parameters; total cholesterol >240mg/dl; 
triglycerides >200mg/dl; and blood glucose >100mg/dl were observed in the HADL+ 
cohort, although these associations were not linked to a specific genotype. Power for 
these associations increased with patient age and HADL status, however, these were 
not genotype driven. In order to validate these associations further investigations in a 
larger population are needed to investigate whether correlation between these 
parameters and a specific genotype can be established.
Knowledge of specific SNPs which increase the risk of developing metabolic 
disorders, including diabetes mellitus and cardiovascular disease, provides an insight 
into future treatment regimens so that individuals with the greatest risk of metabolic 
complications receive treatment which incorporates lipid-sparing ARVs. This 
knowledge will also influence the future development of drugs to treat HIV as more 
is known about the complex mechanisms which underpin HADL and individual 
susceptibility to its development.
Chapter 6 of this thesis detennined the importance of eight known polymorphisms in 
six metabolic genes which were previously associated with lipid abnormalities and 
cardiovascular risk in a HIV+ cohort who were switched to a lipid-sparing regimen 
of un-boosted ATV due to prior display of HADL characteristics.
The ABCA1 rs2230806G/A SNP was previously associated with elevated LDL-c 
levels in men who were homozygous AA (Abelian et aL). This study had insufficient 
male participants with that genotype, so this association was unconfirmed. It was 
interesting, however, that elevated LDL-c in the HIV+ cohort was more prevalent in
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females with at least one copy of the A allele, than had been expected. An 
association with elevated LDL-c in men was established in individuals who carry at 
least one copy of the A allele in the ABCA1 rs2230806G/A SNP and are 
homozygous GG genotype for the rs7575840GT SNP in ApoB. It was also 
interesting to observe that eight of the same female population were also 
homozygous GG genotype for the rs7575840GT SNP in ApoB and all had elevated 
LDL-c levels. It was hypothesised that the combination of the GG genotype for 
ApoB rs7575840GT and a single copy of the A allele from the ABCA1 
rs2230806G/A SNP was sufficient to result in elevated LDL-c in Caucasian HIV+ 
populations; although caution is required when reporting this association due to the 
small patient cohort involved. The studies, however, confirmed the association with 
increased risk previously reported in individuals with a combination of these two 
SNPs (Kathiresan et ah, 2008). Further investigations in a larger population are 
needed to confirm the hypothesis that this association is gender independent in a 
HIV+ cohort. Such confirmation could provide a future predictor of HADL risk in 
HIY+ individuals and provide insights into lipid-sparing alternative therapies.
These studies also confinned associations seen in HIV- populations with other SNP 
combinations and other lipid parameters. It was previously reported that the two 
SNPs investigated in LDLR, rs2228671C/T and rs!529729C/T were associated with 
elevated LDL-c levels and an increased risk of developing coronary artery disease 
(Kathiresan et al., 2008; Linsel-Nitschke et al., 2008), the former has also been 
associated with hypercholesterolaemia (Aulchenko et aL, 2009). An association with 
the C allele in the LDLR rsl529729C/T SNP and elevated total cholesterol, increased
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LDL-c and higher TG levels was observed in these investigations. When this SNP 
was combined with the GG genotype for ApoB rs7575840GT, patients had elevated 
total cholesterol and increased LDL-c levels. In the same group 11/12 patients were 
also homozygous CC for the LDLR SNP rs2228671C/T with the twelfth 
heterozygous CT at the same SNP. This suggested that the outcomes were linked to 
the C allele at this SNP. The increased risk associated with a combination of these 
three SNPs (Kathiresan et al, 2008) was confirmed by these studies. Further 
investigations in larger populations are now required to substantiate the hypothesis 
that these associations are prevalent in larger I-IIV-t- cohorts. Such confirmation may 
prove useful for clinicians requiring a future predictor of HADL risk in HIV+ 
individuals.
These studies were unable to confirm the inverse association with HDL-c levels 
previously reported as a consequence of reduced SRB1 protein levels linked with the 
C allele in the SCARE 1 SNP rs2278986C/T (West et aL, 2009). The investigated 
cohort contained 2 homozygous CC genotypes (both female), and 22 heterozygotes 
carrying one C allele but HDL-c levels were low for the men and women in the 
cohort. The studies were unable to confirm an association with this SNP in the 
homozygous TT patients which would have indicated an opposite effect in ITIV+ 
populations.
An association with decreased HDL-c in patients with the T allele was confinned 
when it was associated with a combination of demographic factors including age, 
height and the following SNPs: ABCA1 rs2230806G/A, A allele; LDLR 
rsl529729C/T, C allele; ABCG1 rsl893590A/C, C allele; ABCG8 rs6544713C/T, T
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allele; and ApoB rs693A/G, G allele. The same combination was also confirmed as 
associated with elevated total cholesterol and increased LDL-c after 24 weeks on a 
lipid-sparing regimen of un-boosted ATV in the 24/32 patients in the HIV-i- cohort. 
This was interesting because these were undesirable lipid profiles and an 
improvement in the parameters was not observed after 24 weeks of RTV absent 
therapy. Whilst previous studies reported an increased risk of combined SNPs in 
non-HIV related metabolic disorders, it is necessary to remain cautious when 
predicting the same outcome in larger HIV+ cohorts in the absence of further 
validation of these findings. If these findings are confirmed in larger populations and 
different ethnicities, these SNPs could form the basis of a matrix for predicting 
HADL outcomes with future treatment regimens.
The association the AA genotype of the ABCG1 rsl893590A/C SNP with lower 
HDL-c levels in women which was previously reported in HIV- patients (Abelian et 
al) was unconfirmed as there were only 9 females in the cohort with the AA 
genotype and their HDL-c levels were higher than was observed in all females and 
the combined genders group. The absence of validation of these associations may be 
attributed to small numbers in the cohort, but the trend in the group was towards 
higher levels of HDL-c in the homozygous AA females. An association was 
observed with reduced baseline TG values and the C allele although again the 
numbers involved were low (7) and validation in a larger cohort would be required 
prior to reporting this as a significant association. Elevated total cholesterol and 
increased LDL-c levels were associated with the C allele at week 24 when the SNP 
was grouped with a number of demographic factors and other SNPs including: age;
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height; and a combination of five SNPs: ABCA1 (rs2230806G/A, A allele); LDLR 
(rsl529729C/T, C allele); SCARB1 (rs2278986C/TJ T allele); ABCG8 
(rs6544713C/T, T allele); and ApoB (rs693A/G, G allele).
In summary, the data in thesis supports the role of LXRa as a master regulator of 
metabolic target genes involved in cholesterol homeostasis, bile acid metabolism and 
the response to RTV in a hepatic cell line. It has confirmed the role of RTV as an 
agonist at LXRa. It has also hypothesised the role of other metabolic NRs, including 
FXR, PPARa and HNF4a, in the contrasting gene expression profiles in response to 
ATV and RTV in the hepatic cell line. It has shown that both FXR and LXRa gene 
expression was simultaneously up-regulated and hypothesised that this dis-regulation 
could be implicated in the deleterious metabolic side effects associated with RTV. It 
has confirmed that tire contrasting profiles of RTV and ATV are not due to higher 
intracellular concentrations of the former. This thesis has shown that antagonism of 
LXRa by chemical and biological means can alter the effects of RTV on key target 
genes, including SREBPl-c, previously implicated in the deleterious lipid side 
effects of PI therapy. This thesis has also identified areas of interest for future 
investigation in the complex mechanisms which regulate lipid metabolism, which 
include a potential therapeutic use for inhibition of LXRa by siRNA or a LXRa 
antagonist. Potential therapeutic inhibition of LXRa needs to be isoform specific and 
site directed to hepatic LXRa to facilitate normal homeostasis between cholesterol 
and bile acid production. The liver is the primaiy site of de novo cholesterol 
biosynthesis and enterohepatic recirculation. To underpin the findings in this thesis it 
would be beneficial to undertake further studies involving multiple NR knockdown
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or antagonism. The use of siRNA to simultaneously knockdown LXRa and PPARot 
would provide the reader with an insight into the influence of LXRo/PPARa 
heterodimers in the response to RTV together with a test of the hypothesis that LXRa 
up-regulates ApoC-III via its down-regulation of PPARa. These experiments could 
be under-pinned by co-incubation of RTV with the LXRa antagonist 22(S)- 
hydroxycholesterol and the PPARa antagonist GW7647 (Tocris Bioscience) initially 
in the Huh7 hepatic cell line. Co-incubation of RTV and HX531 (Tocris Bioscience) 
an antagonist of RXRa would provide an insight as to whether the effects of RTV on 
LXRa and its downstream targets can be inhibited by antagonism of it permissive 
heterodimer partner.
This thesis has also investigated SNPs in LXRa, ABCA1, LDLR, ApoB, SCARE 1, 
ABCG1 and ABCG8 which were previously implicated in metabolic complications 
in HIV- populations to determine whether there was a correlation with impaired lipid 
parameters in two HIV+ patient cohorts with HADL symptoms. These correlations 
and lack of associations were discussed in the context of the small patient cohorts 
involved, with the potential future clinical implications if the associations can be 
validated in larger HIV+ patient cohorts.
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